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INTRODUCTION AND OUTLINE OF THIS THESIS 
The gastrointestinal (GI) tract has two very important functions: (I) the absorption of nutrients
and water, and (II) the maintenance of an effective barrier against harmful dietary antigens, digestive
enzymes, and commensal and foreign bacterial pathogens and toxins. Many physiological and patho-
physiological situations have been reported to compromise the GI system and to disrupt the GI
epithelial barrier, posing a considerable threat to the human body. Examples of such situations are
intestinal ischemia, celiac disease, pancreatitis, systemic inflammatory response syndrome, heavy
physical exercise and the use of specific medication (non-steroid anti-inflammatory drugs, NSAIDs).
The diagnosis of barrier integrity loss is hampered by the absence of reliable, non-invasive tests.
Diagnostic delay interferes with patient recovery and impedes early therapeutic intervention, leading
to higher morbidity and mortality rates.In this chapter, the anatomy and regulation of the GI epithe-
lial barrier will be introduced, including a brief overview of situations associated with GI barrier
dysfunction. Chapter 2 will elaborate on one of these situations, namely strenuous physical exercise,
and discusses modalities to evaluate exercise-induced loss of GI integrity.
Physical GI barrier
Two key features are essential to maintain an effective barrier against luminal components: the
first is the physical barrier of the GI epithelium, the second is an effective immune response. An
uncompromised physical barrier is composed of a continuous epithelial monolayer of enterocytes,
which are differentiated cells originating from stem cells present in the crypt. Furthermore, the
integrity of the gut epithelial barrier is sustained by tight junctions, adherence junctions, gap junc-
tions, and desmosomes (33, 34). 
   The intestinal epithelium undergoes rapid renewal. Stem cells in the crypt give rise to rapidly
amplifying cells, which migrate upwards along the villus axis and differentiate into mature epithe-
lial cells. Upon reaching the villus tip, the mature enterocytes die and are shed into the intestinal
lumen following cell detachment, a process that constantly occurs in physiological situations. In
addition, epithelial cells affected by infection or topical damage are rapidly exfoliated and replen-
ished by neighboring cells. This epithelial cell turnover helps to expel pathogens and prevents
pathological bacterial colonization, translocation, and inflammation (10, 31).
   The tight junctions are major, highly dynamic complexes that are composed of many different
proteins that are anchored in the cell via the actin cytoskeleton (20). The tight junction proteins
are divided into intracellular proteins, the zonula occludens (ZO) proteins, and transmembrane
proteins such as junctional adhesion molecules (JAM), claudins, and occludins. These proteins
tightly act together to form a dynamic fence against foreign antigens and microbes. Adherence
junctions, gap junctions, and desmosomes all work together to form apical junctional complexes
that interact with neighbouring cells to preserve epithelial architecture, facilitate cell migration
during epithelial renewal, and enable intercellular communication (11, 17). 
GENERAL INTRODUCTION
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   The physical intestinal barrier is further reinforced by the presence of a continuous mucus
layer that overlies the intestinal epithelium. The mucus of this layer is produced by goblet cells
that are found scattered along the epithelium (32).
Immunological GI barrier
The main contributors to the immunological barrier within the GI system are the intestinal epithe-
lial cells (IECs), including enterocytes and Paneth cells, and the myeloid and lymphoid cells of the
intestinal tract. The IECs are members of the innate immune system, they produce antimicrobial
proteins, and are able to sense potentially harmful bacterial products via pattern recognition recep-
tors (PRRs). PRRs recognize specific pathogen-associated molecular patterns (PAMPs), including
lipopolysaccharide present on the gram-negative bacterial wall and peptidoglycans mainly on the
wall of gram-positive bacterial pathogens (26). If such PAMPs bind to their associated PRRs, 
signalling cascades are activated, leading to the initiation of an inflammatory response specific to
the recognized microbial molecules (18). Paneth cells, located in the crypts of the intestine in
between the stem cells, contribute to the immunological barrier of the small intestine by producing
and secreting antimicrobial proteins into the intestinal lumen to prevent bacterial translocation
and to protect the stem cells (4). Paneth cells also recognize PAMPs present in the lumen, leading
to the production and secretion of a-defensins (39). In addition, specialized myeloid and lymphoid
structures embedded in the lamina propria of the small intestine contain cells that are capable of
microbial and antigen sampling from the intestinal lumen (2). Subsequent delivery of the sampled
material to the underlying lymphoid tissue results in the generation of an appropriate immune
response with activation and recruitment of innate immune cells (2).
   Another defense mechanism that prevents bacterial pathogens from breaching the epithelial
lining is the presence of approximately 1014 commensal bacteria within the intestinal tract (3).
These commensal bacteria exert an important role in maintaining GI barrier function (9, 19).
Commensal bacteria stimulate epithelial cell turnover, compete with pathogenic bacteria, and
contribute to the development and function of the immune system (3).
Regulation of GI barrier function and GI permeability
GI barrier function is regulated by a number of processes, including the high turnover of intestinal
epithelial cells, the highly dynamic apical junctional complexes that seal the paracellular space in
between the epithelial cells, and the interplay with the innate and adaptive immune response.
   Intestinal epithelial cell damage leads to loss of cellular integrity, likely resulting in increased
transcellular permeability for small solutes across the GI epithelial barrier (21). The junctional
complexes between the epithelial cells largely regulate GI permeability. The tight junctions limit
solute fluxes across the GI epithelium via the paracellular pathway, and are therefore considered
the rate-limiting step in paracellular transepithelial transport (35). Data suggest the existence of
at least two, probably independent, paracellular routes across the tight junction (13, 35, 41).
PART I - CHAPTER 1                                                                                                                        
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The flux of macromolecular solutes occurs via a size-selective ‘leak’ pathway, whereas small (<4
Å radius) solutes permeate through smaller, charge-selective pathways (13, 41). Both the size-
selective and charge-selective tight junction pathways are regulated by a variety of physiological
and pathophysiological stimuli (35). 
Studies have revealed a role for sodium (Na+) as a physiological regulator of the tight junction
barrier (36, 37). Active uptake of Na+ at the villus apex results in glucose co-transport and
absorption of water and small solutes (34). This Na+-induced regulation of tight junction per-
meability occurs via activation of myosin light chain kinase (MLCK), which leads to phospho-
rylation of myosin light chain (MLC) in the actomyosin ring that surrounds the junctional com-
plex and to opening of the tight junction, thereby increasing paracellular permeability (35, 37).
    Immunological stimuli can also increase paracellular permeability via MLCK-induced changes
in the tight junctional complex (35, 37). In addition, tumor necrosis factor a (TNF-a), an impor-
tant mediator of intestinal inflammation, was found to lead to degradation of occludin messenger
RNA (mRNA), resulting in depletion of occludin, a transmembrane tight junction protein (43).
The latter led to increased intestinal permeability and macromolecular flux via the ‘leak’ paracel-
lular pathway (1, 43). 
   Another stimulus that has been described to induce structural changes in the tight junction
complex is intestinal ischemia (16). After ischemia and reperfusion, changes in MLCK protein
levels were suggestive of a phosphorylated MLC-induced epithelial constriction at sites where
epithelial cells had lost contact with the basal membrane (16). After prolonged ischemia followed
by reperfusion, profound epithelial barrier loss was observed, with loss of tight junction proteins
and significant translocation of bacterial endotoxin (15).
   In short, the GI epithelium is constantly exposed to luminal content, including antigens, digestive
enzymes, and bacterial pathogens that produce harmful toxins. The highly dynamic GI epithelial
barrier is tightly regulated to allow only selective transmucosal transport. Loss of GI barrier
integrity results in the permeability of the potentially harmful luminal content, and may cause pro-
found intestinal injury and inflammation.
Loss of GI integrity in physiology and pathophysiology 
Loss of integrity occurs in many physiological and pathophysiological situations. The physiolog-
ical situations associated with GI integrity loss that will be discussed in the current thesis include
heavy physical exercise and experimentally induced GI integrity loss after 2-day oral intake of
NSAID, both in healthy individuals. 
   During heavy physical exercise, redistribution of splanchnic blood flow reduces the circulation
in the abdominal region, leading to splanchnic hypoperfusion (8). Such hypoperfusion or ischemia
gives rise to intestinal mucosal injury due to a lack of oxygen and nutrients, depriving especially the
mature enterocytes of resources necessary for survival, since these cells already are in a hypoxic state
11
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due to the countercurrent circulation of the intestinal villi (7). Injured enterocytes may be rapidly
expelled into the GI lumen, after being detached from the basal membrane. While at this stage the
epithelial lining of the intestine may be macroscopically intact, functional barrier integrity loss and
increased GI permeability are already present (24, 28).
   The second physiological situation associated with GI integrity loss studied was the intake of
NSAIDs. NSAIDs are known to cause GI injury, especially after prolonged use (6, 23), but even
short-term NSAID consumption was described to increase GI permeability (6, 44). These stud-
ies on physiological GI integrity loss aimed to clarify the origin and the extent of the epithelial
compromise. Furthermore, the aim was to develop accurate measures of GI integrity loss. 
   Other, more severe situations that have been associated with loss of GI integrity in relatively
healthy individuals include psychological stress (22), excessive consumption of alcoholic bever-
ages (30), and oral intake of specific types of food (38). In addition, pathological loss of GI
integrity has been described in a wide variety of diseases, including intestinal diseases such as
celiac disease (40), inflammatory bowel disease (5), viral infections (27), as well as systemic dis-
eases such as autoimmune disorders (12) and sepsis (14). While many of the phenomena con-
tributing to GI barrier loss remain to be clarified, we consider that splanchnic hypoperfusion
and inflammation both play an important role in the development of GI barrier integrity loss in
physiological and pathophysiological situations.
   Another severe manifestation of mucosal integrity loss is GI ischemia. Ischemia of the GI
tract may be the result of an acute occlusion of the celiac artery or splanchnic arteries, or may
be the result of a long-term progressive atherosclerotic process in the afferent vessels within the
splanchnic area (25, 29, 42). 
Outline of this thesis
The current thesis deals with two main issues. First of all, we developed and evaluated tools to
assess loss of GI integrity. These tools were subsequently used to improve our understanding of
GI integrity loss in case of splanchnic hypoperfusion during strenuous physical exercise. Chapter
2 is a review of literature on the development and evaluation of splanchnic hypoperfusion during
physical exercise. The role of physiological splanchnic hypoperfusion in the development of
epithelial integrity loss and abdominal distress during physical exercise is discussed, an overview
is given of the available tools to assess loss of epithelial integrity, and some promising preventive
and therapeutic interventions are discussed. In chapter 3, the role of plasma markers intestinal
fatty acid binding protein (I-FABP), ileal bile acid binding protein (I-BABP), and liver fatty acid
binding protein (L-FABP) to assess intestinal injury in patients with acute intestinal ischemia is
described. Chapter 4 describes the evaluation of two permeability tests to analyze loss of GI
barrier function. The first test is based on the urinary excretion of three differently sized poly-
ethylene glycol (PEG) probes, whereas the second test uses two differently sized sugars to eval-
uate small intestinal permeability. The aim of this study was to compare urinary probe excretion
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and accuracy of both tests in healthy volunteers with increased GI permeability after short-term
use of NSAID. In chapter 5, the improved analytical work-up of a multi-sugar test to evaluate
GI permeability in both urinary and plasma samples is reported. The aim of this study was to
expand the application of the sugar-based permeability analysis by adding three sugars for site-
specific whole gut permeability assessment, and to enable permeability analysis in plasma sam-
ples. The study described in chapter 6 focusses on the validation of the multi-sugar permeability
assay described in chapter 5, in healthy volunteers in a randomized crossover study. Urinary
probe excretion and accuracy of the permeability analysis obtained using the multi-sugar assay
were compared with data obtained using the dual sugar lactulose-rhamnose test. 
The second part of this thesis elaborates on splanchnic hypoperfusion and its consequences on
the GI system, including loss of GI integrity in a physiological situation. The study described in
chapter 7 was designed to clarify the effects of splanchnic hypoperfusion during strenuous exer-
cise on the gut, and the relationship between hypoperfusion and loss of GI integrity. In chapter
8, the effect of heavy exercise on epithelial integrity and protein uptake in young healthy volun-
teers is described. Chapter 9 describes a study on the potential role of citrulline to improve
splanchnic perfusion and diminish exercise-induced epithelial injury in healthy, young volunteers.
The effect of citrulline on exercise-induced changes in splanchnic perfusion and microcirculation
were determined using gastric exercise tonometry and sublingual sidestream dark field imaging,
respectively. In chapter 10, the effect of NSAIDs on GI epithelial integrity loss in rest and during
exercise was studied using both plasma I-FABP levels and sugar-based GI permeability analysis. 
Chapter 11 discusses the main issues of this thesis, some of the questions that were raised during
the construction of this thesis, and interesting points for future studies are discussed. Chapter
12 provides a brief English and a brief Dutch overview of the main issues that were addressed
in this thesis.
13
GENERAL INTRODUCTION
Proefschrift laatste versie_Opmaak 1  6/10/13  10:08 AM  Pagina 13
REFERENCES
1.Al-Sadi R, Khatib K, Guo S, Ye D, Youssef M, and Ma T. Occludin regulates macromolecule flux across the
intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol 300: G1054-1064, 2011.
2. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut.
Nat Rev Immunol 8: 411-420, 2008.
3. Ashida H, Ogawa M, Kim M, Mimuro H, and Sasakawa C. Bacteria and host interactions in the Gut epithelial
barrier. Nat Chem Biol 8: 36-45, 2012.
4. Ayabe T, Satchell DP, Wilson CL, Parks WC, Selsted ME, and Ouellette AJ. Secretion of microbicidal a-defensins
by intestinal Paneth cells in response to bacteria. Nat Immunol 1: 113-118, 2000.
5. Bjarnason I, O'Morain C, Levi AJ, and Peters TJ. Absorption of 51chromium-labeled ethylenediaminetetraac-
etate in inflammatory bowel disease. Gastroenterology 85: 318-322, 1983.
6. Bjarnason I, and Takeuchi K. Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J Gas-
troenterol 44 Suppl 19: 23-29, 2009.
7. Blikslager AT. Life in the Gut without oxygen: adaptive mechanisms and inflammatory bowel disease. Gastroen-
terology 134: 346-348, 2008.
8. Bradley SE, Childs AW, Combes B, Cournand A, Wade OL, and Wheeler HO. The effect of exercise on the
splanchnic blood flow and splanchnic blood volume in normal man. Clin Sci (Lond) 15: 457-463, 1956.
9.Cario E, Gerken G, and Podolsky DK. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier
integrity via protein kinase C. Gastroenterology 127: 224-238, 2004.
10.Chichlowski M, and Hale LP. Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone
bad. Am J Physiol Gastrointest Liver Physiol 295: G1139-1149, 2008.
11.Ey B, Eyking A, Gerken G, Podolsky DK, and Cario E. TLR2 mediates gap junctional intercellular communi-
cation through connexin-43 in intestinal epithelial barrier injury. J Biol Chem 284: 22332-22343, 2009.
12.Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoim-
munity, and cancer. Physiological reviews 91: 151-175, 2011.
13.Fihn BM, Sjoqvist A, and Jodal M. Permeability of the rat small intestinal epithelium along the villus-crypt axis:
effects of glucose transport. Gastroenterology 119: 1029-1036, 2000.
14.Fink MP. Gastrointestinal mucosal injury in experimental models of shock, trauma, and sepsis. Critical care med-
icine 19: 627-641, 1991.
15.Grootjans J, Lenaerts K, Derikx JP, Matthijsen RA, de Bruine AP, van Bijnen AA, van Dam RM, Dejong CH, and
Buurman WA. Human intestinal ischemia-reperfusion-induced inflammation characterized: experiences from a
new translational model. The American journal of pathology 176: 2283-2291, 2010.
16.Grootjans J, Thuijls G, Derikx JP, van Dam RM, Dejong CH, and Buurman WA. Rapid lamina propria retraction
and zipper-like constriction of the epithelium preserves the epithelial lining in human small intestine exposed
to ischaemia-reperfusion. J Pathol 224: 411-419, 2011.
17.Harris TJ, and Tepass U. Adherens junctions: from molecules to morphogenesis. Nat Rev Mol Cell Biol 11:
502-514, 2010.
18.Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, and Podolsky DK. CARD15/NOD2
functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 124: 993-1000, 2003.
19.Hooper LV, and Gordon JI. Commensal host-bacterial relationships in the gut. Science 292: 1115-1118, 2001.
20.Ivanov AI, McCall IC, Parkos CA, and Nusrat A. Role for actin filament turnover and a myosin II motor in
cytoskeleton-driven disassembly of the epithelial apical junctional complex. Molecular Biology of the Cell 15:
2639-2651, 2004.
21. John LJ, Fromm M, and Schulzke JD. Epithelial barriers in intestinal inflammation. Antioxid Redox Signal 15:
1255-1270, 2011.
22.Konturek PC, Brzozowski T, and Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diag-
nostic approach and treatment options. J Physiol Pharmacol 62: 591-599, 2011.
23.Maiden L, Thjodleifsson B, Seigal A, Bjarnason, II, Scott D, Birgisson S, and Bjarnason I. Long-term effects of
nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional
capsule enteroscopy study. Clin Gastroenterol Hepatol 5: 1040-1045, 2007.
24.Marchbank T, Davison G, Oakes JR, Ghatei MA, Patterson M, Moyer MP, and Playford RJ. The nutriceutical
bovine colostrum truncates the increase in Gut permeability caused by heavy exercise in athletes. Am J Physiol
Gastrointest Liver Physiol 300: G477-484, 2011.
25.Mensink PB, Moons LM, and Kuipers EJ. Chronic gastrointestinal ischaemia: shifting paradigms. Gut 60: 722-
737, 2011.
26.Meylan E, Tschopp J, and Karin M. Intracellular pattern recognition receptors in the host response. Nature
442: 39-44, 2006.
27.Noone C, Menzies IS, Banatvala JE, and Scopes JW. Intestinal permeability and lactose hydrolysis in human
rotaviral gastroenteritis assessed simultaneously by non-invasive differential sugar permeation. European journal
of clinical investigation 16: 217-225, 1986.
PART I - CHAPTER 1                                                                                                                        
14
Proefschrift laatste versie_Opmaak 1  6/10/13  10:08 AM  Pagina 14
28.Oktedalen O, Lunde OC, Opstad PK, Aabakken L, and Kvernebo K. Changes in the gastrointestinal mucosa
after long-distance running. Scand J Gastroenterol 27: 270-274, 1992.
29.Oldenburg WA, Lau LL, Rodenberg TJ, Edmonds HJ, and Burger CD. Acute mesenteric ischemia: a clinical
review. Archives of internal medicine 164: 1054-1062, 2004.
30.Purohit V, Bode JC, Bode C, Brenner DA, Choudhry MA, Hamilton F, Kang YJ, Keshavarzian A, Rao R, Sartor
RB, Swanson C, and Turner JR. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and
medical consequences: summary of a symposium. Alcohol 42: 349-361, 2008.
31.Radtke F, and Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 307: 1904-1909, 2005.
32.Sansonetti PJ. War and peace at mucosal surfaces. Nat Rev Immunol 4: 953-964, 2004.
33.Schwarz BT, Wang F, Shen L, Clayburgh DR, Su L, Wang Y, Fu YX, and Turner JR. LIGHT signals directly to
intestinal epithelia to cause barrier dysfunction via cytoskeletal and endocytic mechanisms. Gastroenterology 132:
2383-2394, 2007.
34.Shen L, Weber CR, Raleigh DR, Yu D, and Turner JR. Tight junction pore and leak pathways: a dynamic duo.
Annu Rev Physiol 73: 283-309, 2011.
35.Turner JR. Intestinal mucosal barrier function in health and disease. Nature Rev Immunol 9: 799-809, 2009.
36.Turner JR, and Madara JL. Physiological regulation of intestinal epithelial tight junctions as a consequence of
Na(+)-coupled nutrient transport. Gastroenterology 109: 1391-1396, 1995.
37.Turner JR, Rill BK, Carlson SL, Carnes D, Kerner R, Mrsny RJ, and Madara JL. Physiological regulation of
epithelial tight junctions is associated with myosin light-chain phosphorylation. Am J Physiol 273: C1378-1385,
1997.
38.Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM, and Roy NC. Regulation of tight junction
permeability by intestinal bacteria and dietary components. J Nutr 141: 769-776, 2011.
39.Vaishnava S, Behrendt CL, Ismail AS, Eckmann L, and Hooper LV. Paneth cells directly sense Gut commensals
and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci U S A 105: 20858-20863,
2008.
40.van Elburg RM, Uil JJ, Mulder CJ, and Heymans HS. Intestinal permeability in patients with coeliac disease
and relatives of patients with coeliac disease. Gut 34: 354-357, 1993.
41.Van Itallie CM, Holmes J, Bridges A, Gookin JL, Coccaro MR, Proctor W, Colegio OR, and Anderson JM. The
density of small tight junction pores varies among cell types and is increased by expression of claudin-2. J Cell
Sci 121: 298-305, 2008.
42.van Noord D, Sana A, Moons LM, Pattynama PM, Verhagen HJ, Kuipers EJ, and Mensink PB. Combining
radiological imaging and gastrointestinal tonometry: a minimal invasive and useful approach for the workup of
chronic gastrointestinal ischemia. European journal of gastroenterology & hepatology 2013.
43.Ye D, Guo S, Al-Sadi R, and Ma TY. MicroRNA regulation of intestinal epithelial tight junction permeability.
Gastroenterology 141: 1323-1333, 2011.
44.Zeino Z, Sisson G, and Bjarnason I. Adverse effects of drugs on small intestine and colon. Best Pract Res Clin
Gastroenterol 24: 133-141, 2010.
15
GENERAL INTRODUCTION
Proefschrift laatste versie_Opmaak 1  6/10/13  10:08 AM  Pagina 15
      
     
    
        
   
     
  
 
 
 
 
   
  
  
16
Proefschrift laatste versie_Opmaak 1  6/10/13  10:08 AM  Pagina 16
CHAPTER 2
Physiology and pathophysiology of splanchnic hypoperfusion 
and intestinal injury during exercise: 
strategies for evaluation and prevention
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ABSTRACT
Physical exercise places high demands on the adaptive capacity of the human body. Strenuous
physical performance increases the blood supply to active muscles, cardiopulmonary system,
and skin to meet the altered demands for oxygen and nutrients. The redistribution of blood
flow, necessary for such an increased blood supply to the periphery, significantly reduces blood
flow to the gut, leading to splanchnic hypoperfusion and gastrointestinal (GI) compromise. A
compromised GI system can have a negative impact on exercise performance and subsequent
post-exercise recovery due to abdominal distress and impairments in the uptake of fluid, elec-
trolytes, and nutrients. In addition, strenuous physical exercise leads to loss of epithelial
integrity, which may give rise to increased intestinal permeability with bacterial translocation
and inflammation. Ultimately, these effects can deteriorate post-exercise recovery and disrupt
exercise training routine.
This review provides an overview on the recent advances in our understanding of GI physiology
and pathophysiology in relation to strenuous exercise. Various approaches to determine the
impact of exercise on the individual athlete’s GI tract will be discussed. In addition, we will elab-
orate on several promising components that could be exploited for preventive interventions.
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INTRODUCTION
The gastrointestinal (GI) system plays an important role in the athlete’s ability to perform 
strenuous exercise (24). Proper GI function enables endurance performance and promotes early
recovery. In contrast, a compromised GI system will likely impair performance and subsequent
recovery, and may give rise to serious GI problems, such as nausea, vomiting, angine abdominale
and bloody diarrhea (102, 125). Such symptoms, manifestations of a compromised GI system,
are experienced by 25 to 70% of endurance athletes (102, 125). Among the reported deleterious
manifestations of strenuous exercise are mucosal erosions and ischemic colitis, both observed
after long distance running (4, 21, 25, 54, 89, 95). While the etiology of exercise-induced GI 
distress is multifactorial, GI ischemia is often acknowledged as the main pathophysiological mech-
anism for the emergence of such distress (29, 89, 124, 125). 
   This review provides an overview on the current understanding of GI physiology and patho-
physiology during and after exercise. Strategies will be discussed that may be used by athletes to
determine the impact of exercise on the GI tract. Ultimately, we will provide insight into some
promising resources that may be used to prevent exercise-induced abdominal distress. 
Gastrointestinal perfusion
The arterial blood supply of the GI tract consists of three main afferent routes: the celiac trunk,
and the superior and inferior mesenteric artery (81). These three main arteries ramify into three
dense vascular plexus, the serosal, submucosal and mucosal plexus, of which the latter shoots
the microcirculatory capillary network that irrigates the intestinal mucosa. Drainage of the
splanchnic area is covered by the superior mesenteric vein, inferior mesenteric vein, and the 
portal vein that return the venous blood to the heart via the liver and subsequently the inferior
vena cava (81). The splanchnic vasculature constitutes a system with a remarkable capacity to
adapt to physiological stressors promoting vasodilatation or constriction via regulation of the
mesenteric vascular resistance by neuroendocrine, humoral, and paracrine mechanisms (79).
During strenuous physical activity or exercise, the release of norepinephrine near the a-adrenore-
ceptors of the sympathetic nervous system induces splanchnic vasoconstriction, thereby increas-
ing total splanchnic vascular resistance (41, 81, 141). The blood is rapidly redistributed from
the splanchnic area to be used for the perfusion of tissues with increased activity during exercise,
such as heart, lungs, active muscle and skin (Figure 1) (98, 109). 
Although Doppler ultrasound and contrast extraction studies in the nineteen fifties had already
revealed a vast reduction in hepatosplanchnic blood flow during exercise (14, 111), it was the
technique of gastric tonometry that revealed that strenuous physical exercise results in splanchnic
hypoperfusion and mucosal acidosis in healthy individuals (92, 98). Tonometry is a functional
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test that relies on the principle that inadequate tissue perfusion and tissue hypoxia lead to
mucosal accumulation of carbon dioxide (CO2). The exact working mechanism of gastric tonom-
etry during exercise is depicted in Figure 2. In short, the accumulated CO2 increases the gastric
CO2 tonus (pCO2), which is measured by the tonometer (67), and the gap between gastric and
systemic pCO2 reflects the adequacy of splanchnic perfusion. Gastric exercise tonometry revealed
a rapid onset of splanchnic hypoperfusion, with the most pronounced changes in splanchnic
perfusion occurring in the first ten minutes of strenuous exercise (135) (Figure 3A), indicating
a rapid response of the splanchnic vascular bed. In addition, a rapid restoration of splanchnic
20
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Figure 1:  Schematic overview of the processes proposed to play a role in the development of exercise-induced gastrointestinal
injury
Strenuous physical exercise leads to redistribution of blood, shunting blood away from the splanchnic area, thereby
significantly reducing splanchnic blood flow. The ensuing ischemia leads to tissue hypoxia, local depletion of
adenosinetriphosphate (ATP), and acidosis. After exercise, when splanchnic circulation is restored, reperfusion
injury may develop, characterized by local inflammation and formation of reactive oxygen species (ROS). Both
ischemia and reperfusion sequelae lead to mucosal damage and Gut wall integrity loss, which is accompanied by
increased permeability, bacterial translocation and intestinal inflammation. 
It remains to be clarified whether the exercise-induced mucosal injury impairs nutrient uptake, potentially decreas-
ing athletic performance and delaying post-exercise recovery.
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blood flow was observed in the first ten minutes of post-exercise recovery, suggesting rapid reper-
fusion of the splanchnic area (135) (Figure 1 and 3A).
    Tonometry also demonstrated that the severity of splanchnic hypoperfusion was proportional
to exercise intensity as assessed by increasing blood lactate levels (124), without a critical reduc-
tion in splanchnic perfusion during submaximal exercise in healthy individuals (98, 124). The
majority of symptomatic athletes however, already developed splanchnic hypoperfusion during
submaximal exercise (124), suggesting vascular hyperresponsiveness to exercise. In addition, early
studies have pointed out that there is a clear relationship between the reduction in splanchnic
blood flow and relative workload (23), suggesting that regular training has an impact on the sen-
sitivity of the splanchnic vascular responsiveness to exercise. However, data comparing trained
and matched untrained subjects are required to verify whether this is true.
Age has also been suggested to affect blood flow redistribution during exercise, since the vascular
system in elderly may be less responsive to catecholamines (68), while atherosclerotic plaques
and vascular stenosis associated with aging of the vascular system may also play a role. Reductions
in splanchnic blood flow were indeed reported to be less pronounced in elderly (mean age 64
years) compared with their younger counterparts, who were closely matched with respect to max-
imal oxygen uptake capacity, when exercise intensities exceeded 60% of peak oxygen consumption
(65). These observations corroborate the higher frequency of exercise-induced abdominal com-
plaints in young athletes that may be hypoperfusion-related (41, 125), although the latter may of
21
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Figure 2: Working mechanism of gastric tonometry
Gastric tonometry relies on the principle that inadequate perfusion and tissue hypoxia lead to mucosal accumulation
of CO2 due to anaerobic metabolism and decreased transport of CO2 via local blood vessels. The accumulated CO2
diffuses into the stomach, where it increases the CO2 tonus (pCO2), which is detected via the balloon of the tonom-
etry catheter connected to an extracorporeal tonometer. For accurate interpretation of the tonometry data, adequate
suppression of gastric acid production is necessary to prevent buffering of the CO2 by H
+, and arterial or arterialized
blood samples should be collected to enable determination of the gap pCO2 (i.e. gastric-arterial pCO2). Arterialised
blood samples can be obtained from an intravenous catheter inserted in a dorsal hand vein of a hand placed in a
hot box in which the air is heated to ~60oCelsius. 
Adjusted (with permission) from: Ackland et al, Critical Care 2000.
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course also be related to the fact that in general, absolute workloads of young athletes are sub-
stantially higher than for the elderly, leading to more profound circulatory changes. Another expla-
nation for the less extensive splanchnic hypoperfusion observed in the elderly is their reduced
muscle mass. 
   In conclusion, exercise leads to redistribution of blood away from the splanchnic area, resulting
in intestinal hypoperfusion and rapid reperfusion, which may contribute to GI distress in symp-
tomatic athletes.
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Figure 3: Physical exercise results in splanchnic hypoperfusion and intestinal cell damage.
A) Gastric tonometry shows decreased splanchnic perfusion during and after cycling. B) Plasma I-FABP levels
reflect the development of intestinal epithelial cell damage during and after cycling. C) Gastric tonometry shows
two different splanchnic profiles of two individuals during and after exercise. D) Plasma I-FABP levels of the same
two individuals reveal intestinal cell damage individual A (closed symbols), while individual B (open symbols) has
no apparent intestinal damage during exercise, reflected by maintenance of baseline I-FABP levels. Data in A and
B represent mean and SEM. Different from baseline (t = 0) (*p<0.01, **p<0.001, ***p<0.0001). Adjusted from:
Van Wijck et al, PLoS 2011
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GI function: exercise-induced loss of epithelial integrity and barrier function
Decreased oxygenation of the intestinal epithelium may lead to damage at the intestinal villus
tips (Figure 1) (30, 49). In line, exercise-induced hypoperfusion leads to loss of cellular integrity
in the intestine of young, healthy individuals during strenuous exercise, which is reflected by
significantly increased plasma levels of intestinal fatty acid binding protein (I-FABP) (Figure
3B) (135). I-FABP is a small, cytosolic protein present in mature enterocytes at the upper half
of the small intestinal villi, and is rapidly released into the circulation upon cellular injury (30,
101, 128). The susceptibility of the mature enterocyte population to low-flow states and
ischemic events is explained by the counter-current exchange mechanism of the villus (10, 11)
that creates a constant low oxygen, hyperosmolar environment at the villus tip (51).
    Reduced splanchnic perfusion deteriorates the physiological low oxygen state, thereby further
depriving the enterocytes from oxygen and denosinetriphosphate (ATP), leading to epithelial
cell damage, and loss of epithelial integrity (Figure 1) (30, 94). In line, profound intestinal dam-
age presenting as mucosal erosions with GI bleeding was observed during endoscopy in athletes
after strenuous endurance running (21, 95). GI bleeding was also reported by other authors,
after obtaining positive faecal occult blood tests (FOBT) from otherwise healthy athletes after
long-distance running (8, 90, 133). Ultimately, profound intestinal bleeding can lead to exer-
cise-induced haemorrhagic colitis requiring surgery, a condition particularly described in
marathon runners (107, 116). 
   Exercise-induced intestinal injury may be primarily the result of hypoperfusion or the result
of a combination of ischemia with subsequent reperfusion, since restoration of the splanchnic
blood flow can further compromise epithelial integrity due to oxidative stress and inflammation
(Figure 1) (36, 49). Loss of epithelial integrity is associated with increased GI permeability, bac-
terial translocation, and intestinal inflammation (Figure 1) (7, 36). Such barrier integrity loss
includes disruption of the tight junctions interconnecting the intestinal epithelial cells, either by
alteration of the epithelial cytoskeleton or by loss of tight junction proteins (59, 126, 127).
Increased permeability and bacterial translocation may occur (7), and tight junction proteins
are rapidly redistributed to quickly restore an effective intestinal barrier (77). 
   Increased intestinal permeability after strenuous exercise was confirmed by increased urinary
excretion of orally ingested permeability probes such as 51Chromium ethylene diamine tetra-
acetic acid (51Cr EDTA) (95) and sugar permeability probes (76, 99). Sugar-based permeability
analysis relies on the permeation of large and small sugar probes through GI mucosa, which
provides a specific index of GI permeability (9). An increase in this permeability index was also
observed in plasma samples of young athletes, reflecting a transient increase in GI permeability
after 1 hour of vigorous cycling, indicating disruption of the GI barrier (135). While healthy
individuals are well able to cope with a transient increase in GI permeability, in case of prolonged,
vigorous exercise, more profound increases in intestinal permeability lead to translocation of
luminal endotoxins, resulting in endotoxaemia (13, 64). 
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   Another important line of defense in the small intestine that is worth mentioning in the 
setting of intestinal ischemia is the immunological barrier formed by the Paneth cells. These
cells, located in the crypts of the intestine in between the stem cells, continuously produce and
secrete antimicrobial proteins into the intestinal lumen to prevent bacterial translocation. In
addition, they directly sense and respond to bacterial threats (1, 130). Recent studies have
shown that intestinal ischemia-reperfusion in the human intestine is associated with Paneth cell
apoptosis, and loss of these cells was indeed associated with increased bacterial translocation
and inflammation (48). Although never investigated in the setting of physical activity or exercise,
it is tempting to speculate on the involvement of Paneth cell dysfunction in the intestine of
endurance athletes. During prolonged, vigorous exercise, splanchnic hypoperfusion may induce
Paneth cell dysfunction, thereby possibly contributing to intestinal barrier function loss.
Loss of epithelial integrity, increased GI permeability and bacterial translocation induce a strong
inflammatory response, which is characterized by complement activation, production and release
of cytokines, endothelial activation and local neutrophil influx in the intestinal mucosa (30). Indeed,
circulating levels of mannose-binding lectin (MBL), a player of innate immunity and an important
initiating complement component (31), increased after 1 hour of vigorous cycling in healthy, young
athletes (unpublished data), suggesting activation of the complement system. Furthermore, exercise
led to elevated cytokine levels, and an increase in endothelium-derived factors and acute phase
proteins (17, 100). While these inflammatory markers may originate from skeletal muscle (17,
100), increased faecal levels of neutrophil-derived calprotectin and bacterial translocation suggest
an additional role for the intestinal mucosa as a contributor to the inflammatory response after
strenuous exercise (13, 64, 69, 135). 
   In short, splanchnic hypoperfusion during exercise leads to loss of intestinal epithelial integrity,
which may be accompanied by intestinal blood loss. Additionally, strenuous exercise results in
loss of intestinal barrier integrity, reflected by increased permeability, bacterial translocation and
intestinal inflammation (Figure 1).
GI function: exercise-induced changes in digestion and absorption
The consequences of vigorous exercise on GI function are diverse and many aspects remain to
be clarified. For example, the effect of exercise on gastric emptying is very heterogeneous. While
exercise at the individual’s maximum capacity has been reported to delay gastric emptying in
some studies (16, 38), the majority of studies fail to report any major changes in gastric empty-
ing, even during more vigorous physical exercise (43, 121, 132). Based on the current literature,
it seems fair to conclude that gastric emptying is not limiting the speed of nutritional uptake
during exercise when appropriate measures are taken regarding the volume, composition, 
temperature, and osmolality of the ingested drinks (42, 110, 114).
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   After gastric emptying, the luminal content enters the small intestine, the principal site of 
nutrient digestion and absorption. The latter is highly important with respect to digestive tolerance
during exercise and determines the rate of nutrient supply to the active muscles (15). It is tempting
to assume that GI function is reduced during vigorous physical exercise, and several authors have
prompted that decreases in splanchnic perfusion and oxygen supply up to 80% reduce nutrient
digestion and absorption (15, 29, 132). In line, several studies have demonstrated that while 
glucose absorption is unaffected by exercise at low and moderate intensity levels, it is decreased
during strenuous physical exercise (71, 132). Yet corroborative evidence supporting the theory
that splanchnic hypoperfusion accounts for this decrease in absorption is still lacking. In addition
to a putative effect of hypoperfusion on metabolic function, mucosal injury and local inflammation
may exert negative metabolic effects during exercise. On the other hand, specific nutritional strate-
gies may be able to preserve sufficient splanchnic flow during and after exercise. The latter con-
tributes to the maintenance of a positive energy balance necessary to ensure optimal metabolic
recovery and to promote optimal muscular regeneration processes (120). 
    Other factors that may contribute to decreased GI metabolic function are altered neurohor-
monal levels, altered secretory activities and disturbances in the electrolyte and acid-base balance
(91). Last of all, inadequate fluid intake during strenuous exercise in a hot environment, leading
to hypohydration of 3% of body weight did not interfere with digestion and absorption (112), but
may impair intestinal barrier maintenance (69, 70). 
   In short, based on the available data, we consider that if strenuous exercise is prolonged, the
need for energy substitution increases, while the absorptive capacity of the gut may decrease. 
Individual predisposition
There is large heterogeneity in the response of the GI system to exercise. Splanchnic hypoper-
fusion during exercise ranges from mild circulatory changes to profound GI ischemia (Figure
3A and 3C). In line, the consequences of hypoperfusion within the GI tract, i.e. epithelial injury
and changes in GI permeability and epithelial barrier function, greatly differ between individuals
(Figure 3B and 3D). Ultimately, the presence and nature of abdominal symptoms experienced
by athletes vary from mild, exercise-related discomfort to severe ischemic colitis and diarrhoea
(88). A number of factors contributing to the pathophysiology of exercise-related abdominal
distress have been identified, such as age, female sex, medication, dehydration, food intake, a
hot, humid environment, type of exercise, exercise duration and exercise intensity  (29, 41, 102,
125). Another factor that may contribute to the differences in the hypoperfusion sequelae is
genetic background; e.g. previously, carriers of a homozygous MBL2 genotype were reported
to have significantly lower levels of plasma I-FABP after intestinal ischemia (80), indicating that
MBL-deficient individuals may be protected against ischemia/reperfusion-induced intestinal
epithelial injury. An unfavourable combination of factors places the individual at risk of devel-
oping GI problems. 
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   Exercise-induced GI ischemia has been reported to occur in 50% of symptomatic athletes at
submaximal exercise intensities, while asymptomatic athletes do not display intestinal ischemia
during exercise at that level of intensity (124). 
    Importantly, specific underlying pathology may also give rise to GI problems during or shortly
after physical exercise, and exercise-related symptoms may represent an early sign of such pathology.
Vascular conditions known to cause exercise-related complaints can be classified as non-occlusive
or occlusive disease, affecting single or multiple vessels. The main cause of single artery stenosis is
celiac artery compression, in which extrinsic compression of the celiac artery by the median arcuate
ligament of the diaphragm hampers the inflow of blood (82, 119). Critically reduced perfusion
through the celiac artery is thought to produce upper abdominal pain in a similar fashion as exercise
leads to ischemia-associated abdominal discomfort. This also explains why the pain in celiac artery
compression syndrome (CACS) is typically experienced postprandially and during exercise, since
a combination of ischemic factors leads to a greater perfusion mismatch within the splanchnic area.
While the prevalence of CACS in the general population is still unclear, Mensink et al. found a
prevalence of 13.4% in 320 patients with suspected chronic GI ischemia (82). Other conditions
such as splanchnic atherosclerosis may also cause non-occlusive mesenteric ischemia (NOMI),
classically leading to postprandial abdominal pain and exercise-induced symptoms. In addition,
patients with compromised cardiac and/or pulmonary function, e.g. chronic heart failure or chronic
obstructive pulmonary disease (COPD) are suggested to be at risk of developing splanchnic hypop-
erfusion and the associated intestinal injury, barrier dysfunction and inflammation (113). Since
intestinal inflammation may contribute to the state of chronic inflammation that is often seen in
these patients, it is essential to avoid an excessive splanchnic response. On the other hand, regular
physical exercise in these chronic patients is of important clinical relevance, since it helps to maintain
muscle mass and strength, improves cardiovascular fitness, and increases quality of life. 
Evaluation of splanchnic perfusion in athletes 
The currently available clinical tools that may be used to identify whether disproportional splanch-
nic hypoperfusion or ischemia is present during exercise are tonometry and techniques to evaluate
the intestinal microcirculation. An overview of the available tools is depicted in Table 1.
   Exercise tonometry enables detection of GI ischemia in all symptomatic athletes during 10
min of maximal exercise (plasma lactate > 5.5 mmol/L). About 50% of these symptomatic ath-
letes also showed signs of GI ischemia during 10 min of exercise at submaximal workload (3 <
lactate < 5.5 mmol/L) (124). Criteria for positive tonometry outcomes generally differ between
centres. Otte et al. considered tonometry to be positive in symptomatic athletes in case of
increased luminal pCO2 compared with baseline values, in combination with a gap(gastric-arterial, g-a)
pCO2 >0.8 kPa, or for jejunal tonometry gap(jejunal-arterial, j-a) pCO2 > 1.4 kPa (97).
  Ter Steege et al. used the same criteria to identify ischemia during exercise tonometry, and 
found gap(g-a) pCO2 levels of 1.1 and 0.5 kPa during 10 minutes of submaximal exercise in 
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symptomatic and asymptomatic athletes, respectively, and 2.5 and 1.7 kPa during 10 minutes
exercise increasing to maximum intensity (124). We observed increased gap(g-a) pCO2 levels
from -0.85 in rest to 0.85 kPa after 1 hour of cycling at 70% of the individual athlete’s maximal
workload capacity (Wmax) without major abdominal complaints (Figure 3A) (135). An alterna-
tive way to evaluate exercise-induced ischemia may be to consider the increase in gap(g-a)
pCO2from baseline, since physiological baseline differences are common, and cut off points for
ischemia may also be individually determined. We propose to include markers of ischemia-
related epithelial injury and GI compromise such as I-FABP and permeability ratios, respec-
tively, to improve the diagnosis of exercise-induced ischemia. The diagnosis of CACS is largely
similar to the multidisciplinary work-up of GI ischemia, including gastric exercise tonometry
and visualisation of the stenosis, and is described in detail by Mensink et al (82).
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Table 1: Tools to assess exercise-induced splanchnic hypoperfusion and its sequelae in athletes
                                                                 Area of interest        Tool                        Measured in
Splanchnic        Functional                  Small intestine           Tonometry             Stomach / jejunum
perfusion            hypoperfusion            
                           
                           Microcirculatory       Small intestine           OPS                       Stomach / small intestine
                           oxygenation                                                 SDF                      Stomach / small intestine 
                                                                                                                              / sublingual mucosa
                                                                                                NIRS                     Stomach / small intestine
                                                                                                VLS                       Stomach / small intestine
                           Vascular                     Small intestine           CTA                      
                           abnormalities                                              MRA                     
                                                                                                Duplex                   
                                                                                                                              
Hypoperfusion    Mucosal injury           Small intestine           I-FABP                  Blood or urine
sequelae                                                 Ileum                         I-BABP                 
                                                              Stomach / small        Endoscopy             GI tract
                                                              intestine                     Video capsule        GI tract
                           Blood loss                   Intestine                    FOBT                   Faeces
                           Permeability              Intestine                    Sugar test               Blood or urine
                                                                                                51Cr EDTA           Urine
                           Endotoxaemia           Intestine                    LAL assay              Blood
                                                                                                EndoCAb              Blood
                                                                                                assay
                            Inflammation                                              Inflammatory         Blood
                                                                                                markers
                                                              Intestine                    Calprotectin          Faeces
                            Reduced nutrient                                        3-OMG                 Urine
                           uptake                                                          Stable isotope        Blood or urine
                                                                                                   studies
OPS = orhogonal polarization spectral imaging, SDF = sidestream dark field imaging, NIRS = near-infrared spec-
troscopy, VLS = visible light spectroscopy. CTA = computed tomographic angiography, MRA = magnetic reso-
nance angiography, I-FABP = intestinal fatty acid binding protein, I-BABP = ileal bile acid binding protein, FOBT
= faecal occult blood test, 51Cr EDTA = 51Chromium ethylene diamine tetra-acetic acid, LAL assay = limulus
amoebocyte lysate assay, EndoCAb assay = endotoxin core antibodies assay, 3-OMG = 3-O-methyl-glucose
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   Novel techniques introduced to evaluate the intestinal microcirculation are orthogonal polar-
ization spectral (OPS) imaging (44, 47), side stream dark field (SDF) imaging (58), near-infrared
spectroscopy (NIRS) and visible light spectroscopy (VLS).  These techniques provide information
on the mucosal oxygen saturation of haemoglobin in red blood cells of the intestinal microcircu-
lation by emission and detection of backscattered light during endoscopy (5, 81, 134). This provides
a direct measurement of mucosal microcirculatory saturation and simultaneous macroscopic eval-
uation of the mucosa during upper endoscopy in clinical settings. Analysis of the sublingual micro-
circulation using the same techniques provides an indirect, less invasive alternative that may prove
useful for athletes to monitor the effects of training on GI function. Measurements must be 
performed before and directly after cessation of exercise, since movement of the diagnostic probe
during exercise interferes with the quality of microcirculatory imaging. Data on the use of these
techniques in athletes are not yet available. Studies in patients suspected of chronic GI ischemia
are promising (134), and sublingual microcirculation measurements were reported to correlate
closely with measurements of the intestinal microcirculation in animal studies (139). 
If vascular abnormalities or vascular occlusion are considered to explain existing abdominal
symptoms that present either at rest or during exercise, imaging of the abdominal vasculature
should also be obtained. For this purpose, computed tomography angiography (CTA), classic
or magnetic resonance angiography (MRA), or transcutaneous abdominal duplex ultrasound
may be used. The advantages and disadvantages of these techniques are beyond the scope of
this review, but a useful, comprehensive overview of these techniques with respect to chronic GI
ischemia is provided by Mensink et al. (81). Only duplex ultrasound scanning may be used 
during exercise to establish reduced intestinal perfusion, but reproducibility of this technique in
healthy, well-trained athletes is rather poor (103). 
   Finally, if other serious pathology is suspected that may induce or aggravate abdominal com-
plaints during or after exercise, like inflammatory bowel disease or a Helicobacter pylori infec-
tion, endoscopy (in combination with biopsy and/or microcirculatory analysis as described ear-
lier) may be indicated. Video capsule endoscopy provides a non-invasive, elegant alternative for
pathology that can be observed macroscopically (22). It remains to be determined if capsule
endoscopy can contribute to the assessment of exercise-induced intestinal compromise and
whether its use is safe during exercise. 
In summary, evaluation of splanchnic perfusion during and after exercise is possible using the
functional gastric tonometry test, which could be combined with analysis of circulating I-FABP
levels. Furthermore, novel techniques are available to evaluate intestinal microcirculation, and
imaging of the splanchnic vasculature may be useful to exclude vascular abnormalities.
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Evaluation of compromised epithelial integrity in athletes
Circulating plasma I-FABP levels, determined by an enzyme-linked immunosorbent assay
(ELISA), can be used during and after exercise to obtain information on intestinal injury (128,
135). In healthy, trained individuals, plasma I-FABP levels doubled from approximately 300 to
over 600 pg/mL during one hour of cycling at 70% Wmax (135). In addition, plasma I-FABP
levels were found to correlate with exercise-induced splanchnic hypoperfusion determined 20
minutes earlier, emphasizing the suitability of I-FABP as a marker of ischemia-related intestinal
injury in athletes (135). Cut off points for differentiation of normal and abnormal circulating 
I-FABP levels depend on the sensitivity of the test that is used. Ideally, the athlete’s baseline 
I-FABP level is determined (at rest) and subsequent levels measured during exercise should be
expressed accordingly. The change in I-FABP levels (i.e. the delta) likely represents a more reli-
able measure to reflect GI homeostasis during exercise and subsequent post-exercise recovery.
The development of a reliable quick-test to evaluate circulating I-FABP levels in capillary blood
obtained from a fingertip or ear lobe would greatly increase the applicability of I-FABP as marker
of ischemia-related injury. In addition to the analysis of plasma and urinary I-FABP levels for
early detection of exercise-induced intestinal injury, intestinal bile-acid binding protein (I-BABP)
may be used to provide site-specific information on the ileum (135). 
   In addition, plasma citrulline level before and after exercise may be determined by high-per-
formance liquid chromatography (HPLC) as a marker of remaining enterocyte mass (27). 
Similar to I-FABP, the delta of such plasma levels may be used as a parameter of intestinal
integrity. Alternatively, the citrulline generation test has been suggested to assess enterocyte func-
tion, and may be used athletes during exercise and post-exercise recovery. The citrulline gener-
ation test is based on the oral ingestion of a bolus (20 g) of alanine-glutamine, and determination
of plasma citrulline levels that may change in relation to villous atrophy (104). It remains to be
determined whether these tests are useful to assess in exercise-related epithelial injury.
   Occult GI blood loss is another feature of exercise-induced intestinal compromise (8, 133),
and therefore, FOBT may also be used to determine intestinal integrity during and/or immedi-
ately after exercise. The most common commercially available FOBT is the Hemoccult test
(Beckman Coulter Inc. CA, U.S.A.). A ‘positive’ test result is obtained if the tested stool sample
contains over 2-4 mL of blood per 100 g faeces, due to any process that may induce intestinal
bleeding, ranging from physical exercise to colorectal carcinoma (129). To avoid false positive
results, it is important that subjects adhere to dietary recommendations such as avoiding intake
of red meat, raw, peroxide-like fruits and vegetables or vitamin C supplements, may generate
false positive outcomes (129). However, it should be noted that the latest FOBTs no longer
require such dietary protocols.
   Furthermore, among the tests that may be used to assess the impact of exercise on the GI
system are tests that aim to assess gut barrier loss. An elegant test to determine the gut barrier
function is the sugar-based permeability test, in which the individual drinks a test solution com-
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posed of small (< 200 kD) and large (> 200 kD) sugar probes. Preferably, the test drink is
ingested during, or just after exercise. Urinary and/or plasma concentrations are obtained using
HPLC in combination with mass spectometry (HPLC-MS) (136). The urinary excretion of sin-
gle sugars and the ratio of large and small sugars can be used to assess GI permeability. The
advantage of plasma-based permeability analysis is the ability to detect smaller and transient
permeability changes that may not be found on urinary analysis (135). The timing of urinary
collections and the selection of the sugar probes depend on the specific area of interest. If small
intestinal permeability is to be tested, urine should be collected over 0-3 or 0-5 hours, using the
sugar probes lactulose and L-rhamnose. In contrast, for large intestinal permeability 3-24 or 5-
24 hour urinary collections are used, in combination with two sugar probes such as sucralose
and erythritol that are non-degradable by bacteria in the colon (9). A classic alternative for intes-
tinal permeability assessment is the use of 51Cr EDTA) (95), but since this technique is depend-
ent on renal function, which may be changed during strenuous exercise, and because of its
radioactivity (32), its use for exercise-induced changes is not recommended. 
   In addition to permeability tests, loss of intestinal barrier function after strenuous exercise
may be determined by analysis of circulating endotoxin levels (64). High levels indicate that the
GI mucosa was unable to preserve an effective barrier function, resulting in bacterial translocation
from the gut lumen to the circulation. Techniques that may be used to determine whether translo-
cation has occurred are the Limulus Amoebocyte Lysate (LAL) assays, quantifying endotoxin
levels in plasma samples, and a test that measures the concentration of endotoxin core antibodies
(EndoCAb), with reduced antibody levels reflecting antibody consumption by increased circulating
endotoxin. Both assays require sampling prior to exercise and post-exercise to detect changes in
endotoxin or antibody levels, respectively. However, both assays may be influenced by confounding
factors such as previous endotoxin exposure, and fungi or polynucleotides that may produce false
positive results (50, 64).
   Loss of epithelial integrity in the gut is also reflected by the secretion of inflammatory markers.
While determination of circulatory C-reactive protein, white blood cell counts, and neutrophil
products may be useful to estimate the whole body response to exercise, no gut-specific infor-
mation can be derived from such measurements, since other tissues such as muscles are also
known to produce pro-inflammatory cytokines during exercise (100). Mucosal injury triggers
neutrophils and other inflammatory cells to migrate towards the site of injury, where the 
neutrophils are activated and release their antimicrobial peptides (26, 33, 34, 37). Hence, more
specific information on intestinal inflammation may be obtained from quantification of faecal
levels of peptides such as calprotectin, a 36 kD-protein with antimicrobial and immunomodu-
lating ability (37, 122, 123). 
   Changes in the uptake of nutrients, both during strenuous exercise and in the acute recovery
period, remain to be clarified. Active sugar uptake during exercise may be analyzed using 
3-O-methyl-glucose (3-OMG), e.g. during permeability analysis (94). In addition, stable isotope
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studies may help to reveal changes in nutrient uptake and possible correlations with exercise-
induced intestinal compromise. The latter enable the use of dietary products present in an aver-
age every day diet, thereby providing safe and very relevant information on digestion and absorp-
tion of these products (35).  
   The main features of compromised epithelial integrity during and after exercise are small
intestinal injury and increased permeability, which may be determined by analysis of plasma I-
FABP levels and permeability analysis. An overview of the available tools to assess intestinal
compromise in athletes is presented in Table 1.
Future perspectives: evaluation and preventative solutions
Evaluation of the splanchnic response to exercise in asymptomatic athletes
Usually, only symptomatic athletes who are limited by GI symptoms during exercise seek help
to identify the origin of their symptoms and consequently may adjust their training and feeding
strategies based on recommendations provided by the gastroenterologist. However, others may
also benefit from increasing their knowledge of the capacities and limitations of the GI system,
especially professional athletes and individuals with compromised cardiovascular and/or pul-
monary capacity. Individualized information on GI function may be used to modulate the exer-
cise training program, improve feeding strategy, and prevent adverse effects on GI level. Splanch-
nic responses to exercise may be different in women compared to men (53). Therefore,
individualized information could also be used to design training strategies and recommendations
for nutritional strategies specifically for female athletes (53). 
Solutions to prevent intestinal compromise during exercise
Training strategies
Better monitoring of the GI system during training may improve gut function and diminish
abdominal discomfort during exercise in symptomatic athletes if training strategies are adapted
to GI capacity (124). One of the training adaptations may be to reduce exercise intensity, either
temporary or for a longer period of time depending on the individual’s outcome, and to maintain
heart rates below the level at which symptoms generally seem to occur. It will be interesting to
find out whether the application of such a strategy in symptomatic athletes will bring elevated I-
FABP levels back to physiological levels. If the latter is true, exercise intensity may be adjusted
according to the level of I-FABP, and if levels rise above the individual’s predetermined threshold,
training intensity may be reduced. It may also be possible to precondition or train the gut to
withstand prolonged episodes of physical exercise. If the latter is true, athletes may benefit by grad-
ually increasing exercise intensity during a single training session, creating opportunity to establish
an equilibrium that fits the altered physiological situation. Studies that include data on specific
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adaptations of the gut to training show that gastric emptying and intestinal transit are increased in
highly active individuals compared with less active people (18), and that individuals that practice
the intake of food and fluids in training sessions experience significantly less GI distress during
competition (125), suggesting that adaptation of the GI tract to physical exercise is possible.
Feeding strategies
Optimization of feeding strategies reduces abdominal distress in symptomatic athletes (60, 124).
In addition to a well-balanced every day diet, it is recommended to avoid large meals and the intake
of nutritional products that are not easily digested in the 2-3 hours prior to strenuous physical
exercise, such as foods with a high fibre, protein, or fat content (63, 110). The reason for this may
be that postprandially, splanchnic blood flow increases significantly (142). The ingestion of these
specific foods is associated with larger decreases in splanchnic vascular resistance compared with
easily digestible foods (66, 87), which may result in more pronounced splanchnic vasodilatation
and increased splanchnic flow. In fact, the ingestion of a liquid test meal (390 kcal, 21.6 g protein,
15.4 g fat, 41.3 g carbohydrate (CHO)) during the first 10 minutes of a 15-minute exercise bout
on a treadmill at 20% incline was reported to increase splanchnic blood flow (109), suggesting
that oral intake may overrule the exercise-induced decrease in splanchnic circulation. However,
the moderate intensity level in this study may explain why exercise-induced hypoperfusion did not
overrule the increase in blood flow induced by this large food bolus. Future studies are needed to
clarify whether the ingestion of food also interferes with exercise-induced vasoconstriction at higher
intensity levels and whether a mismatch in blood flow gives rise to abdominal distress. Currently,
athletes are recommended to use small amounts of easily digestible foods in the hours before and
during exercise while maintaining euhydration (29). During exercise, CHO ingestion is recom-
mended, since it improves endurance capacity and performance (60, 61). In highly active athletes,
the combination of glucose and fructose may be beneficial since it resulted in higher CHO oxida-
tion rates than the ingestion of a single CHO (62), attenuating the depletion of endogenous energy
stores during exercise and stimulating repletion of these stores during acute post-exercise recovery.
However, care should be taken to avoid the intake of hyperosmolar fluids, since these have been
associated with abdominal distress and hyperosmolar diarrhea during exercise (110).
   Although the intake of high-fat products is not recommended in the 2-3 hours prior to and
during strenuous physical exercise, lipid-enriched nutrition has been described to attenuate intes-
tinal inflammation, bacterial translocation, and intestinal injury following intestinal hypoperfu-
sion (28). These effects have been assigned to the activation of the autonomic nervous system
that increases the splanchnic blood flow via activation of cholecystokinine receptors (28, 118).
In line, lipid-enriched nutrition ingested in the post-exercise period may improve GI function
and reduce the flu-like condition associated with endotoxaemia after strenuous physical exercise
by improving post-exercise splanchnic flow.  
   Nutritional strategies prior to, during and post-exercise should always be tailored to the indi-
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vidual athlete, and trial and error during training sessions will yield the most effective strategy
to be used during competition (61). Oral intake should be practiced in training since athletes
unaccustomed to ingest fluids or foods during exercise experience significantly more GI com-
plaints upon such intake during a competitive run (125). In addition, the athlete’s personal pref-
erence for food and fluids should not be neglected as it is a strong determinant for the athlete’s
tolerance to nutrition during exercise. 
Strategies to improve splanchnic perfusion
Strenuous physical exercise is typically associated with significant splanchnic hypoperfusion, which
can be severe enough to impair the structural and functional integrity of the GI tract. In case of
significant vascular abnormalities or stenosis due to CACS, revascularization treatment may be
required to improve splanchnic perfusion (81). The majority of individuals with exercise-induced
splanchnic hypoperfusion will not need revascularization. Numerous less invasive measures are
available to improve splanchnic hypoperfusion in the absence of vascular abnormalities. Adequate
hydration contributes to splanchnic perfusion maintenance by avoiding systemic hypovolemia.
Since there is considerable variability in fluid loss between individuals, customized fluid replace-
ment is recommended to maintain adequate hydration during exercise (115). In addition, specific
agents may be used to enhance splanchnic perfusion and improve GI homeostasis during exercise.
As stated previously, the splanchnic microvasculature plays a fundamental role in GI homeostasis,
and provides an additional target for enhancement of splanchnic flow. One of the important
endogenous players that significantly contribute to the vasodilator responses within the intestinal
microcirculation is nitric oxide (NO) (52). Interventions that increase the intestinal availability
of NO may improve splanchnic perfusion.
   Normally, intestinal microvessels vasodilate in response to acetylcholine via an NO-dependent
mechanism (52, 138). NO synthase (NOS) oxidizes an N-atom of L-arginine to produce 
L-citrulline and NO. To enable this arginine oxidation, NOS requires the cosubstrate NADPH
(nicotinamide adenine dinucleotide phosphate-oxidase), O2, and a number of cofactors (78). Stim-
ulation via acetylcholine increases the cytosolic calcium levels and activates endothelial NOS
(eNOS), leading to NO production (78). Of the three identified NOS isoforms, eNOS is reported
to be responsible for vascular regulation, particularly in the splanchnic area (78). Regulation of
eNOS occurs via guanylyl cyclases (GC), which are transmembrane receptors with an intracellular
domain that becomes enzymatically active upon stimulation. The way of activation is dependent
on the type of GC, and activation via NO is one of the possibilities. NO-mediated vasodilatation
occurs when the binding of NO to GC induces structural changes in GC. Cyclic guanosine
monophosphate (cGMP) production in endothelial cells increases, resulting in intracellular sig-
nalling to initiate relaxation of the vascular smooth muscles, promoting local vasodilatation (78). 
   There are a number of options to upregulate intestinal NO availability that may be of value
for athletes experiencing abdominal distress associated with splanchnic hypoperfusion. The two
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experimental interventions that will be discussed in this review are NOS-dependent (glutamine-
arginine-citrulline) and NOS-independent (nitrate-nitrite) supplementation. An overview of
these potentially useful strategies is given in Table 2. It is important to bear in mind that while
these interventions may improve splanchnic perfusion, it is possible that this will lead to hypop-
erfusion of other tissues such as the active muscles, which may deteriorate athletic performance.
Additionally, since most of these strategies are still in the experimental phase, it remains to be
determined whether the use of the described supplements by athletes is safe. Future studies are
warranted to clarify these issues.   
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Table 2: Promising supplementation strategies to improve splanchnic perfusion in athletes
Strategy Potential advantages                                 Concerns            Study                    References
                                                                                              population           
(Alanyl) • Increased NO availability may
Glutamine improve GI perfusion                                                                                   
• Attenuated intestinal ischemic injury                                Animals                Mondello (86)
• Decreased infectious comorbidity                                      Multi trauma        Houdijk (56
                                                                                          patients
                                                                                                                      
Arginine • Increased NO synthesis improves           High doses          Athletes               Grimble  (46)
GI blood  flow                                       induce GI 
                                                              distress 
                                                              (including 
                                                              nausea, 
                                                              vomiting,
                                                              diarrhea)
• Enhanced tolerance to high-intensity                                Athletes                Bailey (3) 
exercise
• Reduced systolic BP
                                                                                          
Citrulline • Increased arginine pool for                                               Animals                Osowska (96)
NO synthesis  
• Improves nitrogen balance                                                 
                                                                                          
Nitrite • Increased NO availability improves                                   Animals                Petersson (105)
GI perfusion
• Cytoprotective                                                                   Animals                Shiva (117)
• Decreased ROS formation
                                                              
Nitrate • Increased NO availability improves                                   Animals                Petersson (105)
GI perfusion
• Cytoprotective                                                                   Animals                Shiva (117)
• Decreased ROS formation                     
• Enhanced tolerance to heavy exercise                                Athletes                Cermak (20)
                                                                                                                      Vanhatalo (137)
• Improved time-trial performance                                                                   Bailey (2) 
BP, blood pressure - ROS, reactive oxygen species - NO, nitric oxide - GI, gastrointestinal.
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Glutamine, arginine and citrulline supplementation
Glutamine plays an important role in the arginine-NO pathway, as it can be converted in the
intestine into citrulline, the precursor of arginine (131). Arginine is the sole natural precursor
for the synthesis of NO (55), and can be converted to NO and citrulline in the intestine or metab-
olized in the liver into urea and ornithine by arginase. Citrulline is synthesized and released into
the circulation, from which it is taken up by the kidneys, and converted back into arginine for
production of NO and other amino acids (84). The supplementation of glutamine in patients
resulted in enhanced citrulline uptake and higher arginine levels (56, 72). However, the outcome
and positive effects on arginine production depend on the route of administration and the molec-
ular form of the supplemented glutamine (140). Parenteral glutamine supplementation resulted
in higher plasma arginine levels compared to enteral supplementation (72). Unfortunately, nutri-
tional enrichment with glutamine is complicated due to the relative aqueous instability (140). A
promising alternative is supplementation of the dipeptide form, alanyl-glutamine, a stable alter-
native in aqueous solutions with the same positive effects on arginine plasma availability (57).
Glutamine supplementation showed no adverse events even in high dosage (93), making the lat-
ter a promising alternative to enhance the arginine-NO production in the splanchnic vascular
bed during abdominal distress associated with splanchnic hypoperfusion.
    To improve arginine availability for NO synthesis, oral arginine supplementation was suggested,
but controversy exists on the results of arginine supplementation (12). Arginine supplementation
has been described to result in elevated NO synthesis in the hepatosplanchnic area in human and
animal studies supplementation (12, 19, 106). Blood flow in the porcine portal vein increased
(106), while systemic cardiovascular variables such as mean arterial pressure and cardiac index
did not deteriorate (73, 106). In fact, a single 500-mL drink containing 6 g of arginine significantly
reduced the O2 cost of the athletes during moderate-intensity exercise, and enhances high-intensity
exercise tolerance (3), suggesting improved cardiopulmonary function. On the other hand, inability
to increase porcine mesenteric blood flow by enteral supplementation of arginine has also been
reported (108). Furthermore, high doses of arginine have been reported to cause osmotic diarrhoea
exercise (46). Therefore, it can be concluded that the effect of arginine supplementation on the
splanchnic vascular bed in man, especially in athletes, remains to be clarified.
    Citrulline, derived from glutamine conversion, can also be converted to arginine and used for
NO synthesis after entering the systemic circulation. Furthermore, it is not subjected to extensive
hepatic metabolisation like arginine, making it a promising exogenous source of NO, possibly
enabling local vasodilatation and improved splanchnic blood flow. Comparing oral citrulline to
oral arginine supplementation, oral citrulline intake is more efficient in increasing body arginine
levels (96) and has a higher bioavailability (85). Furthermore, high doses of citrulline do not cause
osmotic diarrhoea, whereas arginine does (46, 75). Citrulline has been demonstrated to increase
arginine availability for NO production (96), but whether the latter will improve splanchnic per-
fusion and reduce GI distress in athletes remains to be clarified.
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Nitrate and nitrite supplementation
An alternative, NOS-independent pathway to increase NO availability for vasodilatation is to
generate NO is via nitrate and nitrite, which involves the reduction of ingested nitrate to nitrite
and NO, particularly in acidic or hypoxic conditions. Nitrate is normally ingested via food and
drinking water, and via the ingestion of mainly green leafy vegetables such as lettuce, spinach,
as well as beetroot (74, 137). After ingestion much of the nitrate is reduced to nitrite by com-
mensal bacteria in the saliva of the oral cavity, while the remaining nitrate enters the entero-
salivary pathway after absorption in the upper GI tract. The nitrite formed by the bacteria, is
reduced to NO upon entering the acidic environment of the stomach, a process that is enhanced
by the presence of vitamin C and polyphenols (75). A small part of the ingested nitrate and
nitrite is absorbed in the small intestine and converted to NO in blood and tissue under physi-
ological acidic and hypoxic conditions (75).
   The potency of NO to produce vasodilatation is enhanced under conditions of hypoxia or meta-
bolic stress such as strenuous physical exercise (75, 83). Nitrate and nitrite should preferably be
supplemented per os, for example as a vegetable juice, since such a vegetable juice also contains
vitamin C necessary for the reduction of nitrite to NO and maybe even more important, it is the
physiological route of nutrient ingestion. Animal studies have demonstrated that both nitrate and
nitrite, administered orally and endoluminally, respectively, increased gastric mucosal blood flow
(105). Supplementation of nitrate and nitrite was also demonstrated to act cytoprotective and
decrease formation of reactive oxygen species (117). And recently, dietary nitrate supplementation
(ca. 8 to 11 mmol nitrate in beetroot juice as a single dose or for 6 consecutive days) enhanced tol-
erance to moderate to high-intensity exercise (20, 137), and improved time-trial performance (20).
All together, these data suggest that nitrate ingestion during or immediately after exercise can stim-
ulate splanchnic perfusion, which may reduce intestinal injury and prevent loss of intestinal barrier
function triggered by hypoperfusion during exercise. As such, intake of dietary nitrate could prevent
exercise-related GI problems.
Avoidance of medication that may compromise the GI system
It is of utmost importance to increase the awareness of athletes and trainers towards the delete-
rious effects of drugs that may compromise the GI system. High numbers of athletes have been
reported to use analgesics to relieve existing or anticipated pain (45). Whereas the use of specific
analgesics may paradoxically aggravate GI distress and cause significant small intestinal injury
especially during exercise (unpublished data). The use of non-selective non-steroidal anti-inflam-
matory drugs (NSAIDs), has been associated with a 3 to 5 fold increased risk of upper gastroin-
testinal complications, mucosal bleeding, or perforation compared to no medication (39). Data
indicate that these NSAID-induced complications are the result of two detrimental mechanisms:
inhibition of cyclo-oxygenase (COX)-1 reduces blood flow in the upper GI region, whereas inhi-
bition of COX-2 promotes adherence of neutrophils to the vascular endothelium (40). Further-
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more, NSAIDs may interfere with NO production and inhibit the formation of nitrate via 
regulation of the NFκB pathway (78), thereby further compromising GI homeostasis during
exercise-induced hypoperfusion. Last of all, studies have demonstrated that if active (chronic)
intestinal inflammation is present, NSAID-induced COX inhibition may result in vasoconstric-
tion (6, 52). We consider that the latter in combination with exercise-induced splanchnic hypop-
erfusion may account for the exacerbation of intestinal injury in athletes using NSAIDs.
Future perspectives
Although our knowledge on the role of GI function in relation to exercise has greatly improved
over the past decades, future studies are warranted. One of the main issues to be clarified is the
significance of exercise-induced hypoperfusion and GI integrity loss for digestive and absorptive
processes. Consequently, the tools described previously should be further developed to enable easy,
non-invasive monitoring of the intestinal response to exercise by athletes. 
   Future studies will reveal whether it is feasible to obtain individualized information on GI
physiology during and upon cessation of exercise and to use this information to improve training
and nutritional strategies to match cardiovascular, musculoskeletal and GI capacities, without
significantly compromising of any of these systems. Such individualized information may help
symptomatic athletes to increase understanding of the nature of their symptoms, and may also
assist professional athletes and patients with compromised cardiopulmonary function to improve
athletic performance. 
   Despite the large number of GI symptoms known to occur during exercise, athletes and train-
ers pay little attention to improving GI function. Future studies may provide clarification on the
potential preventative and therapeutic interventions that may be used for this purpose. 
CONCLUSIONS
The extensive plasticity of the gut is generally sufficient to meet the requirements imposed by
strenuous physical exercise. However, redistribution of blood away from the splanchnic bed
towards active muscle tissue, the cardiopulmonary system, and skin can strongly affect the GI
system negatively. Exercise-induced splanchnic hypoperfusion and the subsequent loss of epithe-
lial integrity may lead to the onset of disturbing GI symptoms. However, even in the absence of
such symptoms, athletes may want to consider adjusting training and nutritional strategies in
terms of the type, amount, and timing, to meet nutritional needs while taking into account existing
GI compromise caused by prolonged exercise-induced splanchnic hypoperfusion. 
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CHAPTER 3
Early diagnosis of intestinal ischemia using urinary and 
plasma fatty acid binding proteins
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ABSTRACT
This study aims at improving diagnosis of intestinal ischemia, by measuring plasma and urinary
fatty acid binding protein (FABP) levels.
   Fifty consecutive patients suspected of intestinal ischemia were included and blood and urine
were sampled at time of suspicion. Plasma and urinary concentrations of intestinal FABP 
(I-FABP), liver FABP (L-FABP), and ileal bile acid binding protein (I-BABP) were measured
using enzyme linked immunosorbent assays.
   Twenty-two patients suspected of intestinal ischemia were diagnosed with intestinal ischemia,
24 patients were diagnosed with other diseases, and 4 patients were excluded from further analy-
sis fulfilling exclusion criteria. Median plasma concentrations of I-FABP and L-FABP and uri-
nary concentrations of all 3 markers were significantly higher in patients with proven intestinal
ischemia than in patients suspected of intestinal ischemia with other final diagnoses (plasma 
I-FABP; 653 pg/mL vs. 109 pg/mL, P = 0.02, plasma L-FABP; 117 ng/mL vs. 25 ng/mL, 
P = 0.006, urine I-FABP; 3377 pg/mL vs. 115 pg/mL, P = 0.001, urine L-FABP; 1,199 ng/mL
vs. 37 ng/mL, P = 0.004, urine I-BABP; 48.6 ng/mL vs. 0.6 ng/mL, P = 0.002). Positive and
negative likelihood ratios significantly increased positive posttest probability and decreased neg-
ative posttest probability on intestinal ischemia. In patients with intestinal ischemia a trend to
higher plasma I-BABP levels was observed when the ileum was involved (18.4 ng/mL vs. 2.9
ng/mL, P = 0.05).
   In conclusion, plasma and especially urinary I-FABP and L-FABP levels and urinary I-BABP
levels can improve early diagnosis of intestinal ischemia. Furthermore, plasma I-BABP levels
can help in localizing ileal ischemia.
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INTRODUCTION
Acute intestinal ischemia is a severe intestinal emergency with high mortality (17). It can be pre-
cipitated by a number of pathophysiological processes such as arterial embolism, arterial and
venous thrombosis, aortic dissection, intestinal obstruction due to adhesive diseases after previ-
ous operations, and non-occlusive disorders (e.g., hypovolemia, hypotension). Clinical diagnosis
of intestinal ischemia remains difficult, because of the nonspecific clinical signs in the early phase.
Especially, in high-risk patients clinical history taking and physical examination is hampered
because of sedation and analgesia. In addition, the lack of appropriate diagnostic tests further
hampers correct diagnosis (15). In most patients, intestinal ischemia is recognized only when
the patient has extensive transmural necrosis or sepsis. Delayed diagnosis is a major reason for
the high-mortality rates of intestinal ischemia, because a diagnostic delay of 24 hours decreases
survival rates by more than 20% (17). Therefore, it is important to improve early diagnosis of
intestinal ischemia. 
   In this context, fatty acid binding proteins (FABPs) are potentially interesting. Fatty acid binding
proteins are small cytosolic proteins, which are released upon enterocyte membrane integrity loss.
They are readily released into the circulation and renally cleared, which makes them useful as
plasma and urine markers for enterocyte damage (5, 9, 11). Previously, we showed increased
plasma FABP levels after induction of intestinal ischemia using a newly developed human, exper-
imental controlled model of 30 minutes of intestinal ischemia followed by variable periods of reper-
fusion (4). Also following major vascular surgery and in diseases with known intestinal hypoper-
fusion, such as necrotizing enterocolitis increased plasma and urinary FABP levels were observed
(6, 10, 14). Three FABP isoforms are expressed in the intestine; intestinal fatty acid binding protein
(I-FABP), ileal bile acid binding protein (I-BABP) and liver fatty acid binding protein (L-FABP).
The presence of I-FABP is limited to mature enterocytes of the small and large intestine (6, 18).
Ileal bile acid binding protein is solely expressed in mature enterocytes of the ileum (21), whereas
L-FABP is expressed in small and large intestine, liver, and kidney epithelial cells (6, 16, 18).
   To investigate the usefulness of FABPs as new diagnostic tests for acute intestinal ischemia
the following research questions can be evaluated: Phase 1 question - patients with the target
disorder have different test results from normal individuals? Phase 2 question - are patients with
certain test results more likely to have the target disorder than individuals with other test results
(19)? These phase 1 and 2 questions have been studied by Lieberman et al. (14) and Kanda et
al (11). They showed that I-FABP plasma and urine levels are significantly higher in patients
with intestinal ischemia than in healthy controls. 
    The phase 3 question is: do circulating and urinary FABP levels distinguish patients with intes-
tinal ischemia and patients without intestinal ischemia among patients in whom acute intestinal
ischemia is suspected? This phase 3 question has been studied in a selected patient population sus-
pected of ischemia due to small bowel obstruction by Cronk et al (3). They showed elevated plasma
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and urine I-FABP levels in 3 of 3 patients with necrosis and 4 of 18 patients without necrosis and
concluded that I-FABP is a sensitive marker for ischemia in mechanical small bowel obstruction.
Because one of the diagnostic problems of intestinal ischemia is the diversity in pathophysiological
processes, we aimed to improve diagnosis of intestinal ischemia no matter of the origin. Therefore,
we investigated whether circulating and urinary FABP levels distinguish patients with intestinal
ischemia and patients without intestinal ischemia among all patients in whom intestinal ischemia
is suspected.
MATERIALS AND METHODS
Patients
Following sample size analysis (based on the results of the study of Kanda et al (11), 50 consecutive
patients clinically suspected of acute intestinal ischemia by the treating physician were included at
the Maastricht University Medical Center from September 2007 to July 2009. This patient group
consisted of patients presenting with acute abdominal pain on the emergency department and
high-risk in hospital patients. Patients with preexisting intestinal damage due to intestinal surgery
within 7 days before suspicion of intestinal ischemia were excluded. The study was approved by
the local ethics committee and informed consent was obtained from each participant. After inclu-
sion EDTA plasma samples and urine samples were collected, centrifuged at 4C, 4000 rpm, 15
minutes, and stored at –20ºC until analysis. Plasma and urine samples were collected immediately
at suspicion of intestinal ischemia, and at least 1 hour after suspicion of ischemia. For this reason,
urine samples could only be collected from 19 patients. Diagnosis was based on findings during
surgery or autopsy and verified by histopathological examination of the intestine.
  In case no surgery or autopsy was available for diagnosis, final diagnosis was determined by
consensus among 2 of the authors (G.T. and M.P.) without prior knowledge of plasma and urine
FABP values. In all patients diagnosed with intestinal ischemia, diagnosis was objectively made.
Also, in the patient group with other diagnosis, there was no diagnostic difficulty because of
clear diagnosis in most cases. Only in 4 patients the ultimate diagnosis was unknown, because
of complete recovery after conservative management we agreed that no clinically relevant
ischemia occurred.
Conventional Markers for Intestinal Ischemia
To compare the studied markers with the classical markers to diagnose intestinal ischemia,
plasma lactate level, leukocyte count, and base excess, determined as routine patient care in the
first blood sample upon suspicion of acute intestinal ischemia by the clinical chemistry labora-
tory, were analyzed. Blood samples of these reference tests are taken at the same time-point as
the samples for FABP measurement.
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Urinary and Plasma FABP Measurement
Plasma and urinary I-FABP and L-FABP concentrations were determined using standard
enzyme linked immunosorbent assays (Hycult Biotech, Uden, the Netherlands) and I-BABP
concentration was determined as previously described.16 The detection limit for IFABP, 
L-FABP, and I-BABP was 40 pg/mL, 2 ng/mL and 0.25 ng/mL, respectively. Human FABP
enzyme linked immunosorbent assays kits are solid-phase enzyme-linked immunosorbent assays
based on the sandwich principle with a working time of 3 1/2 hours.
Statistics
Statistical analysis was performed with GraphPad Prism 4 for Windows (GraphPad Software
Inc., San Diego, CA). Normality of all data obtained was evaluated by Kolmogorov-Smirnov
test. Mann-Whitney U test was used for between group comparisons. Data are presented as
median and range. Sex, number of patients (unnecessary) operated, and number of patients died
was compared using Fisher exact test. To find the cutoff points of plasma and urinary FABP levels
that most accurately discriminated patients with intestinal ischemia and patients with other final
diagnoses, receiver operating characteristics (ROC) curves were drawn by plotting sensitivity
against 1-specificity for all thresholds. Furthermore, a ROC curve was drawn for plasma I-BABP
to find the cutoff point that most accurately discriminated patients with ileal ischemia and patients
with intestinal ischemia without ileal involvement. Overall accuracy of the markers was summarized
using area under the curve. The best cutoff point was defined as the maximum sum of sensitivity
and specificity. Cutoff points were used to calculate sensitivity, specificity, positive and negative
likelihood ratios, and positive and negative posttest probabilities. P < 0.05 was considered statisti-
cally significant. Standards for Reporting of Diagnostic Accuracy statement for reporting studies
of diagnostic accuracy was used in this study (2).
RESULTS
Patients suspected of intestinal ischemia
A total of 50 patients were enrolled is this study as scheduled. In 22 patients suspected of intes-
tinal ischemia, diagnosis was confirmed by histopathology. Twenty-four patients were diagnosed
with other final diagnosis; coprostasis (n = 2), pancreatitis (n = 2), diverticulitis (n=4), chole-
cystitis (n =3), ileus (n=1), intestinal stenosis (n = 1), concealed perforation (n = 2), urosepsis
(n = 1), perforated appendicitis (n = 1), retroperitoneal bleeding of unknown origin (n = 1),
stomach perforation (n = 1), small intestinal herniation (n = 1), gastrointestinal problem of
unknown origin (n = 4). Four patients were not included in the analyses because of preexisting
intestinal damage due to a preceding colon operation (Table 1).
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Conventional blood laboratory tests
Laboratory tests currently in use to aid in the diagnosis intestinal ischemia are lactate, leukocyte
count, and base excess. These markers were not able to discriminate patients with intestinal
ischemia and patients with other diseases (lactate; 2.5 mmol/L [0.4–23.1] vs. 2.3 mmol/L [1.0–
5.2], P = 0.56, leukocyte count; 13.9 mg/L [1.7– 28.0] vs. 12.7 mg/L [3.3–33.7], P = 0.89, base
excess; –3.0 mmol/L [–15.9–3.9] vs. –3.7 mmol/L [–6.9–2.5], P = 0.60) (Figure 1).
FABPs for diagnosis of intestinal ischemia
Median plasma I-FABP and L-FABP levels were significantly higher in patients with proven
intestinal ischemia than in patients with other diagnoses (I-FABP; 653 pg/mL [40–74,711] vs.
109 pg/mL [40–1,691], P = 0.02 and L-FABP; 117 ng/mL [6–37,422] vs. 25 ng/mL [5–419],
P = 0.006) (Figure 2). Plasma I-BABP levels were not able to discriminate patients with ischemia
and patients with other diseases (14.5 ng/mL [0.3–616.6] vs. 4.9 ng/mL [0.3–305.2], P = 0.15)
(Figure 2). In 19 patients of whom urine was collected at the moment of suspicion of intestinal
ischemia, urinary levels of all 3 markers were significantly higher in patients with intestinal
ischemia (n = 10) than in patients with other diagnoses (n = 9) (I-FABP; 3,377 pg/mL [142–
442,795] vs. 115 pg/mL [40–1,620], P = 0.0006, L-FABP; 1,199 ng/mL [138–39,176] vs. 37
ng/mL [2–536], P = 0.004, IBABP; 48.6 ng/mL [1.8–900] vs. 0.6 ng/mL [0.25–38.9], P = 0.002)
(Figure 3). Ideal cutoff points to discriminate patients with intestinal ischemia and patients with-
out intestinal ischemia among patients suspected of intestinal ischemia were assessed as maxi-
mum sum of sensitivity and specificity using ROC curves. Ideal cutoff points, sensitivity, speci-
ficity, and area under the ROC curve are depicted in Table 2.
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Table 1: Baseline characteristics of patients with intestinal ischemia or other diagnoses.
       Intestinal ischemia Other diagnoses P value
Group size (no. of patients) 22 24
Age (years) 69(11-84) 67(42-86) 0.62
Sex (M:V) 8:14 10:14 0.77
Operated 21 13 0.002
Unnecessarily operated 0 5 0.005
Died 7 0 0.003
Time interval between sampling 5h 10h 0.32
and operation (0-42h) (0-23h) 0.003
Data are presented as median (range).
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Accuracy of FABPs in diagnosing intestinal ischemia
Diagnostic accuracy of plasma and urinary FABPs is represented by the probability on intestinal
ischemia after performing the test. Posttest probabilities are determined using pretest probability
and likelihood ratios. The pretest probability on intestinal ischemia in our patient population
was 48%, because 22 of 46 patients suspected of intestinal ischemia were ultimately diagnosed
with intestinal ischemia. In the patients of whom urine was sampled the pretest probability on
intestinal ischemia was 53%, given that 10 of 19 patients were ultimately diagnosed with
ischemia. Detection of plasma I-FABP and L-FABP levels above their ideal cutoff points resulted
in an increase of disease probability to 68% (52–81) and 82% (59–93) respectively. Urinary I-
FABP, L-FABP and I-BABP levels above their determined cutoff points increased the chance
on disease to respectively 90% (58–81), 80% (53–94), and 88% (51–98). Test results below the
cutoff point, that is, negative test results, decreased the chance on disease. Negative test results
for plasma I-FABP and LFABP resulted in a likelihood of having the disease of 29% (18–45)
and 30% (21–42). Urinary I-FABP, L-FABP, and I-BABP levels below their cutoff point resulted
in a likelihood of having the disease of respectively 11% (2–45), 23% (7–51), and 28% (13–50).
Combining the described markers did not improve diagnostic accuracy because of large 
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Figure 1: No conventional marker did differ between patients with intestinal ischemia an patients with other final diagnoses 
A)Median plasma lactate levels; B) blood leukocyte count; C) base excess. Data are reported as median and range. 
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colinearity of the markers (data not shown). The clinical accuracy of all markers reflected by
posttest probability and their corresponding pretest probabilities and likelihood ratios are
depicted in Table 3.
Localizing ischemia using plasma I-BABP levels
Because I-BABP is solely expressed in the ileum, we investigated whether increased plasma 
I-BABP levels can be used as marker for ileal ischemia. Indeed, within the patient group with
intestinal ischemia median plasma I-BABP levels showed a clear trend to be increased in patients
with ileal ischemia compared with patients without ileal involvement (18.4 ng/mL (0.4–616.6)
vs. 2.9 ng/mL (0.3–51.5), P = 0.05) (Figure 4). The ideal cutoff point to discriminate patients
with ileal involvement and patients without ileal involvement was 12.2 ng/mL, with a sensitivity
of 69%, and a specificity of 83%. The pretest probability of ileal involvement in patients with
intestinal ischemia was 73%. Posttest disease probability of a positive test result was 92% (64–
99) and the likelihood of having the disease when test result was negative was 50% (31–69). The
current study could not be used to determine whether increased urinary I-BABP levels indicate
ileal ischemia, due to lack of appropriate sample size. 
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Figure 2: Plasma I-FABP and L-FABP concentrations were significantly higher in patients with intestinal ischemia (n=22)
than in patients with other final diagnoses (n=24).
A) Plasma I-FABP; B) plasma L-FABP; C) plasma I-BABP concentrations. Data are reported as median and range.
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Figure 3: Urinary I-FABP (A), L-FABP (B) and I-BABP (C) concentrations were significantly higher in patients with
intestinal ischemia (n=10) than in patients with other final diagnoses (n=9)
Data are reported as median and range.   
Table 2: Overall accuracy1 to differentiate patients with intestinal ischemia or other diagnoses.
Marker                   Cutoff point         Sensitivity    Specificity           Area under the curve   P value
                                                                                                                             (95% CI)
Plasma  I-FABP       268 pg/ml                0.68               0.71                    0.70 (0.53-0.86)            0.02
Urine    I-FABP       551 pg/ml                0.90               0.89                    0.93 (0.82-1.04)            0.001
Plasma L-FABP       78 ng/ml                0.69               0.88                    0.74 (0.59-0.88)            0.006
Urine   L-FABP       180 ng/ml                0.80               0.78                    0.88 (0.72-1.03)            0.006
Plasma I-BABP        7 ng/ml                0.64               0.63                    0.63 (0.45-0.80)            0.15
Urine   I-BABP        5 ng/ml                0.70               0.89                    0.91 (0.78-1.05)            0.003
1Area under the curve and cutoff points, defined as the maximum sum of sensitivity and specificity, using receiver
operating characteristics curves, with corresponding sensitivity and specificity of fatty acid binding proteins
(FABPs) to differentiate patients with intestinal ischemia and patients without intestinal ischemia.
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DISCUSSION
Early and correct diagnosis and treatment of intestinal ischemia is crucial to reduce mortality
(12). A high suspicion after patient history and physical examination serves as the cornerstone
to early diagnose mesenteric ischemia. However, discrepancy often exists between the signs and
symptoms during clinical examination, leading to diagnostic uncertainty. Next to the clinical
features leading to the suspicion of intestinal ischemia, also laboratory tests are used to improve
the diagnostic accuracy of intestinal ischemia. Currently used laboratory tests are mainly plasma
lactate, blood leukocyte count and base excess. In accordance with previous studies, we show
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Table 3: Likelihood ratios and pre- and posttest probabilities of FABPs
Marker Positive Negative Potential Positive test Negative test
likelihood likelihood probability posterior posterior 
ratio (95% CI) ratio (95% CI) (%) probability probability
(95% CI) (95% CI)
Plasma  I-FABP 2.34 (1..18-4.67) 0.45 (0.23-0.87) 48 68 (52-81) 29 (18-45)
Urine    I-FABP 8.18 (1.25-52.0) 0.11 (0.02-0.73) 53 90 (58-98) 11  (2-45)
Plasma L-FABP 4.92 (1.57-15.0) 0.47 (0.28-0.79) 48 82 (59-93) 30 (21-42)
Urine   L-FABP 3.64 (1.02-13.0) 0.26 (0.07-0.93) 53 80 (53-94) 23  (7-51)
Plasma I-BABP 1.70 (0.93-3.11) 0.58 (0.31-1.10) 48 61 (46-74) 35 (22-50)
Urine   I-BABP 6.31 (0.94-42.0) 0.34 (0.13-0.89) 53 88 (51-98) 28 (13-50)
CI, confidence interval
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Figure 4: Plasma I-BABP concentrations were significantly higher in patients with ileal ischemia (n=16) than in
patients with intestinal ischemia without ileal involvement (n=9)
Data are reported as median and range.
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that these 3 markers do not allow differentiation of our patients with intestinal ischemia and
patients without intestinal ischemia (7, 17). 
   It could be argued that imaging modalities can be used to improve diagnosis. However, the value
of current (radiological) investigations to diagnose intestinal ischemia is limited because of the
diversity of causes leading to intestinal ischemia (1, 8, 13). Accordingly, the need for other (plasma
and urine) markers to diagnose intestinal ischemia early remains high. Evennett et al. (7) recently
reviewed studies on serological markers for diagnosing intestinal ischemia. They concluded that
novel markers for intestinal ischemia such as D-lactate, Glutathione S-transferase (GST), and I-
FABP may offer improved diagnostic accuracy, although the number of studies evaluating novel
markers for intestinal ischemia is limited. Previous studies showed that plasma FABP levels were
able to discriminate patients with intestinal ischemia and healthy controls (11, 14).
   Because one of the diagnostic problems of intestinal ischemia is the diversity in pathophysio-
logical processes, we aimed to improve diagnosis of intestinal ischemia no matter of the origin.
Therefore, we investigated whether plasma and urinary FABP levels were able to distinguish
patients with intestinal ischemia from patients without intestinal ischemia without differentiation
in underlying pathophysiological process. 
   Plasma and urinary I-FABP and L-FABP levels and urinary I-BABP levels were significantly
higher in patients with intestinal ischemia than in patients with other final diseases. Although
measurement of plasma FABP levels was shown to increase the posttest probability on intestinal
ischemia only minimally, detection of urinary FABP levels resulted in markedly increased positive
posttest probabilities and clearly decreased negative posttest probabilities. The rapid clearance
of plasma FABPs (half-life time of 11 minutes) into urine and urinary FABP accumulation
reflecting intestinal damage over a period of time could explain the higher diagnostic accuracy
of urinary FABP levels than plasma levels of the same marker (20). Also studies investigating
the value of FABPs in diagnosing intestinal ischemia with specific underlying pathophysiology
are useful, because especially in high-risk patients with bowel obstruction due to adhesive disease,
unnecessary or delayed operation with perforation should be avoided. Cronk et al. showed that
urinary and plasma FABP are elevated in this selected patient group (3). 
   In this study, we determined optimum cutoff points for all markers described, represented by
the maximum sum of sensitivity and specificity of the marker. Instead of using an optimum
cutoff point, also cutoff points can be applied with maximum sensitivity at the expense of speci-
ficity or vice versa. Because intestinal ischemia is a severe disease with high morbidity and 
mortality, which steeply increase if operation is delayed, a diagnostic test with high sensitivity is
desirable. However, a resultant decrease in specificity can lead to unnecessary morbidity due to
a surgical procedure that may ultimately prove negative for intestinal ischemia. This taken into
account, we considered the cutoff points represented by the sum of maximum sensitivity and
specificity as best cutoff point to differentiate in patients with and without intestinal  ischemia
in a population of suspected ischemia. Furthermore, these clinical tests should be used as a sup-
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plement to patient history and physical examination, because plasma and urinary levels
above/below a predetermined cutoff point increase/decrease the likelihood of having a disease
but are not conclusive. This is especially true for levels closely approaching their cutoff point.
High plasma and urinary FABP levels at the moment of suspicion may justify early operation,
whereas low levels can be the reason for a conservative policy guided by clinical disease course,
thereby reducing the rate of unnecessary surgical interventions. 
   Tests with high diagnostic accuracy greatly contribute to a correct diagnosis of disease. The
described markers improve diagnostic accuracy markedly. To further improve diagnostic accuracy
we investigated if combining the markers yielded better test results. Unfortunately, combining the
described markers did not improve diagnostic accuracy due to large colinearity of the markers. 
   Finally, we investigated if plasma I-BABP levels could differentiate in patients with ileal
ischemia and patients with intestinal ischemia without ileal involvement. We observed a trend
to increased I-BABP levels in patients with ileal involvement. Establishing the localization of
ischemia could facilitate the operative procedure. 
In this study, samples were prospectively collected if there was a clinical suspicion of intestinal
ischemia and analyzed after completion of patient inclusion. The median time between sampling
and operation in patients with intestinal ischemia was 5 hours 44 minutes (0–42 h), indicating
that diagnosis and consequently treatment can be earlier following measurement of FABP. How-
ever, future analyses should and can be performed at the moment of suspicion of intestinal
ischemia to be of clinical use and to evaluate whether doing these tests results in better patients
outcome.
   In conclusion, plasma and urinary I-FABP and L-FABP levels and urinary I-BABP levels
were significantly increased at the moment of suspicion of intestinal ischemia in patients with
proven intestinal ischemia compared with patients with other final diagnoses. Although plasma
FABP levels only minimally increased posttest probability on intestinal ischemia, measurement
of urinary FABP levels resulted in markedly increased positive posttest probabilities and clearly
decreased negative posttest probabilities. Therefore, urinary levels of these markers can improve
early diagnosis of intestinal ischemia and can prevent a delay in surgical intervention. Further-
more, plasma I-BABP levels may help localizing ileal ischemia.
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CHAPTER 4
Polyethylene glycol versus dual sugar assay for gastrointestinal 
permeability analysis: is it time to choose?
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ABSTRACT 
Increased intestinal permeability is an important measure of disease activity and prognosis. Cur-
rently, many permeability tests are available and no consensus has been reached as to which test
is best suited. The aim of this study was to compare urinary probe excretion and accuracy of a
polyethylene glycol (PEG) assay and dual sugar assay in a double-blinded crossover study to
evaluate probe excretion and accuracy of both tests.
   Gastrointestinal (GI) permeability was measured in nine volunteers using PEG 400, PEG
1500 and PEG 3350 or lactulose-rhamnose. On four separate days, permeability was analyzed
after oral intake of placebo or indomethacin, a drug known to increase intestinal permeability.
Plasma intestinal fatty acid binding protein (I-FABP) and calprotectin were determined to verify
compromised intestinal integrity after indomethacin consumption. Urinary samples were col-
lected at baseline, hourly up to 5 hours after probe intake, and between 5-24 hours. Urinary
excretion of PEG and sugars was determined using HPLC-ELSD and LC-MS, respectively. 
I   ndomethacin intake increased plasma I-FABP and calprotectin levels, reflecting loss of intes-
tinal integrity and inflammation. In this state of indomethacin-induced GI compromise, urinary
excretion of the three PEG probes and lactulose increased compared to the placebo situation.
Urinary PEG 400 excretion, PEG 3350/PEG 400 ratio, and lactulose/rhamnose ratio could
accurately detect indomethacin-induced increases in GI permeability, especially within two hours
after probe intake. 
   In conclusion, hourly urinary excretion and diagnostic accuracy of PEG and sugar probes
show high resemblance for detection of indomethacin-induced increases in GI permeability. This
comparative study improves our knowledge of permeability analysis in man by providing a clear
overview of both tests and demonstrates equivalent performance in the current setting. 
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INTRODUCTION
Under physiological conditions, the gastrointestinal (GI) epithelium provides an effective barrier
between the internal and external environment, protecting the body from potentially harmful
luminal substances such as bacterial products, digestive enzymes and antigens (3). Loss of GI
barrier integrity is accompanied by an increase in epithelial permeability, reflecting a state in
which luminal substances can permeate the barrier and enter the systemic circulation, where
they may contribute to a systemic inflammatory response and organ dysfunction (11, 16).
Increased GI permeability plays a role in the etiology and worsening of various intestinal and
systemic diseases (1, 18, 19, 38), and is considered an important measure of disease activity and
prognosis (3).
   Analysis of GI permeability is based on the appearance of orally administered probes such as
sugars, 51Chromium-labelled EDTA (51CrEDTA), and polyethylene glycol (PEG), in the circu-
lation and urine after permeation of the intestinal epithelium. Each probe has its specific advan-
tages and disadvantages, and requires a specific method of detection (3).
Radioactive 51CrEDTA is easily detectable as it is not naturally present in man. The commonly
applied dose of 100 mCi (3.7 Mbq) 51CrEDTA is similar to the burden of other clinical nuclear
diagnostic tests, and its estimated total radiation dose of 0.12 mSv (13) is small compared to
the worldwide annual background radiation exposure of approximately 3 mSv (37). However,
51CrEDTA-based permeability tests do expose patients to additional radiation. Therefore, the
use of 51CrEDTA should be avoided in pediatric patients, women of childbearing age, and in
patients requiring multiple permeability analyses. Another concern is that the 51CrEDTA assay
is the only test that uses a single probe for permeability analysis; therefore, no correction for the
influence of individually determined factors such as intestinal transit is performed. 
   Sugars provide the opportunity to obtain site-specific information on GI permeability when
applied in a multiple-sugar test solution (3, 36). Classically, the dual sugar (DS) test is used for
intestinal permeability analysis. The DS test combines the disaccharide lactulose (MW 342 Da)
with the monosaccharide L-rhamnose (MW 164 Da). While the exact routes of permeation
remain to be clarified, macromolecules such as lactulose are commonly thought to permeate the
intestinal mucosa via the size-selective paracellular pathway, while smaller probes such as rham-
nose are considered to permeate the mucosa transcellularly as well as paracellularly (3, 15, 33).
Various other sugar probes may be added to the permeability test mix, and by exploiting the dif-
ferences in digestibility and degradation of these sugar probes, permeability assessment can be
performed on the gastroduodenal part, small intestine and large intestine (26, 27). Furthermore,
quantification of plasma sugar concentrations after intake of the sugar test solution enables detec-
tion of moderate and transient changes in GI permeability (35). The use of HPLC-MS allows
the quantification of very low sugar concentrations, but this technique is expensive and the sys-
tem is not yet standard laboratory equipment, thereby limiting the applicability of the sugar-
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based permeability analysis. In addition, sugar permeability analysis may be hampered by the
presence of food-derived sugars in urine and plasma (12, 36), stressing the importance of an
adequate analytical technique for accurate permeability analysis. 
   Another commonly used option for permeability analysis is based on the application of dif-
ferently-sized PEG probes. While the addition of PEG to some food products such as artificially
sweetened sodas (8, 14), and its occasional use in clinical practice for colonic lavage limit its
applicability (3), PEG has a number of advantages over the use of 51CrEDTA and sugars for
permeability analysis. It does not require radioactivity, is not metabolized by enzymes or
degraded by bacteria within the human GI tract (3, 9, 10), and the required method of analysis
is less expensive and time-consuming than for the other probes. Therefore, PEG probes are sug-
gested to be particularly suitable markers for whole gut permeability assessment in man. 
   The current lack of consensus for GI permeability assessment has led to many studies on intes-
tinal permeability using different probes, which making it very difficult to compare and interpret
results. Therefore, our aim was to resolve part of this diversity by comparing urinary probe excre-
tion and accuracy of a PEG-based permeability assay with the DS lactulose-rhamnose test in a
double-blinded crossover study, using the non-steroidal anti-inflammatory drug (NSAID)
indomethacin to induce a state of increased GI permeability in healthy individuals (5, 6).
MATERIALS AND METHODS
The current study was approved by the medical ethical committee of Maastricht University
Medical Center and was conducted according to the revised version of the Declaration of
Helsinki (October 2008, Seoul). The study is part of a larger project that has been registered at
the US National Library of Medicine (http://www.clinicaltrials.gov, NCT00943345). 
Participants 
Nine healthy men and women (5 men, 4 women; mean age 31.2±4.7 years; body mass index
23.9±0.9) were included in this study. Subjects were not experiencing abdominal complaints
during their normal daily activities, as assessed by a questionnaire prior to inclusion. Exclusion
criteria were recent (defined as in the past 30 days) use of any medication, history of abdominal
surgery, known hypersensitivity to NSAIDs or food products, pregnancy, alcohol or substance
abuse, and any other medical condition that could influence the experimental results (eg gas-
trointestinal diseases). Volunteers were informed about the nature and risks of the experiments.
Written consent was obtained at least 5 days before the experiments. No medication use was
permitted during the study period.
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Pre-test restrictions/arrangements 
In the 2 days prior to the experimental test days, test subjects were instructed to maintain normal
dietary patterns and to record dietary intake. In addition, subjects were instructed to avoid alco-
hol, caffeine or spicy products, and to maintain diet as recorded for the subsequent test days to
minimize the effects of variations in dietary intake. The evening before each test day, participants
received a standardized meal (1695 kJ, consisting of 62.6 g carbohydrate, 18.9 g protein and
7.9 g of fat). All participants maintained normal activities of daily living and refrained from heavy
physical activity in the 2 days prior to each test day. Subjects were kept fasted overnight, but
were allowed to drink tap water (maximum of 300 mL) in the morning.
Test mix preparation
The PEG test mix used consisted of 5.7 g PEG 400 (Chempri BV, Raamsdonksveer, the Nether-
lands), 2.5 g PEG 1500 (Chempri BV) and 13.8 g of PEG 3350 (Norgine BV, Amsterdam, the
Netherlands), dissolved in 150 mL of tap water, based on previous studies by Parlesak et al and
Kerckhoffs et al. (20, 29). All PEG used in the test mix were tested for safe oral consumption by
Basic Pharma BV (Geleen, the Netherlands). The DS mix consisted of 5 g lactulose (Centrafarm,
Etten-Leur, the Netherlands) and 0.5 g of L-rhamnose (Danisco Sweeteners, Copenhagen, Den-
mark), also dissolved in 150 mL of tap water. Both sugars were intended and tested for safe oral
human consumption by the manufacturer. 
Study design and sampling 
The current study was randomized controlled and double-blinded in set-up. All subjects com-
pleted 4 test days. On all these days, GI permeability analysis was performed, using either PEG
probes or DS probes. Subjects were tested twice using the PEG probes; once to assess perme-
ability under basal (placebo) conditions, and once to assess permeability after indomethacin.
On two other, separate test days, DS probes were used to assess basal and indomethacin-induced
permeability. The interval between test days was at least 7 days, but incidentally extended up to
a maximum of 20 days. Subjects received either placebo capsules (to test basal permeability) or
capsules with indomethacin (Actavis B.V. Baarn, the Netherlands) 75 mg at 22:00 the evening
before the test day and 50 mg at 7:30 (1 hour prior to the start of the tests) to increase GI per-
meability (6). Capsules were macroscopically identical. Both participants and executing
researchers were unaware of the content of the capsules. Participants were instructed to drink
200 mL of tap water per hour during the test. After ingestion of the probes, urinary samples
were collected at baseline and every hour, up to 5 hours after ingestion of the test mix. Urinary
volumes were recorded and 4 mL of each sample was put in a polypropylene tube (Greiner 
Bio-One, Kremsmünster, Austria) and kept on ice until centrifugation (within 30 minutes after
sampling). In addition, subjects collected 5-24 h urine at home and returned the bottles the next
morning. Urinary volume was recorded, and urine was immediately processed.
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   Baseline blood samples were collected in pre-chilled ethylenediaminetetra-acetic acid (EDTA)
tubes (BD vacucontainer, Becton Dickinson Diagnostics, Aalst, Belgium) and immediately cen-
trifuged. Both plasma and urine samples were centrifuged at 4°C at 2,300 x g for 15 minutes
and stored at -80°C until analysis.
Analysis of intestinal epithelial damage and inflammation
Intestinal epithelial cell damage was assessed by quantification of plasma concentrations of
human Intestinal Fatty Acid Binding Protein (I-FABP) using a highly specific in-house developed
enzyme linked-immunosorbent assay (ELISA) (detection window 20-5,000 pg/mL), as previ-
ously described (35).
   Inflammation was determined in the same plasma samples by analysis of calprotectin con-
centrations using a commercially available calprotectin ELISA (detection window 0.78–50
ng/mL) kindly provided by Hycult Biotechnology (Uden, the Netherlands). Both markers were
determined on all experimental days, in each first blood sample of the day (t=0). 
Analysis of permeability probes
All chemicals used for laboratory purposes were of analytical grade, and unless specified other-
wise, purchased from Sigma Aldrich (St. Louis, MO). Ultra-pure water was generated though a
Super-Q water purification system (Millipore, Billerica, MA) and used as the source of water
for all analytical assays. 
   Urinary sugar concentrations were determined by isocratic ion-exchange chromatography in
combination with mass spectrometry detection, as previously described (36).
   Urinary PEG concentrations were analyzed by reversed phase HPLC in combination with evap-
orative light scatter detection (ELSD). The analysis was based on PEG analysis described by Ker-
ckhoffs et al. (20). In short, samples were thawed to room temperature and transferred to 1.5 mL
Eppendorf cups containing 6 mg 5-sulfosalicylic acid. After thorough mixing, samples were cen-
trifuged at 50,000 x g for 10 minutes at 4°C in a high-speed centrifuge (Model Biofuge Stratos,
Heraeus, Hanau, Germany). Clear urinary supernatant was injected to the HPLC system (2 Model
PU-980 pumps, Jasco Easton, MD) using a WISP auto sampler (Model 715, Waters, Milford, MA).
Separation of PEG was achieved by reversed phase chromatography on an Allsphere ODS-2 column
(particle size of 3 mM, 150x4.6 mm ID, Grace Alltech, Deerfield, IL), mounted in a Mistral column
oven (Separations Analytical Instruments, Ambacht, the Netherlands) set to 50°C. The simplified
work-up of the urinary samples, using only high-speed centrifugation to prepare the urinary samples,
did not lead to accelerated degradation of the Allsphere column. Solvents used were water (solvent
A) and methanol/water (90/10 v/v; solvent B). The gradient of the mobile phase used for separation
of the PEG probes was: 0 min, 95% solvent A; 9 min, 95% solvent A; 10 min, 70% solvent A; 11
min, 45% solvent A; 12 min, 45% solvent A; 13 min, 20% solvent A; 14 min, 10% solvent A; 15
min, 10% solvent A; 16 min, 0% solvent A. PEG detection was performed using ELSD on a model
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2000 ES detector (Grace Alltech). Optimal signal-to-noise ratios for PEG determination were
obtained by setting the ELSD detector to a temperature of 50°C with a nitrogen gas flow of 1.5
mL/min at 5 bar and with the impactor off, while maintaining a gradient flow of 1.00 mL/min.
   PEG concentrations in samples were determined using external standard calibration. Analyt-
ical standards were prepared by dissolving analytical grade PEG 400, PEG 1500 and PEG 3350
in water, after which aliquots of this standard were stored at -80°C. Standards were run before
each set of 10 samples. PEG 400 concentration was measured by injecting 2 ml of sample into
the detector, and for optimal detection of the lower concentrated PEG 1500 and PEG 3350,
the injection volume was increased to a maximum of 100 ml. If urinary probe concentrations in
samples collected at baseline were above zero, these baseline levels were subtracted from con-
centrations measured in urinary samples collected at subsequent time points. Urinary excretions
of sugars and PEG were calculated by multiplying urinary concentrations with urine volume.
Urinary recovery of the orally ingested probe dose was calculated and expressed as percentage
of the orally ingested dose. Probe ratios were calculated from the urinary excretion values. 
   Urine spiked with PEG 400 was analyzed before and after addition of indomethacin, and urinary
samples containing indomethacin were spiked with PEG 400 to confirm our hypothesis that the
presence of indomethacin (MW 358 Da) did not interfere with PEG 400 analysis in urine. 
Statistical analysis
Statistical analysis was performed using GraphPad Prism (Version 5.00, San Diego, CA). Nor-
mality of all data was verified by the Kolmogorov-Smirnov test. Measurements of basal intestinal
permeability and permeability after indomethacin intake were compared using the Wilcoxon
signed rank test, considering the small number of study participants. For the PEG assay and the
DS permeability test, Receiver Operating Characteristics (ROC) curves were plotted to deter-
mine the cutoff points to discriminate between basal and indomethacin-induced intestinal per-
meability in our healthy participants. The ideal cutoff point, defined as the maximum sum of
sensitivity and specificity, was reported. Correlations were computed by calculating Spearman
correlation coefficients (rS), unless specifically stated otherwise. Data of 9 healthy individuals
with and without intake of indomethacin are presented as mean ± standard error of the mean
(SEM) if most data were normally distributed, or as median (range) if not. P<0.05 was consid-
ered statistically significant.
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RESULTS
PEG analysis: linearity, accuracy, and limit of detection
Linearity of PEG detection was determined by injecting a standard containing the three PEG
probes. Calibration curves were linear in a range from 0 to 200 mM. The results of linear regres-
sion analysis of the calibration curves are given in Table 1. The lower limit of quantification
observed at a signal-to-noise ratio of 5:1 was 0.63 mM for PEG 400, 0.14 mM for PEG 1500,
and 0.054 mM for PEG 3350. Coefficients of variation were calculated from 10 measurements
of urinary samples obtained from different individuals. These samples were spiked with different
PEG concentrations ranging from 0 to 100 mL, resulting in overall coefficients of variation of
3.6% for PEG 400, 2.7% for PEG 1500, and 1.2% for PEG 3350. 
Indomethacin induces loss of GI barrier integrity
To verify the putative loss of GI barrier integrity induced by indomethacin, plasma I-FABP and
calprotectin were analyzed. I-FABP levels, determined in plasma samples collected at baseline
(ie before intake of permeability probes), were significantly higher after intake of indomethacin
(443(206-1306) pg/mL) compared with placebo (336(76-885) pg/mL; P<0.01; Figure 1A),
reflecting small intestinal injury in the indomethacin-challenged situation. In line, plasma cal-
protectin levels increased after intake of indomethacin (116(28-273) ng/mL), compared with
placebo (76(26-138) ng/mL; P=0.0005; Figure 1B). While none of the volunteers experienced
GI complaints during the test days or in the week thereafter, these plasma data confirm the puta-
tive loss of small intestinal integrity and inflammation in the indomethacin-challenged situation.
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Table 1: Slope, intercept and determination coefficient (R2) of linear regression analysis of the calibration curves of PEG
400, PEG 1500 and PEG 3350
Slopea Y-intercepta X-intercept R2
PEG 400 8.761e+006 ± 489706 -95362 ± 43874 0.01088 0.9816
PEG 1500 7.846e+007 ± 3.468e+006 -743532 ± 310682 0.00948 0.9884
PEG 3350 1.955e+008 ± 1.388e+007 -1.718e+006 ± 816305 0.00879 0.9754
aData are presented as mean ± SD
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Indomethacin-induced permeability changes assessed by PEG probes
Indomethacin increases urinary PEG probe excretion
Urinary PEG 400 excretion increased significantly after indomethacin-intake compared to basal
(placebo) conditions in the 0-1h, 0-2h, and 0-5h urinary collection (Figure 2AB;  Table 2), and
a trend towards increased 0-24h PEG 400 excretion was observed (P=0.06; Figure 2A). In line
with PEG 400 data, urinary excretion of PEG 1500 increased significantly after intake of
indomethacin in the 0-2h and 0-5 urinary collection. No differences in 0-24h PEG 1500 excre-
tion were observed between placebo and the indomethacin-challenged state (Figure 2CD; Table
2). Urinary excretion of the largest probe, PEG 3350, significantly increased after indomethacin
intake only in the 0-5h urinary collection (Figure 2EF; Table 2).
   Interestingly, 2 of the 9 individuals consistently showed decreased 0-2h urinary PEG excretion
in the indomethacin-challenged state (Figure 2BDF). Decreased plasma I-FABP levels (454
pg/mL at baseline to 433 pg/mL after indomethacin intake) corroborated the decreased PEG
excretion in one of these individuals, suggesting a lack of indomethacin-induced epithelial
integrity loss. The other person had increased plasma I-FABP levels but decreased PEG probe
excretion after intake of indomethacin.
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Figure 1: Intake of indomethacin results in small intestinal cell damage and inflammation
A) Plasma I-FABP levels increase after intake of indomethacin, indicating indomethacin-induced enterocyte dam-
age. B) Plasma calprotectin levels increase after intake of indomethacin, indicating inflammation after indomethacin
ingestion. Data are median (range) of baseline plasma samples (t=0) of 9 healthy individuals. 
Different from basal (placebo) conditions (* P<0.05; ** P<0.01; *** P=0.0005).
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Figure 2: Urinary excretion of PEG probes increases after intake of indomethacin
A)Urinary PEG 400 excretion is elevated after intake of indomethacin. B) Individual 0-2h urinary PEG 400 excretion
of 9 healthy individuals in basal and indomethacin-challenged state. C) Indomethacin increases the urinary excretion
of PEG 1500. D) Individual 0-2h urinary PEG 1500 excretion of 9 healthy individuals in basal and indomethacin-
challenged state. E)Urinary excretion of PEG 3350 tends to increase after indomethacin. F) 0-2h urinary PEG 3350
excretion is increased in the majority of the volunteers. Data are mean ± SEM of 9 healthy individuals unless stated
otherwise. Different from basal (placebo) conditions (* P<0.05; ** P<0.01). In two volunteers, indicated as † and #
respectively, decreased urinary PEG excretion was observed for each individual PEG probe, while one individual had
excessively high indomethacin-induced PEG 3350 excretion in 3h and 0-5h urine and was therefore not included in
figure 2E.
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Table 2: Urinary PEG probe excretion in basal (placebo) and indomethacin-challenged state
  Basal Indomethacin P
  probe excretion (mmol) probe excretion (mmol)
  Median Range Median Range
  
PEG 400  (0-1h urine) 1,487 (108-8,260) 5,795 (1,272-9,923) < 0.05
PEG 400  (0-2h urine) 1,969 (458-11,013) 8,230 (2,908-12.942) < 0.01
PEG 400  (0-5h urine) 4,597 (2,081-12,123) 9,893 (4,180-14,808) < 0.01
PEG 1500 (0-1h urine) 3.20 (0.40-318.30) 35.90 (6.70-165.90) 0.20
PEG 1500 (0-2h urine) 11.90 (1.30-383.30) 111.00 (22.60-339.60) < 0.05
PEG 1500 (0-5h urine) 18.90 (2.80-386.50) 174.20 (35.50-366.10) 0.05
PEG 3350 (0-1h urine) 0.00 (0.00-8.60) 0.40 (0.00-9.80) 0.67
PEG 3350 (0-2h urine) 0.10 (0.00-10.30) 1.10 (0.00-11.50) 0.20
PEG 3350 (0-5h urine) 0.40 (0.00-10.30) 1.80 (0.00-104.00) < 0.05
Table 3: Overall accuracy and cutoff points of both urine-based permeability tests
                                  Urinary                Cutoff       Sensitivity     Specificity      AUCa (95% CIb)             P
                                collection                point
                                                              (mmol)
PEG 400                   0-1h                    2,288           89%           67%         0.79 (0.57-1.01)        < 0.05
                                  1-2h                    1,507           100%           67%         0.85 (0.67-1.03)         0.01
                                  0-2h                    5,226           89%            78%          0.84 (0.65-1.03)        < 0.05
                                  0-5h                    7,251           89%           78%         0.83 (0.63-1.03)        < 0.05
                                                                                                                                                                
PEG 1500                 0-1h                    5.00           100%           56%         0.74 (0.49-0.99)         0.09
                                  1-2h                    9.00           100%           67%         0.79 (0.56-1.01)        < 0.05
                                  0-2h                    20.00           100%           56%         0.77 (0.53-1.01)         0.06
                                  0-5h                    33.00           100%           67%         0.74 (0.48-1.00)         0.09
                                                                                                                                                                
PEG 3350                  0-1h                     0.05            78%           56%         0.64 (0.38-0.90)         0.31
                                  1-2h                     0.15            78%           78%         0.77 (0.53-1.00)         0.06
                                  0-2h                     0.15            89%           56%         0.74 (0.50-0.98)         0.09
                                  0-5h                     0.75            89%           78%         0.78 (0.54-1.02)      < 0.05
                                                                                                                                                                
PEG 3350/400           0-1h                   5e-005          67%           89%         0.77 (0.54-1.00)         0.05
                                  1-2h                   5e-005          78%           89%         0.79 (0.55-1.03)        < 0.05
                                  0-2h                   5e-005          78%           89%         0.80 (0.58-1.03)      < 0.05
                                  0-5h                   5e-005          89%           89%         0.85 (0.66-1.06)        0.01
                                                                                                                                                                
L/R ratio                    0-1h                     0.17            75%           100%         0.85 (0.62-1.09)        < 0.05
                                  1-2h                     0.105          78%            89%          0.86 (0.68-1.04)        < 0.05
                                  0-2h                     0.13            78%           100%         0.87 (0.69-1.07)        < 0.05
                                     0-5h                     0.18            78%           78%         0.77 (0.65-1.08)         0.08
                                                                                                                                                                   
a AUC, area under the curve
b CI, confidence interval
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Statistical analysis of the PEG excretion rates revealed that early urinary collections can be used
to detect increased permeability with acceptable sensitivity and specificity (Table 3). Alternatively,
0-5h urinary PEG excretion may be used to detect increased GI permeability after indomethacin
intake (Table 3). 
   To increase our understanding of the relation between cellular injury and increased GI per-
meability, correlations between intestinal cell integrity loss (ie plasma I-FABP levels) and
increased GI permeability (i.e. urinary PEG excretion) were studied. Normalized levels of 
I-FABP, a small 14-15 kDa protein (30) measured in plasma samples collected just before probe
intake, correlated significantly with PEG 3350 excretion (RS=0.51; P<0.05 for 0-2h urinary
excretion and RS=0.69; P<0.005 for 0-5h urinary excretion), while no correlations were found
between I-FABP and other PEG probes. Hence, urinary PEG 3350 excretion correlates with
increased I-FABP levels after indomethacin consumption, suggesting a role for enterocyte
integrity loss and subsequent release of cytosolic protein I-FABP in the development of intestinal
barrier loss reflected by increased PEG 3350 permeation. 
Indomethacin and urinary PEG probe ratios
GI permeability can be assessed either by determination of urinary probe excretion, or by cal-
culation of probe ratios (3). Expressing permeability information as the ratio of a larger probe
over a smaller probe has a couple of advantages over the use of single probe urinary excretion
rates (3). Most importantly, permeability probe ratios are less affected by individually determined
factors unrelated to GI permeability, such as renal clearance (34). Therefore, the three PEG
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Figure 3: Changes in PEG probe ratios after intake of indomethacin
A) The majority of the volunteers had an increased 0-2h urinary PEG 1500/PEG 400 ratio after indomethacin
intake. B) Indomethacin resulted in an increased urinary PEG 3350/PEG 400 ratio in most individuals. C) Indi-
vidual 0-2h urinary PEG 3350/PEG1500 ratios increased after indomethacin intake (*P<0.05).
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Figure 4: Urinary excretion of sugar probes increases after intake of indomethacin
A)Urinary excretion of lactulose tended to increase after intake of indomethacin.B) Individual 0-2h urinary lactulose
excretion of 9 healthy individuals in basal and indomethacin-challenged state. C) Rhamnose excretion decreased after
intake of indomethacin. D) 0-2h urinary rhamnose excretion of 9 healthy individuals decreased significantly in the
indomethacin-challenged state. E) Urinary L/R ratio increased after intake of indomethacin, indicating increased intes-
tinal permeability. F) Individual 0-2h urinary L/R ratios are increased after indomethacin intake. Data are mean ±
SEM of 9 healthy individuals. Different from basal (placebo) conditions (* P<0.05; ** P<0.01).
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probes were also analyzed as urinary PEG ratios. The PEG ratios determined in the 0-2h urinary
collections are displayed in Figure 3. 
   While the majority of individuals showed an increase in all three urinary PEG ratios after
indomethacin consumption (Figure 3), no significance was reached. In line with these data, uri-
nary PEG ratios did not correlate with plasma I-FABP levels. Only the PEG 3350/PEG 400
ratio increased significantly after intake of indomethacin compared to basal conditions (P≤0.05
in 0-1h, 2-3h, and 0-5h urine).
   In line with these results, statistical analysis revealed that only the urinary PEG 3350/PEG
400 ratio could accurately detect indomethacin-induced increases in GI permeability (Table 3). 
Indomethacin-induced permeability changes assessed by the DS test 
The urinary excretion of the 342 Da sugar probe lactulose increased after intake of
indomethacin, an increase that was most pronounced in the first two hours after intake of the
sugars (Figure 4AB). Urinary recovery in these first two hours was roughly 0.110±0.030% after
intake of indomethacin compared with 0.096±0.024% under basal conditions. Two individuals
had decreased lactulose excretion in the indomethacin-challenged state, but these individuals
were not the same individuals that showed decreased PEG excretion after indomethacin intake. 
   Urinary excretion of the 164 Da sugar probe rhamnose decreased after intake of
indomethacin, reaching significance in the 0-2h and 0-5h urinary collection (P<0.01 and
P<0.05, respectively; Figure 4CD). 
   0-5h urinary rhamnose excretion levels were equivalent to 8.6±0.8% and 6.4±0.5% urinary
recovery after placebo and indomethacin intake, respectively (P<0.05). Due to the increased
lactulose excretion and simultaneous decrease in rhamnose excretion, urinary ratios of the large
sugar probe lactulose and the smaller rhamnose probe increased significantly after indomethacin
intake (Figure 4EF). In keeping with the excretion profiles of lactulose and the PEG probes, this
increase was most pronounced in the first two hours after probe intake (Figure 4EF).While lac-
tulose excretion could not provide accurate sensitivity and specificity to detect indomethacin-
induced intestinal permeability as single probe, urinary L/R ratios in these first two hours could
accurately detect increased permeability in the indomethacin-challenged state (Table 3). 
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DISCUSSION
Intestinal permeability is an important parameter of gut barrier function, but the availability of
multiple permeability tests impedes the interpretation and comparison of urinary probe excre-
tion. The aim of the current study was to compare urinary probe excretion and accuracy of a
PEG assay and DS lactulose-rhamnose permeability assay in a double-blinded crossover study,
using the NSAID indomethacin to induce increased GI permeability.
   Before executing the human study, the time-consuming sample preparation protocol for analy-
sis of the PEG probes was optimized. Analysis of PEG probes in biological samples was previ-
ously described by Parlesak et al using HPLC with differential refraction index detection (29).
We enhanced the analytical sensitivity of PEG analysis using ELSD detection as described by
Kerckhoffs et al (20), while simultaneously reducing the sample preparation protocol to a single
sample centrifugation step prior to HPLC analysis. Due to this simple high-speed centrifugation
step, the time consuming extraction methods previously required to obtain satisfactory lower
limits of detection were no longer necessary (20, 29), making PEG analysis quick and easy. Sugar
analysis was performed by HPLC-MS detection, as previously described (36). The human study
was performed to analyze the application of this optimized PEG approach in a controlled, exper-
imental setting and to compare its results with data obtained using the classical DS test.
   Increased GI permeability was previously described after short-term consumption of
indomethacin (6). Since indomethacin was used in the current study as a method to increase
GI permeability, we first verified the putative loss of GI barrier integrity in our participants.
Indeed, significantly increased plasma levels of I-FABP and calprotectin were observed after
indomethacin intake, allowing the use of this setting for controlled evaluation of the PEG test
and the DS test for GI permeability analysis. 
   In this experimental setting of integrity loss, urinary excretion of PEG 400, PEG 1500, and
PEG 3350 increased after indomethacin consumption. While the absolute excretion rates of the
three different-sized PEG probes varied, the urinary excretion profiles of the PEG probes showed
high consistency. Urinary excretion of lactulose, the 342 Da sugar probe, increased in the
indomethacin-challenged situation in a similar fashion. The indomethacin-induced increases in
urinary excretion of PEG and lactulose were most pronounced in the first two hours after probe
intake. The latter suggests the presence of increased upper GI permeability after indomethacin
intake, which correlates with the established injury profile of NSAIDs, especially affecting the
upper GI tract and small intestine (17). 
   It is thought that urinary permeability ratios of two different-sized probes provide more reli-
able information on GI permeability than single probe excretion rates in case of a one-time
analysis (3). The main reason for this assumption is that urinary probe ratios are less affected by
every-day variations in urinary output due to gastric emptying, intestinal transit, et cetera (3).
In the current study, both the PEG probes and the sugar probes were expressed as urinary ratios
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and as single probe excretion rates. PEG probes are not commonly expressed as excretion ratios
(21, 22), and since the excretion of all three PEG probes increased after indomethacin con-
sumption, the increase in urinary PEG ratios was not very pronounced in this study. Only the
PEG 3350/PEG 400 ratio could detect increased GI permeability after indomethacin use with
accurate sensitivity and specificity. Compared to the PEG ratios, the urinary L/R ratio increased
more distinctly, especially in the first two hours after probe intake, due to an indomethacin-
induced increase in lactulose excretion and a simultaneous decrease in urinary rhamnose excre-
tion. The standing theory is that large (>300 Da) probes permeate the GI mucosa paracellularly,
while smaller probes such as rhamnose travel via both paracellular and transcellular routes (28).
This theory dictates that the PEG-based permeability assay provides information on the para-
cellular permeability pathway (23), while the dual sugar test assesses both the paracellular and
transcellular pathway. However, since the diffusion of water also occurs transcellularly, a hyper-
osmolar luminal content such as the 5-g lactulose dose given in the current study may affect the
permeability of the small, transcellular traveling probes by directing the water and small probe
(i.e. rhamnose) flux towards the hyperosmolar intestinal lumen (2). It remains to be clarified
whether changes in osmolarity affect the reliability of the permeability test.
   Our aim was to compare urinary probe excretion as well as the accuracy of both tests. The
main finding of this study was that the urinary excretion of the large (>300 Da) probes, the uri-
nary probe ratios, and the accuracy of the tests are very much alike. Single PEG 400 excretion,
the PEG 3350/PEG 400 ratio and the L/R ratio determined in 0-2h urine after probe intake all
provided accurate detection of indomethacin-induced increases in GI permeability. The L/R cut-
off point of 0.18 in 0-5h urine is in line with data from previous studies using the DS test after
short-term indomethacin consumption (7, 32) and prolonged indomethacin intake (24, 25, 31).
Unfortunately, no cutoff points were reported in previous studies using PEG for permeability
analysis in healthy individuals after indomethacin. Previously, Bjarnason et al. studied the intes-
tinal permeability of healthy subjects and patients with celiac disease with PEG 400, lactulose,
rhamnose, and 51CrEDTA, and found similar excretion and sensitivity rates for both the DS test
and 51CrEDTA permeability test (4). However, PEG 400 excretion was decreased in the latter
study in case of increased permeability due to celiac disease (4). We have to conclude that due
to the numerous factors that influence urinary probe excretion, cutoff points and accuracy data,
one needs to evaluate the different permeability tests in one study in order to enable a correct
comparison of test performance.
   Data of the current study improve our knowledge of permeability probe excretion by giving
a clear overview of urinary PEG and sugar probe excretion over time in a controlled, experi-
mental setting. Future studies are warranted to evaluate the applicability of the permeability
tests in clinical settings, e.g. for permeability assessment in patients with intestinal diseases such
as celiac disease. Based on the current findings, we consider that both tests may be used to assess
GI permeability, using urinary probe ratios if multiple testing is impossible such as in patients
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with active disease. Furthermore, we recommend combining GI permeability assessment with
the analysis of plasma I-FABP and calprotectin levels, providing a more thorough overview of
GI mucosal integrity. PEG analysis may provide information on whole-gut permeability, while
the dual sugar assay requires additional, inert sugars in the test mix to allow large intestinal per-
meability analysis (3). 
   In conclusion, the current study demonstrates that GI permeability tests based on the urinary
excretion of PEG and lactulose-rhamnose show equivalent performance in healthy individuals
after NSAID consumption. Since a clear demand for a standardized whole gut permeability test
continues to exist, efforts to develop the ideal permeability test should be continued.
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CHAPTER 5
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ABSTRACT
Many pathophysiological conditions are associated with increased gastrointestinal permeability,
reflecting an elevated risk of endotoxaemia, inflammation, and sepsis. Permeability tests are
increasingly used in clinical practice to obtain information on gastrointestinal functioning, but
tests are often restricted to the small intestine, and require large oral sugar doses. Therefore, a
novel multi-sugar assay was developed, allowing assessment of whole gut permeability changes
in urinary and plasma samples collected at regular intervals from 10 healthy volunteers at base-
line and after intake of monosaccharides (rhamnose and erythritol) and disaccharides (sucrose,
lactulose, and sucralose). Samples were analyzed by isocratic cation-exchange LC-MS. Sample
preparation and detection conditions were optimized. After centrifugation, chromatographic
separation was achieved on an IOA-1000 column set at 30°C. Column effluent was mixed with
ammonia for sugar adduct formation. The lower limit of detection was 0.05 mmol/L for disac-
charides and 0.1 mmol/L for monosaccharides. Linearity for each probe was between 1 to 1,000
mmol/L (R2 0.9987-0.9999). Coefficients of variation were <5% in urine, and <9% in plasma.
Recovery data were within the 90% to 110% range at all spiked concentrations. This highly sen-
sitive novel LC-MS approach resulted in a significant decrease of the detection limit for all sugar
probes, allowing a 5-fold reduction of the commonly used lactulose dose and the addition of
sugar probes to assess also gastroduodenal and colon permeability. In combination with its
extended application in plasma, these features make the novel assay a promising tool in the
assessment of site-specific changes in gastrointestinal permeability in clinical practice.
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INTRODUCTION
Many pathophysiological conditions are associated with increased gastrointestinal (GI) permeability,
including celiac disease (8), inflammatory bowel disease (10), and acute pancreatitis (3). Increased
intestinal permeability has even been reported in patients with chronic heart failure (19) and in elite
long distance runners (13), probably as a result of intestinal hypoperfusion. Increased GI permeability
is an undesirable condition that renders the host more susceptible to noxious compounds present in
the gut lumen, including microbes and their products (17), potentially leading to systemic endotox-
aemia and sepsis. Permeability analysis is considered to provide crucial information on GI function-
ing, and it is increasingly used in clinical practice and research (4). Classically, human GI permeability
is assessed by measurement of the urinary excretion of an orally administered disaccharide (usually
lactulose) and a monosaccharide (mannitol or L-rhamnose). The urinary excretion ratio of the two
sugars is considered to be a parameter of small intestinal permeability. A common technique for
determining these urinary sugars concentrations is HPLC in combination with refractive index detec-
tion (12). However, there is room for significant analytical improvement (4). Therefore, the aim of
this study was to improve the classical sugar-based permeability test on three different levels.
   First, the intake of the relatively large amount of lactulose (5 g) used in the classical sugar
test can influence GI function, probably by increasing the speed of passage through the GI sys-
tem, thereby affecting the sensitivity of the permeability analysis (5, 18, 25). The lack of sensitivity
and specificity of the existing methodology currently prevents the use of lower sugar doses.
Increasing the analytical sensitivity was therefore our key target in this study. Secondly, the
colonic degradation of the classical sugar probes restricts the usefulness of the dual sugar assay
to the small intestine. In addition, the classical dual sugar test does not allow specific analysis of
the upper part of the duodenum. The ideal assay includes additional probes to provide specific
permeability information on the upper GI tract, i.e. the stomach and duodenal bulb, and the
colon. Such an expanded sugar test mix would theoretically affect intestinal transit, if applied at
the classical dose. Hence, expansion of the sugar test composition requires a further increase in
analytical sensitivity to reduce the cumulative oral sugar dose, and requires a specific method of
detection to assess all applied sugar probes in a single analytical run. Thirdly, the dual sugar
assay is classically performed in 0-5 h urinary collections, and plasma analysis is not commonly
performed. Nevertheless, frequent plasma sampling provides advantages over urinary perme-
ability analysis, since it enables the detection of modest, transient gastrointestinal permeability
changes. Plasma analysis requires a more extensive sample preparation, and a more sensitive
analysis, since plasma sugar concentrations are low compared to urinary concentrations. There-
fore, a novel, more sensitive approach was set up, enabling the analysis of multiple sugar probes
in urine and plasma. Here, we describe this analytical method which is based on liquid chro-
matography in combination with mass spectrometry (LC-MS), and the potential advantages of
the novel multi-sugar permeability assay for application in clinical practice.
NOVEL MULTI-SUGAR PERMEABILITY ANALYSIS
81
Proefschrift laatste versie_Opmaak 1  6/10/13  10:09 AM  Pagina 81
MATERIALS AND METHODS
The study was approved by the medical ethical committee of the Maastricht University Medical
Center and conducted according to the revised version of the Declaration of Helsinki (October
2008, Seoul).
Materials
All chemicals used for laboratory purposes were of analytical grade, and unless specified other-
wise, purchased from Sigma Aldrich (St. Louis, MO). Ultra-pure water was generated through
a Super-Q water purification system (Millipore, Billerica, MA) and used as the source of water
throughout the assay. 
   The permeability test mix consisted of 1 g sucrose (342.3 Da; Van Gilse, Suiker Unie, 
Dinteloord, the Netherlands), 1 g lactulose (342.3 Da; Centrafarm B.V., Etten-Leur, the Nether-
lands), 1 g sucralose (397.6 Da; Brenntag Mülheim an der Ruhr, Germany), 1 g erythritol (122.1
Da; Danisco Sweeteners, Copenhagen, Denmark) and 0.5 g of L-rhamnose (rhamnose; 164.2
Da; Danisco Sweeteners, Copenhagen, Denmark), freshly dissolved in 150 mL of tap water. All
products used in the test mix were intended and tested for safe oral consumption. The purity of
these sugar probes was reported to be 98.0-99.9%. 
Preparation of standards
Standards were prepared by dissolving analytical grade sugars into Super-Q water to a concen-
tration of 10 mmol/L each. Next, a mixture was composed of each individual sugar to a final
concentration of 500 mmol/L and aliquots were stored at -80°C.
Sampling from healthy human volunteers
Included were 10 healthy men and women aged 18-75 years. The volunteers did not take med-
ication in the month prior to participation, and had no history of GI disease or abdominal sur-
gery. The volunteers were informed about the nature and risks of the experiments. Written con-
sent was obtained 5 days before the experiments. Subjects refrained from strenuous physical
activity and from oral intake of caffeine, alcohol, spicy foods and drinks, and any of the sugars
used in the permeability test from 2 days before, to the morning after the test day.
   Subjects were tested after an overnight fast. In short, a catheter (20 Gauge, B. Braun, Mel-
sungen, Germany) was placed in the participant’s forearm vein. Blood was collected into pre-
chilled ethylene-diamine-tetra-acetic acid tubes (Vacucontainer, Becton Dickinson, Franklin
Lakes, NJ), and kept on ice. Urine was collected by the subjects in plastic cups of 1 L, after
which urinary volume was recorded and 4 mL was directly transferred to pre-chilled polypropy-
lene tubes (Greiner Bio-One, Kremsmünster, Austria). Blood and urine samples were cen-
trifuged within one hour at 4°C at 2300 x g for 15 minutes and aliquoted. Both plasma and
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urine were immediately stored at -80°C until analysis. Following the collection of baseline plasma
and urine samples, the test subjects ingested the test mix described above. Plasma samples were
collected every 20 min and urine every hour until 5 h after intake of the test mix. Moreover, all
urine produced in the 5-24 h interval after intake was collected by the subjects in a 3 L flask,
which was returned to the laboratory the following morning and immediately processed as above. 
Sample preparation 
Due to the selectivity of the LC-MS approach, we could suffice with centrifugation of the urinary
samples. Aliquots with 500 mL of urine were thawed to room temperature, transferred to 1.5
mL Eppendorf cups, centrifuged at 50,000 x g for 10 min at 4°C in a high-speed centrifuge
(model Biofuge Stratos, Heraeus, Hanau, Germany). Clear urine supernatant (200 mL) was
transferred into a 300 mL glass insert; spring loaded in a 4 mL WISP style vial (Waters, Milford,
MA) and placed into a Peltier chilled Gilson 233 XL sample processor (Gilson, Middleton, WI). 
   Two plasma sample preparation protocols were tested to remove plasma proteins. The first
one involved the addition of sulfosalicylic acid (SSA) after which the samples were vortexed and
centrifuged. In the second protocol, 300 mL of sample was transferred to Eppendorf cups con-
taining a 3,000 Da cut-off filter (Amicon Ultra 0.5 ml 3K, Millipore) to remove the plasma pro-
teins. The filter cups were centrifuged for 30 min at 11,000 x g at 4°C, and clear plasma filtrate
(200 mL) was inserted in the Gilson sample processor as described.
Optimized LC-MS procedure
Chromatographic separation was based on isocratic elution of individual sugars probes on an
IOA-1000 9 mm cation exchange column (300 mm x 7.8 mm ID; Grace, Deerfield, IL), mounted
in a Mistral column oven (Separations, H.I. Ambacht, the Netherlands) at 30°C. An aqueous
solution of 20 mmol/L formic acid and 10 mmol/L trichloroacetic acid (TCA), was delivered
using a Model PU-1580 HPLC pump (Jasco Easton, MD) at a flow rate of 0.225 mL/min. Sam-
ples and standards were injected using a Model 233XL sample processor with Peltier chilled
sample storage compartments (10°C), equipped with a 20 mL sample loop (Gilson, Middleton,
WI). After separation, the column effluent was mixed with 30 mmol/L ammonia in 20%
methanol/water (v/v) delivered by an additional Model PU 980 pump (pump B, Figure 1) at a
flow of 0.15 mL/min to allow the formation of ammonium adducts. MS detection was performed
using a model LTQ XL (Thermo Fisher Scientific, Waltham, MA) equipped with an ion-Max
electrospray probe. The MS was operated in positive mode. Spray voltage was 4.8 kV. Sheath
and auxiliary gas were 99 and 30 units, respectively, while capillary temperature was 220°C. The
system was set to a mass range of 125-460 Da in full scan enhanced mode.
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RESULTS
Optimizing of chromatographic procedure
To obtain optimal chromatographic results, two approaches were tested. The first involved the
use of straight phase chromatography using a carbohydrate ES column (Grace) as described
before (20). As we intended to apply MS for detection, ionization of sugars was a prerequisite.
Adduct formation using sodium (11), iodine (16), formic acid (1), and ammonia (26) has been
described. In our setting, sodium rapidly blocked the ionization probe, while iodine contaminated
the ion trap considerably. Adducts formed by formic acid or ammonia showed better results,
with the latter giving a more abundant response. However, formic acid and ammonium adducts
are only generated at very low concentrations of organic solvent (acetonitrile), while high ace-
tonitrile concentrations are required for straight phase gradient elution of chromatographic sep-
aration. One way to solve this inconsistency is to apply isocratic elution of the sugars, and exploit
the differences in molecular weight to identify and quantify the sugars (26). Unfortunately, phys-
iological samples contain many endogenous isobaric sugars which have to be separated from the
exogenously applied sugar probes for their correct quantification. Consequently, we studied the
application of cation-exchange chromatography to separate the sugar probes of interest from
the endogenous isobaric sugars. From all columns tested, only the IOA-1000 9 mm column (300
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Figure 1: Schematic set-up of the detection system
Samples are delivered by pump A to the solvent stream via valve 1, which is equipped with a 20 mL sample loop.
The solvent is then directed to the cation exchange column, mounted in a thermostatic oven. After separation by
the column, the solvent goes through the detector, and is mixed with an ammonia/methanol mixture delivered by
pump B to allow formation of sugar-ammonium adducts. Finally, the solvent stream is directed to the MS system
through valve 2.
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mm x 7.8 mm ID) could sufficiently separate the sugars. Therefore, due to the required column
dimensions necessary for adequate separation, we had to sacrifice analysis time. To optimize
chromatographic separation, the influence of column temperature on the chromatograms was
determined in the range of 10 to 90°C. As expected, peak symmetry and separation of especially
the monosaccharides improved at higher temperatures. Since a temperature-dependent insta-
bility has been described for disaccharides in solutions (20), we studied whether this decay of
disaccharides also occurred on the column above 30°C. In an attempt to reduce the tempera-
ture-dependent instability, we reduced the retention times by applying a shorter IOA-2000 8
mm column (150 mm x 6.5 mm ID). Unfortunately, even though this column was filled with
smaller ion-exchange particles, it did not provide sufficient separation of the sugar probes, as
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Figure 2: Plasma deproteinization techniques and calibration curves
A)The application of SSA for deproteinization decreases signal in time due to contamination of the MS. B) Cut-
off filters provide sufficient plasma deproteinization and stable MS signal strength. C) Calibration curves of target
sugar are linear up to 1000 mmol/L. Equations and R2 are given in the text.
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was the case when the larger IOA-1000 column was used. Therefore, we continued to use the
IOA-1000 column, and the column temperature was set to 30°C. 
   To enable the analysis of plasma samples, protein had to be removed. For this purpose, two
procedures were evaluated, i.e. addition of SSA and the application of cut-off filters. Addition
of SSA resulted in a rapid decrease of the MS signal (Figure 2A), whereas the application of cut-
off filters resulted in a stable MS signal over time (Figure 2B). Therefore the latter procedure
was applied.
Next, we studied the influence of solvent-pH and solvent-anion. Application of a stronger acid
like TCA gave a lower solvent-pH, thereby improving peak symmetry and the monosaccharide
ionization response, but decreasing the disaccharide ionization response, probably due to
enhanced decomposition. Application of a weaker acid, like formic acid, enhanced the disaccha-
ride response, but strongly reduced the monosaccharide response. Therefore, we compromised
to a solvent containing 20 mmol/L formic acid and 10 mmol/L TCA, resulting in satisfactory
separation and peak symmetry for all target sugar probes (Figure 3). Accumulation of buffer
salts on the spray shield was minimized by flushing the electrospray source in-between runs with
a mixture of methanol/water (15/85 v/v), delivered by a third pump at a flow rate of 0.4 mL/min,
resulting in a stable run-to-run response for all components. Every analytical run started with
analysis of the standard from the described standard batch. If the results were similar to the pre-
vious results for the standard batch, i.e. if the variation coefficient between standard results was
less than 2%, sample analysis was initiated. After each set of 5 samples (either urinary or plasma),
a standard was injected for external standard calibration. 
Optimizing of MS signal
The formation of ammonium adducts was initiated by mixing the column effluent with a solution
of 30 mmol/L ammonia dissolved in methanol-water (20/80 v/v), delivered to the system through
a second pump that was set at a flow rate of 0.15 mL/min. The methanol concentration was cru-
cial to obtain maximal signal intensity (26). Alternative organic solvents such as acetonitrile or
isopropanol only increased the MS signal marginally. The concentration of ammonia in such
solutions was less important. An ammonia concentration of 30 mmol/L gave the best results.
The MS system was set to a high-flow situation, by infusing the sugars through a T-piece into
the combined ionization solvent-column effluent solution. Maximal signal intensity was obtained
with the following settings: sheath gas 99 (arbitrary) units, auxiliary gas 30 units, spray voltage
4.8 kV, heated capillary temperature 220°C, capillary voltage 44 V and tube lens: 100 V.
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Figure 3 (page 86): The molecular mass-based separation of sugar probes is obtained by chromatography 
A)Aqueous standard (250 mmol/L). B) Plasma sample obtained 1 h after oral intake of the sugar test mix. C)Urine
sample obtained 1 h after oral intake of the sugar test mix. For each panel, component names and mass to charge
ratios of the monitored [M+NH4]
+ ions (m/z values) are provided.
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Linearity and limit of detection
Aqueous standards of the sugar probes of interest were run individually and as well as combined
in one standard sugar solution. Combination of the sugars in one solution did not change the
individual sugar responses (data not shown). The linearity of the detection method was deter-
mined by injecting aqueous standards containing all sugars ranging from 1 to 1,000 mmol/L.
Linear regression analysis of the calibration curves revealed the following slopes, intercepts, and
correlation coefficients (R2): Sucrose: y = 28,777(338)x + 1,787(13,779) with R2 = 0.9992.
Lactulose: y = 68,418(240)x + 21,190(10,464) with R2 = 0.9999. Rhamnose: y = 49,822(745)x
+ 99,218(30,352) with R2 = 0.9987. Erythritol: y = 49,046(553)x + 65,236(22,535) with R2 =
0.9992. Sucralose: y = 33,383(310)x + 27,250(12,614) with R2 = 0.9995 (data are presented
as mean(SD); Figure 2C). The limit of detection, the concentration which generates a signal-to-
noise ratio of 3:1, was 0.05 mmol/L for the disaccharides and 0.1 mmol/L for the monosaccha-
rides.
   To investigate potential matrix interference on the slope of the calibration curves, different
concentrations of sugars were spiked to plasma and urine samples, after which samples were
analyzed. The data shown in Table 1, revealed that the slopes of the calibration curves were very
similar in different matrices. Hence, external calibration in aqueous solution can be applied
safely. Internal standard application was not applied.
Coefficient of variation and recovery
To determine the coefficient of variation, a urine and plasma sample (obtained 1 h after the oral
intake of the sugar test mix) were analyzed in an alternating fashion with a 250 mmol/L standard
in 10-fold. Coefficients of variation ranged from 2.4% for sucralose to 4.5% for rhamnose in
the standard, from 1.6% for rhamnose to 4.3% for sucrose in urine and from 1.2% for rhamnose
to 8.5% for lactulose in plasma (Table 2). Recovery data were obtained by spiking aliquots of a
plasma pool prepared from aliquots of fasted volunteers, with aqueous standards with increasing
sugar concentrations. Calculated recoveries were never below 90% or above 110%, even at the
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Table 1: Comparison of calibration curve equations of sugar permeability probes spiked in water, plasma and urine*
      
    Aqueous Plasma Urine
Sucrose y =(2.9 x 104) x + 1.8 x 103 y =(2.9 x 104) x + 2.5 x 105 y =(2.8 x 104) x + 2.5 x 105
Lactulose y =(6.8 x 104) x + 2.1 x 104 y =(7.0 x 104) x + 6.4 x 103 y =(6.8 x 104) x + 1.5 x 104
Rhamnose y =(5.0 x 104) x + 9.9 x 104 y =(5.2 x 104) x + 2.0 x 106 y =(5.2 x 104) x + 2.0 x 106
Sucralose y =(3.3 x 104) x + 2.7 x 104 y =(3.0 x 104) x + 2.9 x 104 y =(3.1 x 104) x + 3.7 x 104
Erythritol y =(4.9 x 104) x + 6.5 x 104 y =(5.2 x 104) x + 3.9 x 105 y =(5.1 x 104) x + 5.0 x 107
*Plasma and urine were obtained from 10 fasted, healthy volunteers. Samples were pooled, and spiked with 
the sugar probes.
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lowest spiked concentration (Table 3). In fact, 67% of the measurements showed a recovery
between 95% and 105%. To investigate the intra-assay accuracy, aliquots of plasma and urine
specimens collected after 1h intervals after ingestion of the test mix by a healthy volunteer were
measured in 6-fold. The results were plotted in time (Figure 4). Both standards and samples
were stored at 4˚C during the analytical process, and a stable response was observed for at least
24 hours at this temperature. 
Background sugar concentrations in plasma and urine
The optimized chromatography enabled the separation of all sugar probes. In addition, a number
of components were found in both urine and plasma samples, with molecular masses similar to
the target sugars. While most of these components eluted from the column at different time
points, some of the components had elution times close to our sugar probes, thereby interfering
with the quantification of the sugar probes. Most components could be identified by injecting a
range of sugar components in the chromatographic column and comparing the chromatograms
of these sugars with the chromatograms of the interfering components (Figure 3B and C).
   In addition, we observed baseline sugar concentrations both in plasma and urine samples of
individuals who had been deprived from food and drinks for 10 h. To investigate the relevance
of these baseline levels in relation to the increase in concentration caused by oral intake of the
test mix, we determined inter-individual and intra-individual differences in 10 volunteers, meas-
ured at 4 different days (Supplementary tables). No plasma baseline concentrations of the 
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Table 2:  Coefficient of variation (CV) of sugar concentration measurements in aqueous 
standard, urine*, and plasma* 
Sucrose Lactulose Rhamnose Sucralose Erythritol
                           Conc.      CV          Conc.     CV          Conc.     CV          Conc.     CV          Conc.      CV
                          (mmol/L) (%)        (mmol/L) (%)        (mmol/L) (%)        (mmol/L) (%)        (mmol/L) (%)
                           
Standard          250        3.1          250         2.5          250      4.5          250        2.4          250      4.4
Urine               28.2        4.3          6.5          3.2          234.4     1.6          25.7        2.6          4199      3.8
Plasma             0.30        5.0          0.26       8.5          102.1      1.2          0.24       3.0          117.7      2.7
Table 3: Recovery of sugar permeability probes in spiked plasma*
Spike (mmol/L) Sucrose Lactulose Rhamnose Sucralose Erythritol
1.0                              90.1                   90.1                   107.2                  93.9 97.1
2.5                              97.0                   97.0                   107.8                  94.0 100.8
10.0                             103.9                  103.9                  106.3                  90.7 101.2
25.0                             101.6                  101.6                  102.0                  93.2 105.0
50.0                             100.4                  100.4                  99.9                   90.6 105.3
100.0                             99.1                   99.1                   104.9                  91.8 105.3
*Plasma was obtained from 10 fasted, healthy volunteers. Plasma was pooled, and spiked with the sugar
probes. Recovery (%) is presented.
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disaccharides lactulose and sucralose were found, while we did observe baseline concentrations
of monosaccharide rhamnose in plasma. These concentrations nearly doubled 1 h after intake
of the test mix. In urine, baseline levels ranged from undetectable for lactulose to 724 mmol/L
for erythritol (Supplementary Table 1). However, these high baseline concentration for erythritol
was low compared to the 21,867 mmol/L measured on average 1 h after intake of the test mix
(data not shown). Therefore, the reported baseline erythritol levels did not interfere with the
erythritol measurements necessary for colon permeability assessment (Figure 4).
DISCUSSION 
Various intestinal and systemic diseases are associated with increased GI permeability. Perme-
ability analysis can help to clarify its role in disease. Moreover, for evaluation of interventions
directed at preventing increased GI permeability or ameliorating the integrity of the GI epithe-
lium, a sensitive analysis of GI permeability is essential. To improve GI permeability analysis, we
developed a new method to measure multiple permeability sugar probes in both plasma and urine.
   The new method had to meet three goals: (a) increase the analytical sensitivity, allowing
smaller quantities of the sugar probes to be used, (b) measure the classical and additional sugar
probes simultaneously in one run, enabling permeability assessment of the stomach, and the
small and large intestine, and (c) allow the analysis of the applied sugar probes in both urine
and plasma. 
   Increased analytical sensitivity was obtained by combining isocratic cation-exchange chro-
matography in combination with MS. Adduct formation, necessary for MS detection, was stud-
ied using ammonia and formic acid. Sugar adduct synthesis was much more abundant after
addition of ammonia, and therefore sugar-ammonium adducts were analyzed with MS. This
approach allowed quantification of all sugar probes of interest in both urine and plasma in one
run, with a detection limit of 0.05 mmol/L for disaccharides and 0.10 mmol/L for monosaccha-
rides. These lower limits of detection are significantly lower than previously reported (7, 22),
including a recent report of Camilleri et al. who found detection limits of 4.98 mmol/L (1.7
mg/mL) for disaccharide lactulose and 1.92 mmol/L (0.035 mg/mL) for monosaccharide mannitol
using normal phase LC-MS for permeability analysis in urine (7). 
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Figure 4 (page 90): Amount and intra-assay variation of sugar permeability probes over time in urine and plasma
after oral intake of the probes
Amount and intra-assay variation of sugar permeability probes over time in urine and plasma after oral intake of
the probes. Amount of sugar probes in urine over time, given as mean and standard deviation (bold lines). In a
majority of cases, the standard deviation is too small to indicate. Dotted lines indicate the intra-assay coefficient of
variation (CV) from a 6-fold measurement. Urinary excretion of sucrose (A), lactulose (B), rhamnose (C), sucralose
(D) and erythritol (E). Plasma concentration of sucrose (F), lactulose (G), rhamnose (H), sucralose (I) and erythritol
(J).
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   In our study, the increased analytic sensitivity allowed a 5-fold reduction of the oral lactulose
dose. The latter made it possible to complement the original dual sugar test mix with additional
sugar probes, enabling the assessment of the small and large intestine in one analytical run, with
a lower total oral sugar load. Additional sugar probes were selected to assess gastroduodenal
(sucrose) and colon permeability (sucralose and erythritol), in addition to small intestinal per-
meability (lactulose and rhamnose). The disaccharide sucrose is considered a marker of gastro-
duodenal permeability, since it is short-lived in the upper part of the duodenum due to hydrolysis
by sucrose (24). The disaccharide sucralose and the sugar alcohol erythritol are not degraded
by human colonic bacteria (2, 14) allowing their use as markers of colonic and total GI perme-
ability. Alternatively, assessment of samples (either urine or plasma) collected more frequently
than the classical 0-5h urinary collection, might reflect permeability of specific parts of the gas-
trointestinal tract (7). Considering that sugar probes first appear in plasma after permeation
through the mucosal epithelium, we aimed to perform plasma-based permeability analysis next
to the classical urinary approach. Analysis of plasma samples provided additional analytical chal-
lenges. In urine, the ingested sugar probes accumulate, resulting in high urinary sugar concen-
trations compared to plasma. Another important difference between urine and plasma is the
necessity to remove plasma proteins. While at all times, sample preparation was kept as simple
as possible to avoid prolongation of the turn-around time, it was necessary to remove these
plasma proteins that would otherwise clog the chromatographic column. Whereas conventional
plasma deproteinization with SSA resulted in a decrease of the MS signal over time due to con-
tamination of the MS, the application of 3,000 Da cut-off filters proved to be a good and fast
alternative. Analysis of frequently sampled plasma samples allows the detection of short-lived
changes in GI permeability. Furthermore, combined urinary and plasma analysis might help in
the clinical interpretation and understanding of increased or decreased transepithelial permeation
of probes.
   Analysis of baseline plasma samples revealed MS signals at the m/z values of rhamnose and
erythritol, strongly suggesting the presence of these monosaccharides in plasma of individuals
who had been deprived from food and drinks for 10h. Such baseline concentrations of sugars
and sugar alcohols have been reported in serum and plasma of fasted individuals (6, 9, 15).
These results suggest that monosaccharides may be present in the daily human diet. Small
amounts of erythritol have been found in some fruits and red wine for example (23), mannitol
can be found in seaweed and other plants (21), and rhamnose naturally occurs in bound form
in a variety of plants. Since baseline concentrations of these monosaccharides increased sub-
stantially after intake of the probes, these baseline concentrations did not interfere with perme-
ability analysis. Nevertheless, we propose to always collect a baseline sample of each test subject,
so that baseline endogenous sugar concentrations can be subtracted from the measured con-
centrations, thereby giving an accurate reflection of the increase in sugar levels after oral intake
of the sugar test mix. The presence of the baseline sugar concentrations implies that a further
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reduction of the oral sugar dose would compromise correct measurement of raised plasma con-
centrations after intake of the sugar test mix, even though the high analytical sensitivity of the
current assay would allow such a reduction. In urine, baseline sugar concentrations did not inter-
fere with the analysis of the sugar permeability probes. Analysis of both plasma and urine revealed
the presence of components with identical molecular masses as the target sugars. While most of
these products had other retention times than the sugar probes of interest, some components
for instance co-eluted with the sucrose peak, thereby hampering accurate measurement of
sucrose at the applied oral dose of 1 g. We assume that the application of more sucrose in the
test drink would increase the sucrose levels after intake to a higher level, thereby reducing the
interfering effect of other components. However, a larger sucrose dose would also increase the
osmolarity of our test drink, and since our aim was to improve the sensitivity of the permeability
analysis without affecting the GI mucosa through a sugar overload, we chose not to increase the
amount of sucrose in our test drink.
   The newly developed assay enables the detection of small changes in sugar concentrations in
both urine and plasma, allowing accurate assessment of small and large intestinal permeability.
The lactulose/rhamnose (L/R) ratio is used as a parameter of small intestinal permeability, while
the sucralose/erythritol (S/E) ratio determined in 24 h urinary collections reflects total GI per-
meability. Moreover, the combination of the L/R and S/E ratio might enable specific assessment
of colon permeability. Further study is necessary to determine the most suitable time frames to
collect urine and plasma samples for the assessment of site-specific gastrointestinal permeability.
Furthermore, we are performing validation studies to evaluate the usefulness of our novel
approach to assess changes in GI permeability in healthy individuals with and without an oral
challenge with indomethacin, after which we plan to conduct further studies to test the applica-
bility of the test in clinical practice. Especially for application in clinical practice, timing of sam-
pling is important to obtain accurate and site-specific information.
   In conclusion, we developed a novel analytical approach, based on isocratic cation-exchange
LC-MS. This technique enables highly sensitive detection of sugar probes allowing a 5-fold
reduction of the oral lactulose dose, and the addition of probes to assess site-specific changes in
GI permeability. This assay, applicable to urine and plasma samples, may prove useful in clinical
practice for screening, prognosis estimation, and treatment decisions in conditions with sus-
pected gut dysfunction. 
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Supplementary Table 1: Baseline concentrations of sugars in urine* after overnight fast.
Individual Sucrose Lactulose Rhamnose Sucralose Erythritol 
    (mmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L)
Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM)
1 77.1 (24.7) 0.7 (0.7) 46.5 (4.7) 0.6 (0.6) 415.7 (62.0)
2 86.4 (25.2) 0.7 (0.7) 265.6 (109.5) 0.0 (0.0) 1,041.4 (247.1)
3 109.3 (34.8) 0.0 (0.0) 87.3 (18.4) 0.0 (0.0) 580.2 (105.8)
4 21.6 (4.3) 0.0 (0.0) 28.6 (10.9) 1.3 (0.7) 416.1 (159.5)
5 75.6 (22.0) 1.3 (0.8) 141.3 (45.1) 0.0 (0.0) 987.7 (197.0)
6 51.1 (4.7) 0.2 (0.2) 55.5 (20.6) 21.1 (20.4) 1,004.3 (227.5)
7 68.6 (44.8) 0.7 (0.7) 62.0 (13.5) 42.9 (33.4) 958.8 (636.1)
8 15.1 (4.0) 0.2 (0.2) 70.6 (2.4) 3.9 (3.9) 1,063.5 (136.0)
9 50.0 (20.2) 1.2 (0.8) 93.4 (57.5) 0.0 (0.0) 221.1 (47.4)
10 61.4 (33.8) 0.0 (0.0) 35.0 (13.0) 0.0 (0.0) 555.0 (297.2)
Total 61.6 (9.1) 0.5 (0.2) 88.6 (22.2) 7.0 (4.5) 724.4 (100.6)
*Urine was obtained from 10 fasted, healthy volunteers at 4 different test days. Sugar concentrations are 
measured in these samples and depicted as mean with standard error of mean (SEM).
Supplementary Table 2: Baseline concentrations of sugars in plasma* after overnight fast.
Individual Sucrose Lactulose Rhamnose Sucralose Erythritol 
    (mmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L)
Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM)
1 2.9 (1.1) 0.1 (0.1) 42.7 (7.0) 0.1 (0.1) 13.2 (3.3)
2 2.9 (1.2) 0.1 (0.1) 51.4 (8.8) 0.1 (0.1) 7.9 (0.5)
3 1.5 (0.4) 0.0 (0.0) 75.2 (6.1) 0.0 (0.0) 4.9 (0.5)
4 8.7 (7.1) 0.1 (0.1) 56.9 (4.6) 0.1 (0.1) 13.4 (2.0)
5 1.0 (0.4) 0.0 (0.0) 51.4 (7.4) 0.0 (0.0) 5.1 (1.2)
6 2.1 (0.3) 0.0 (0.0) 70.7 (10.4) 0.3 (0.2) 10.4 (2.7)
7 5.9 (3.7) 0.0 (0.0) 84.4 (15.9) 0.0 (0.0) 6.2 (0.9)
8 1.4 (0.1) 0.0 (0.0) 95.6 (9.5) 0.1 (0.1) 6.8 (1.5)
9 3.8 (0.9) 0.0 (0.0) 63.7 (8.4) 0.0 (0.0) 8.4 (1.3)
10 0.9 (0.1) 0.0 (0.0) 47.6 (4.9) 0.0 (0.0) 7.4 (0.4)
Total 3.1 (0.78) 0.0 (0.0) 63.9 (5.5) 0.1 (0.0) 8.4 (1.0)
*Plasma was obtained from 10 fasted, healthy volunteers at 4 different test days. Sugar concentrations are
measured in these samples and depicted as mean with standard error of mean (SEM).
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CHAPTER 6
Novel multi-sugar assay for site-specific gastrointestinal 
permeability analysis: a randomized controlled crossover trial
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ABSTRACT 
Increased gastrointestinal (GI) permeability is an important hallmark of many conditions, poten-
tially leading to antigen exposure and sepsis. Current permeability tests are hampered by ana-
lytical limitations. This study aims to compare the accuracy of our multi-sugar (MS) and the
classical dual sugar (DS) test for detection of increased GI permeability.
   Ten volunteers received permeability analysis using MS (1 g sucrose, lactulose, sucralose, 
erythritol, 0.5 g rhamnose in water) or DS (5 g lactulose, 0.5 g rhamnose), after indomethacin
or placebo. Blood and urine were analyzed by isocratic LC-MS.
   MS testing revealed significantly elevated urinary lactulose/rhamnose (L/R) ratios after
indomethacin, due to enhanced lactulose excretion (P<0.01) and unaltered rhamnose excretion.
The DS test showed increased L/R ratios, due to increased lactulose excretion and decreased
rhamnose excretion (both P<0.05). After indomethacin, plasma L/R increased in both assays
(P<0.05 and P<0.01). Urinary and plasma L/R ratios correlated significantly. Indomethacin
increased sucrose excretion and 0-1h sucrose/rhamnose. Colon permeability was unchanged. 
   In conclusion, sensitive permeability analysis is feasible in plasma and urine using MS or DS
test. In contrast to the DS test, monosaccharide excretion is not decreased by the MS test. In
short, the MS test provides accurate, site-specific information on gastroduodenal, small, and
large intestinal permeability.
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INTRODUCTION
Proper gastrointestinal (GI) functioning is crucial for absorption of nutrients, a process facilitated
by the extended absorptive area of the GI system. However, its large absorptive area complicates
the other main function of the intestine, which is to preserve an effective barrier between internal
and external environment. When epithelial integrity is compromised, GI permeability increases,
rendering the host more susceptible for potentially harmful elements, such as digestive juices
and microbial products (5, 28).  Increased permeability may initiate pathogenic processes of
various intestinal and systemic disorders, and contribute to the development of complications
in surgical patients and patients in the ICU (5, 16, 23). Therefore, accurate assessment of gut
permeability is of great importance (5).
   Most techniques to assess human gut permeability rely on the urinary excretion of orally
administered test probes. Classically, a disaccharide (usually lactulose) and monosaccharide
(mannitol or L-rhamnose) are administered together, and appear in blood and urine after per-
meating the epithelial barrier (26). The calculated urinary excretion ratio of these probes reflects
small intestinal permeability (5, 26). We recently developed a detection method that yielded a
detection limit of 0.05 mmol/L for disaccharides and 0.10 mmol/L for monosaccharides (36, 37),
which meant a significant improvement with respect to previous studies reporting limits of 5-30
mmol/L for disaccharide lactulose and 2-5 mmol/L for monosaccharide mannitol. This lowering
of the detection limit enabled a 5-fold reduction of the oral lactulose load and allowed concomi-
tant expansion with probes to assess gastroduodenal and colonic permeability simultaneously
with small permeability assessment. 
   The current randomized, controlled, crossover trial was performed to validate the novel site-
specific MS permeability test in healthy volunteers, challenged with the non-steroidal anti-
inflammatory drug (NSAID) indomethacin to increase GI permeability (6, 7, 30, 31). 
MATERIALS AND METHODS
This study was approved by the medical ethical committee of Maastricht University 
Medical Center and conducted in Maastricht, according to the Declaration of Helsinki (revised
version, October 2008, Seoul). The study is registered at US National Library of Medicine
(http://www.clinicaltrials.gov, NCT00943345). 
Materials
The MS mix consisted of 1 g sucrose (Van Gilse, Dinteloord, the Netherlands), 1 g lactulose
(Centrafarm, Etten-Leur, the Netherlands), 1 g sucralose (Brenntag, Sittard, the Netherlands),
1 g erythritol (Danisco Sweeteners, Copenhagen, Denmark) and 0.5 g of L-rhamnose (Danisco),
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dissolved in 150mL of tap water. The DS mix consisted of 5 g lactulose and 0.5 g L-rhamnose.
All products were intended and tested for safe oral human consumption by Basic Pharma
(Geleen, the Netherlands). The sugar probes were 95.0-99.9% pure, and were calibrated against
analytical grade products for concentration analysis in plasma and urine.
Participants 
Healthy men and women, aged 18-70 years, were selected. Sample size was determined using
PS Power and Sample Size Calculations, based on a previous study using indomethacin to
increase GI permeability (14). A power calculation showed that a sample size of 10 individuals
was required to achieve 80% power for detection of a statistically significant effect size of 2.5
(standard deviation of 2.5) with an a-error of 0.05. Exclusion criteria were reported abdominal
complaints assessed by questionnaire prior to inclusion, recent use of medication, history of GI
surgery, family history of inflammatory bowel disease, hypersensitivity to NSAID or food prod-
ucts, pregnancy, alcohol or substance misuse, and any other medical condition that could influ-
ence the experimental results. Volunteers were informed about the nature and risks of the exper-
iments. Written consent was obtained 5 days before the experiments. Use of medication other
than indomethacin was prohibited during the study period.
Pre-test restrictions 
Test subjects were instructed to maintain normal activities of daily living and normal dietary
patterns, to record dietary intake, starting 2 days prior the experiments, and to avoid intake of
sugars that were part of the MS mix and alcohol, caffeine or spicy products. Participants received
a standardized evening meal (1695 kJ, consisting of 62.6 g carbohydrate, 18.9g protein and 7.9
g fat) and thereafter fasted overnight. Subjects were allowed to drink water (maximum 200mL
per hour).
Study design 
The study is randomized placebo-controlled and double-blinded in set-up. The random alloca-
tion sequence was established by computer-generated simple randomization. For the random-
ization process, numbers were assigned to each test situation. All subjects completed 4 days to
test basal and indomethacin-induced GI permeability with both tests. Interval between test days
was at least 7 days. Study design is depicted in Supplementary Figure 1. Subjects ingested placebo
capsules (basal permeability) or indomethacin-filled capsules (Actavis, Baarn, the Netherlands)
75 mg at 22:00 P.M. the day before the test and 50mg at 7:30 A.M. on the test day. Capsules
were macroscopically identical. Subjects were tested in fasted state. During the experiments,
subjects drank 150-200 mL water or tea without additives per hour to maintain sufficient urinary
output for hourly urinary collection. After completion of the 5h urinary collection, subjects were
given a standardized meal consisting of sandwiches and tea. Following this delayed breakfast,
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subjects were allowed to go home and eat and drink as preferred, with the exception of sugars
included in the test mix, alcohol, caffeine and spicy products. After completion of the 24h urinary
collection the next morning, subjects were allowed to eat and drink without restrictions. Urine
and blood were collected and stored as previously described (36). 
Analysis of intestinal damage and inflammation
To assess intestinal damage and inflammation caused by indomethacin, plasma concentrations
of human Intestinal Fatty Acid Binding Protein (I-FABP) and calprotectin were determined,
respectively, by ELISA, as previously described (36). Both these secondary outcome measures
were determined on all experimental days, in each first blood sample of the day (t=0). 
Permeability analysis 
Primary outcome measures were urinary sugar excretion rates and sugar permeability ratios for
GI permeability assessment. Isocratic ion-exchange HPLC (Model PU-1980 pump, Jasco Eas-
ton, MD) with mass spectrometry (Model LTQ XL, Thermo Fisher Scientific, Waltham, MA)
was used to determine sugar concentrations in plasma and urine as previously described (37).
The following formulas were used:
Urinary sugar excretion = (urine sugar concentration - baseline urine sugar concentration)
x urine volume 
Sugar recovery (in %) = urinary sugar excretion / orally ingested sugar dose x 100 
Sugar permeability ratio = sugar excretion (urine) or sugar concentration (plasma) of large
probe / sugar excretion or concentration of smaller sugar probe
Sucrose in the MS mix was used for gastroduodenal permeability assessment (25, 32). Since
this disaccharide is rapidly hydrolyzed by sucrase in the duodenum (9), it is considered specific
for the upper GI tract. Lactulose and monosaccharide rhamnose, and the lactulose/rhamnose
(L/R) ratio were used for small intestinal permeability assessment as usual. Since lactulose and
rhamnose are degraded in the human colon, two non-degradable probes, sucralose (12, 24) and
erythritol (15) were used to assess colonic permeability, by calculation of the sucralose/erythritol
(S/E) ratio in 5-24h urine. 
Statistical analysis
Statistical analysis was performed using GraphPad Prism (Version 5.00, San Diego, CA). Nor-
mality of data was verified by Kolmogorov-Smirnov test. One outlier identified using Grubbs
analysis, was excluded from statistical analysis for plasma calprotectin analysis. Area under the
curve (AUC) was determined for L/R ratios and sugar concentrations. Measurements of basal
intestinal permeability and indomethacin-induced permeability were compared using Wilcoxon
signed rank test. Receiver Operating Characteristics (ROC) curves were plotted to determine
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cutoff points discriminating between basal and indomethacin-induced permeability. Best cutoff
points, defined as the maximum sum of sensitivity and specificity, were reported. Correlations
were computed by calculating Spearman correlation coefficients (RS). Data are presented as
mean ± standard error of the mean (SEM) if normally distributed, or as median (range) of 10
healthy individuals with and without intake of indomethacin. P<0.05 was considered statistically
significant. 
RESULTS
Participant characteristics 
Ten healthy volunteers (5 men, 5 women; mean age 35.2±5.9 years) were included in this study
and each volunteer performed 4 test days. Baseline characteristics of all participants are shown
in Table 1. No GI complaints were experienced during test days or day thereafter. 
Table 1: Baseline characteristics of healthy participants 
Characteristics
Group size (no. of volunteers) 10
Sex (male : female) 5 : 5
Age (years) 35.2 ± 5.9
Height (cm) 173 ± 3.7
Weight (kg) 76.2 ± 3.8
Body Mass Index (kg/m²) 25.5 ± 1.1
Indomethacin-induced intestinal damage and inflammation
Plasma I-FABP levels were significantly higher after intake of indomethacin (818 (321-2578)
pg/ml), compared to placebo (509 (233-1272) pg/mL; P<0.001; Figure 1A). Indomethacin-
induced inflammation, determined by plasma calprotectin, was also increased after indomethacin
(121 (25-273) ng/mL) compared to placebo (103 (19-176) ng/mL; P<0.01; Figure 1B). While
both I-FABP and calprotectin levels varied among the test subjects (Figure 1A and 1B), the intra-
individual values were consistent. Only one subject showed an apparent decrease in plasma cal-
protectin level after intake of indomethacin; such a decrease was not observed for plasma 
I-FABP levels. The indomethacin-induced damage and inflammation correlated significantly
(RS=0.46; P<0.01; n=10). 
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Changes in small intestinal permeability assessed in urine
Indomethacin significantly increased small intestinal permeability, reflected by increased urinary
L/R ratios in both permeability tests (Figure 2). Using the MS test, indomethacin resulted in a
0-5h L/R ratio of 0.060±0.011 compared to the baseline L/R ratio of 0.026±0.004 (P<0.05;
Figure 2A). The 0-5h L/R ratio measured with the DS test was 0.262±0.034 after indomethacin,
compared to 0.129±0.014 at baseline (P<0.05; Figure 2B). 
   Since it was suggested that lactulose influences rhamnose excretion (17, 35), we compared
absolute urinary excretion of lactulose and rhamnose. Lactulose excretion increased in both tests
after intake of indomethacin, but was more pronounced when the MS test was used, showing
an increase in the 0-1h, 1-2h, and 0-5h urinary collections (all P<0.01; Figure 2C). 0-5h urinary
lactulose excretion was 15.2±2.1 mmol versus 7.5±1.3 mmol at baseline. Lactulose excretion
using the DS test increased only in 0-5h (44.7±8.3 mmol versus 32.7±5.7 mmol at baseline;
P<0.05; Figure 2D). Interestingly, rhamnose in 0-5h urine decreased considerably in this test
after indomethacin (255±26 mmol versus 185±15 mmol; P<0.05; Figure 2F), while an opposite
observation was done using the MS test (305±45 mmol at baseline versus 404±88 mmol after
indomethacin; Figure 2E). 
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Figure 1: Indomethacin results in small intestinal cell damage and inflammation
A) Plasma I-FABP levels are increased after intake of indomethacin, indicating indomethacin-induced enterocyte
damage. B) Plasma calprotectin levels are increased after intake of indomethacin, indicating the presence of
indomethacin-induced inflammation. One outlier with a very high plasma calprotectin level (972 ng/ml) after
indomethacin on the MS test day was excluded. (*P<0.05, **P<0.01, ***P<0.001 compared to basal).
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Both tests were evaluated for accuracy to discriminate between basal permeability and experi-
mentally increased permeability. The MS test had a sensitivity and specificity of 100% in the 
0-1h collection, compared to 90 and 89%, respectively, with the DS test (Table 2). Both perme-
ability tests could discriminate indomethacin-induced permeability from basal permeability in
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Figure 2: Urinary L/R ratios and excretion rates increase after intake of indomethacin
A) MS test: Indomethacin elevates urinary L/R ratios. B) DS test: Urinary L/R ratios are increased after intake of
indomethacin.. Indomethacin increases urinary lactulose excretion, measured by the MS (C) and DS (D) test. 
E) Urinary excretion of rhamnose is not significantly increased after indomethacin challenge when measured with
the MS test. F) Indomethacin decreases urinary rhamnose excretion when the DS test is used for small intestinal
permeability analysis. (*P<.05, **P<.01 compared to basal).
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0-2h. However, while accuracy of the MS test was still acceptable in 0-5h urine (AUC 0.83,
P=0.01), the DS test was insufficient (AUC 0.62, P=0.38). Urinary recoveries of all applied sugar
probes, analyzed by the MS and DS test, are depicted in the Supplementary file as Figure 2.
Changes in small intestinal permeability assessed in plasma
In line with urine, plasma L/R ratios increased in both tests after indomethacin (Figure 3AB).
1h after intake of the test mix, plasma L/R ratios were higher after indomethacin challenge (Fig-
ure 3CD). Interestingly, these ratios determined in 1h plasma samples correlated significantly
with plasma I-FABP levels determined at baseline  (RS=0.53; P<0.05 for low-dose lactulose test
and RS=0.58; P<0.01 for the high-dose test; Supplementary Figure 3AB). Furthermore, plasma
L/R ratios also correlated significantly with urinary L/R ratios determined in both tests (RS=0.69;
P<0.001 for MS and RS=0.59; P<0.01 for DS; Supplementary Figure 3CD), emphasizing the
validity of the novel detection method. Both assays could differentiate increased permeability
from basal permeability by evaluation of the 1h plasma L/R ratio, albeit the DS test did slightly
better than the MS test (Table 2). In the following hours, increases in plasma L/R were less pro-
nounced using the latter, while the high-dose test showed elevated L/R ratios also at later time
points (data not shown). 
   Plasma sugar concentrations of both tests were studied to find out the origin of the increased
plasma L/R ratios. For both assays, significant increases in plasma lactulose concentration were
observed in 0-5h (P<0.05 and P=0.01). Plasma rhamnose levels did not change after
indomethacin when the MS test was used, while lower plasma rhamnose concentrations after
indomethacin were found using the DS test (data not shown).
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Table 2: Overall accuracy and cutoff points of both urine-based permeability tests
    Cutoff Sensitivity Specificity AUC1 P
    point (95% CI2)
    
L/R in MS test (0-1h urine) 0.0305 100% 100% 1.00 (1.00-1.00) < 0.001
L/R in DS test (0-1h urine) 0.1140 90% 89% 0.97 (0.90-1.04) < 0.001
L/R in MS test (0-2h urine) 0.0210 90% 90% 0.88 (0.71-1.06) < 0.01
L/R in DS test (0-2h urine) 0.1015 100% 90% 0.98 (0.96-1.02) < 0.001
L/R in MS test (0-5h urine) 0.0450 67% 100% 0.83 (0.63-1.04) 0.01
L/R in DS test (0-5h urine) 0.2510 70% 60% 0.62 (0.35-0.88) 0.38
L/R in MS test (0-1h plasma) 0.045 90% 70% 0.80 (0.58-1.02) <0.05
L/R in DS test (0-1h plasma) 0.260 80% 100% 0.86 (0.66-1.00) <0.01
L/R in MS test (0-5h plasma) 0.0075 41% 79% 0.57 (0.50-0.60) <0.05
L/R in DS test (0-5h plasma) 0.0315 57% 96% 0.85 (0.81-0.89) <0.001
Sucrose (0-1h urine) 1.125 90% 50% 0.66 (0.41-0.91) 0.23
Sucrose (0-1h plasma) 1.519 70% 80% 0.73 (0.49-0.96) 0.09
S/R (0-1h urine) 0.0565 60% 90% 0.78 (0.57-0.99) <0.05
1AUC, area under the curve
2CI, confidence interval
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Figure 3:  Plasma L/R ratios increase after intake of indomethacin
Indomethacin increased the area under the curve (AUC) of the plasma L/R ratios determined in the 0-5h time
period measured by the MS test (A) and DS test (B). Plasma L/R ratios 1h after intake of the test mix were increased
after indomethacin, measured with the MS test (C) and DS test (D). (*P<.05, **P<.01 compared to basal).
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Indomethacin-induced changes in gastroduodenal permeability 
Urinary excretion of sucrose is considered to reflect upper GI permeability (25, 32), and classi-
cally, high oral sucrose doses of 20 g (29) to 100 g (31, 32) are used. Due to our sensitive detec-
tion method, we could reduce this oral dose to 1g. Analysis revealed significantly elevated 0-5h
urinary sucrose excretion (9.9±2.4 mmol versus 5.8±1.9 mmol; P<0.05; Figure 4A). Plasma
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Figure 4: Indomethacin increases gastroduodenal, but not colonic permeability
A) Indomethacin increases sucrose excretion in urine. B) Indomethacin elevated the sucrose/rhamnose (S/R) ratio
in 0-1h urine, reflecting enhanced gastroduodenal permeability. C) Indomethacin did not significantly increase
large intestinal permeability, as shown by the 5-24h urinary sucralose/erythritol (S/E) ratio. (*P<.05, **P<.01 com-
pared to basal).
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sucrose concentrations increased after intake of indomethacin compared to baseline (1.8±0.2
mmol versus 1.3±0.2 mmol; P<0.02). Interestingly, increased sucrose excretion was also observed
in the last 3h of urinary collection (Figure 4A), reflecting late intestinal sucrose uptake. Discrim-
ination of increased gastroduodenal permeability in the indomethacin-challenged state was pos-
sible in the majority of individuals by early assessment of urinary sucrose excretion or plasma
concentrations, however, accuracy could be improved (Table 2). In this study, sufficient discrim-
inatory accuracy for indomethacin-induced increased gastroduodenal permeability was obtained
using the 0-1h urinary sucrose/rhamnose ratio (Figure 4B; Table 2). 
Indomethacin-induced changes in large intestinal permeability 
The effect of indomethacin on large intestinal permeability was analyzed through determination
of 5-24h sucralose excretion and the S/E ratio. In this study, no significantly increased sucralose
excretion was observed after indomethacin (52±13 mmol versus baseline 35±7.6 mmol; P=0.20).
In line, indomethacin did not significantly change the 5-24h urinary S/E ratio (P=0.10; Figure 4C).
These results indicate that indomethacin did not significantly affect large intestinal permeability.
DISCUSSION
The novel method of detection enabled highly sensitive quantification of permeability sugar
probes in urine and plasma. It allowed a 5-fold reduction in the classically applied dose of lac-
tulose, necessary for small intestinal permeability analysis. Lactulose and rhamnose were com-
plemented with three additional sugars permitting simultaneous assessment of gastroduodenal
and colonic permeability. In the current study, the low-dose lactulose MS test was compared
with the classical high-dose lactulose DS test in an established human model of indomethacin-
induced enhanced GI permeability in healthy individuals.
   The noxious effect of NSAID such as indomethacin on the GI tract is evident (27), and small
intestinal mucosal lesions have been described in healthy individuals after 2 weeks of diclofenac
ingestion (21). In addition, Tibble et al. described intestinal inflammation measured by faecal cal-
protectin in 44% of patients taking NSAID (33), while Bjarnason et al. reported inflammation in
up to 70% of long-term users (4). In the current study, we observed intestinal damage, reflected
by enhanced plasma I-FABP levels, and inflammation measured by plasma calprotectin after only
two doses of indomethacin (75 and 50 mg p.o.). Our data indicate that even such short-term use
of NSAID causes intestinal injury and disruption of the intestinal barrier in healthy individuals. 
   The MS test was designed to perform site-specific GI permeability analysis. Interestingly,
increased gastroduodenal permeability following indomethacin could accurately be determined
by sucrose in 1h plasma, or by calculation of the 0-1h urinary S/R ratio. We consider that these
early samples allow accurate gastroduodenal permeability assessment, since gastric emptying of
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liquid in fasted individuals takes approximately 40 minutes (22). Remarkably, we also observed
high urinary sucrose excretion 3-5h after intake of the test mix in the indomethacin-challenged
state, which may be explained by indomethacin-induced reductions in small intestinal sucrase
activity as previously reported by Meddings et al. in rats (24). 
   Comparison of the MS and DS test showed that urinary L/R ratio allowed assessment of
indomethacin-induced permeability, especially in the first two hours after probe intake. For the
MS test, individual sugar probe analysis revealed that increased urinary and plasma L/R ratio
resulted from higher small intestinal permeability for disaccharides (lactulose) with unchanged
permeability for monosaccharides (rhamnose). Remarkably, elevated disaccharide concentrations
were observed to a lesser extent with the DS test, which also revealed decreased monosaccharide
concentrations after indomethacin. Reduced monosaccharide excretion has been described pre-
viously in case of increased permeability (17, 26, 34, 35), and has been attributed to decreased
mucosal absorptive surface due to intestinal disease such as celiac disease (5). However, this
assumption can be negated based on the present study, since we observed increased monosac-
charide levels when the low-dose MS test was used, performed in the same subjects. The latter
data are consistent with data of Dawson et al. showing that monosaccharide permeation is
increased in untreated celiac disease when corrected for mucosal surface area (10). Alternatively,
the reduced monosaccharide excretion measured with the DS test may be caused by disturbance
of the mucosal osmotic equilibrium by indomethacin in combination with the high lactulose
dose. Intestinal permeation of monosaccharides is highly dependent on water absorption induced
by agents or by oral hydration (2, 13, 19). Indomethacin-induced disturbances in the counter-
current flow (1, 11) reduce the physiological hyperosmolarity of the villus tip (3). The combina-
tion of reduced villus osmolarity and the high luminal amount of lactulose may direct the water
flux towards the lumen, and the resulting ‘solvent drag’ of monosaccharides could explain our
observations with the DS test. The MS test appears to provide a more physiological situation
for permeability analysis due to a reduction of the osmotic laxative lactulose. 
   Interestingly, the novel detection method enabled plasma-based permeability analysis. Plasma
analysis provides several advantages. Frequent sampling is easy, and allows the assessment of
permeability changes over time. Also, short-lived, more modest permeability changes, such as
increased small intestinal permeability induced by physical exercise, are detected more easily
(36, 37). Accurate plasma-based permeability analysis was possible using both tests within one
hour after test mix intake. Importantly, these 1h L/R ratios strongly correlated with L/R ratios
in 0-1h urine, and with plasma I-FABP levels determined at baseline. Finally, reduced mono-
saccharide rates measured with the DS test were more pronounced in urine than in plasma. We
consider that these results may be explained by accumulation of sugar probes in the urinary
bladder, thereby magnifying the effect.
   The early increase in L/R ratios and the high accuracy of early urinary samples compared to
the 0-5h urinary L/R ratio are in line with the observations of Camilleri et al. who showed that
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2h after intake of a liquid test mix, approximately 50% of the mix was located in the colon ascen-
dens (8). Taken together, these data suggest that earlier urinary collections than the classical 
0-5h collection are more useful for small intestinal permeability analysis. 
   Colonic inflammation and perforation have been described after NSAID intake (20), while
only few studies report on the effect of indomethacin on large intestinal permeability (18, 24).
We observed unaltered colon permeability after indomethacin, which is in line with results of
Smecuol et al. who used 2g of sucralose delivered by capsules (31). This led us to conclude that
indomethacin does not lead to increased large intestinal permeability. Consequently, the useful-
ness of our MS test to detect increased colonic permeability remains to be determined in a sit-
uation with definite increased colon permeability such as in patients with colitis.
In conclusion, the current study shows that sensitive permeability analysis is feasible in plasma
and urine using the MS or DS test. The MS test provides a more physiological situation for per-
meability analysis due to its reduced oral lactulose dose, and it allows accurate, site-specific infor-
mation on gastroduodenal, small, and large intestinal permeability. Future studies are needed
to assess the accuracy of the MS test in patient groups with increased intestinal permeability,
before implementation of the MS test in standard clinical practice is possible.
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Supplementary figures
Supplementary figure 1: Study design of a test day
Overview of a test day, including moments of blood sample collection (indicated by dotted lines) and urinary col-
lection (gray bars with annotation of sample collection times). Further indicated are the two moments of oral intake
(i.e. the evening before the test day and the morning of the test day) of indomethacin or placebo pills, and the
moment that the sugar test solution is ingested by the volunteers. 
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Supplementary figure 2: Urinary recovery of sugar probes after intake of indomethacin
Indomethacin-induced changes in urinary recovery of lactulose measured by the MS test (A) and DS test (B). Urinary
recovery of rhamnose after intake of indomethacin measured by the MS test (C) and DS test (D). Indomethacin
changed the urinary recovery of sucrose (E), sucralose (F), and erythritol (G), all part of the MS test.
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Supplementary figure 3: Correlations
Plasma I-FABP levels significantly correlate with L/R ratios measured in 1h plasma samples (MS test: RS = 0.53;
P<.05; (A) and DS test: RS = 0.58; P<.01; (B)). Plasma 0-5h L/R ratios correlate significantly with urinary L/R
ratios (MS test: RS = 0.69; P<.001; (C) and DS test:  RS = 0.59; P<.01; (D)). 
Proefschrift laatste versie_Opmaak 1  6/10/13  10:10 AM  Pagina 115
     
    
 
     
  
 
   
  
  
  
116
Proefschrift laatste versie_Opmaak 1  6/10/13  10:10 AM  Pagina 116
CHAPTER 7
Exercise-induced splanchnic hypoperfusion results in 
gut dysfunction in healthy men
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ABSTRACT
Splanchnic hypoperfusion is common in various pathophysiological conditions and often con-
sidered to lead to gut dysfunction. While it is known that physiological situations such as physical
exercise also result in splanchnic hypoperfusion, the consequences of flow redistribution at the
expense of abdominal organs remained to be determined. This study focuses on the effects of
splanchnic hypoperfusion on the gut, and the relationship between hypoperfusion, intestinal
injury and permeability during physical exercise in healthy men. 
   Healthy men cycled for 60 minutes at 70% of maximum workload. Splanchnic hypoperfusion
was assessed using gastric tonometry. Blood, sampled every 10 minutes, was analyzed for ente-
rocyte damage parameters (intestinal fatty acid binding protein (I-FABP) and ileal bile acid
binding protein (I-BABP)). Changes in intestinal permeability were assessed using sugar probes.
Furthermore, liver and renal parameters were assessed. Splanchnic perfusion rapidly decreased
during exercise, reflected by increased gapg-apCO2 from -0.85±0.15 to 0.85±0.42 kPa (p<0.001).
Hypoperfusion increased plasma I-FABP (615±118 vs. 309±46 pg/ml, p<0.001) and I-BABP
(14.30±2.20 vs. 5.06±1.27 ng/ml, p<0.001), and hypoperfusion correlated significantly with
this small intestinal damage (rS=0.59; p<0.001). Last of all, plasma analysis revealed an increase
in small intestinal permeability after exercise (p<0.001), which correlated with intestinal injury
(rS=0.50; p<0.001). Liver parameters, but not renal parameters were elevated. 
   In conclusion, exercise-induced splanchnic hypoperfusion results in quantifiable small intes-
tinal injury. Importantly, the extent of intestinal injury correlates with transiently increased small
intestinal permeability, indicating gut barrier dysfunction in healthy individuals. These physio-
logical observations increase our knowledge of splanchnic hypoperfusion sequelae, and may help
to understand and prevent these phenomena in patients.
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INTRODUCTION 
Splanchnic hypoperfusion occurs in many pathophysiological conditions, and is often considered
to lead to epithelial barrier dysfunction. Vascular disease, trauma, and shock can induce splanch-
nic hypoperfusion and ischemia (13, 40). In addition, gastrointestinal (GI) dysfunction is one
of the more frequent complications in surgical patients, in whom organ perfusion and oxygen
delivery are often impaired as a consequence of surgery-induced alterations in cardio-respiratory
and metabolic demands (11). In critically ill patients, inadequate splanchnic blood flow causes
intestinal damage, thereby compromising the intestinal mucosal barrier, potentially inducing
and aggravating endotoxaemia and systemic inflammation (7).  
   Splanchnic hypoperfusion also occurs in physiological conditions. Young, healthy individuals
endure episodes of splanchnic hypoperfusion during strenuous physical exercise (29), whereas
older individuals may experience similar events during less exhausting activities. Moreover, there
is considerable evidence supporting the theory that splanchnic hypoperfusion plays an important
role in the development of GI complications in patients with chronic diseases, such as chronic
heart failure or pulmonary disease (17, 20). Interestingly, the consequences of short-term
splanchnic hypoperfusion on the organs in the splanchnic area remain to be determined. 
   In the current study, we focus on the direct effects of splanchnic hypoperfusion on gut, liver,
and kidney epithelium in healthy young volunteers who perform moderate-to-high intensity
physical exercise. This study is based on the fact that functional splanchnic hypoperfusion occurs
during physical exercise, when rapid redistribution of the splanchnic blood flow occurs to secure
supply of adequate amounts of oxygen and energy to the active muscle tissue, heart, and lungs
(29, 35). In addition, during exercise a reduction of the total circulatory blood volume, caused
by transpiration and inadequate fluid intake, can decrease cardiac output and compromise
splanchnic perfusion even more (39). Especially during prolonged running or cycling, athletes
can experience abdominal symptoms such as cramping, nausea, abdominal pain, and (bloody)
diarrhea (33). This points towards compromised GI functioning, but only few studies have
looked at exercise-induced intestinal mucosal lesions in man (4, 28).
   In the current study, we determined the consequences of exercise-induced splanchnic hypop-
erfusion on gut, liver and kidney epithelium, with particular emphasis on intestinal barrier
integrity loss in healthy individuals.
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METHODS AND MATERIALS
Ethical approval
This study was approved by the medical ethical committee of Maastricht University Medical
Centre+, and conducted in accordance with the Declaration of Helsinki (revised version, Octo-
ber 2008, Seoul).
Participant characteristics
Fifteen healthy male volunteers were recruited via posters at the University. All volunteers spent
4 to 10 hours per week performing endurance sports as part of their normal life style. The vol-
unteers had no abdominal complaints during daily activities, had not taken any medication for
at least one month prior to participation, had no history of GI disease, and had had no abdominal
surgery. Volunteers were informed about the nature and risks of the experiments. Written consent
was obtained 5 days before the experiments. 
    Participants had a mean age of 23.6±0.7 years and body mass index of 21.0±0.4 kg/m². Baseline
characteristics and maximum workload capacity did not differ between the study groups. Subjects’
characteristics are reported in Table 1. All participants were able to complete the 1-hour exercise
bout, except for 1 volunteer, who discontinued cycling after 42 minutes due to exhaustion. 
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Table 1: Baseline characteristics of the healthy male participants¹. 
    GI perfusion Intestinal GI permeability p value
    damage
Group size (no. of participants) 9 15 6
Age (years) 24.2 ± 1.0 23.8 ± 0.8 25.0 ± 0.6 0.67
Height (m) 1.79 ± 0.02 1.80 ± 0.02 1.79 ± 0.00 0.79
Weight (kg) 68.4 ± 2.8 68.1 ± 1.7 66.8 ± 3.8 0.92
Body Mass Index (kg/m²) 20.3 ± 0.6 21.0 ± 0.5 20.8 ± 0.7 0.68
Total body: fat percentage (%) 11.6 ± 0.7 11.9 ± 0.8 12.5 ± 0.6 0.81
fat mass (kg) 8.0 ± 0.6 8.1 ± 0.6 8.4 ± 5.8 0.92
fat free mass (kg) 61.1 ± 2.6 60.3 ± 1.5 59.4 ± 3.8 0.91
Both legs: fat percentage (%) 12.6 ± 0.8 12.6 ± 0.9 13.5 ± 0.6 0.77
fat mass (kg) 3.1 ± 0.3 3.1 ± 0.3 3.3 ± 0.3 0.87
lean mass (kg) 20.2 ± 1.2 20.5 ± 0.7 20.1 ± 1.5 0.97
Maximum workload (W/kg) 5.0 ± 0.09 5.2 ± 0.1 5.3 ± 0.1 0.33
Data are presented as mean ± SEM. 1Of all study participants, three subjects participated in all three substudies,
and four subjects participated in two substudies. Hence, in total, 20 individuals took part in the study.
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Pre-exercise restrictions/arrangements 
Prior to the experiments, maximal workload capacity (Wmax) was assessed on a stationary cycle
ergometer (Lode Excalibur, Groningen, the Netherlands), during electrocardiographic moni-
toring (MAC 5500, GE Medical Systems, Freiburg, Germany) to exclude cardiologic abnor-
malities. A dual energy X-ray absorptiometry scan (DXA™, Hologic Inc., the Netherlands) was
performed to assess body composition.
   Test subjects recorded dietary intake 2 days prior to the first experimental day, and maintained
dietary intake as recorded for subsequent test days to prevent dietary influence. Participants
were not allowed to consume alcohol or caffeine 2 days prior to each test day. Moreover, partic-
ipants maintained normal activities of daily living, but refrained from strenuous physical activity.
The evening before each test day, participants received a standardized meal (1.7 MJ, consisting
of 62.6 g carbohydrate, 18.9 g protein and 7.9 g fat). 
Study design and sampling 
Subjects were tested after an overnight fast. The test design is depicted as Supplementary figure 1.
In short, a catheter (20 Gauge, Braun, Melsungen, Germany) was placed in the participant’s
forearm vein. Every 10 minutes, blood was collected into pre-chilled EDTA tubes (Vacucon-
tainer, Becton Dickinson (BD), Helsingborg, Sweden), and kept on ice. Urine was collected by
the participants in 1 l plastic cups before and within 1 hour after exercise. Urinary volume was
recorded and 4 ml was directly transferred to pre-chilled tubes. Blood and urine samples were
centrifuged within 1 hour at 4°C at 2300 x g for 15 minutes and immediately stored at -80°C
until analysis. Following 1 hour rest in supine position, participants started cycling at 150 W.
After 3 minutes, workload was increased to 70% of the individual’s pre-assessed Wmax. Subjects
maintained pedal rates of 60 rpm, and workload was decreased by 25 W if the participant was
unable to maintain 60 rpm. Participants were only allowed to drink a maximum of 200 ml tap
water per 10 minutes. Faeces were collected by 6 participants, before and after cycling, and
stored at -4°C until analysis. Subjects were asked to report GI complaints experienced on the
test day and the following day.
Assessment of GI perfusion
Gastric air tonometry was performed in 9 participants. The evening before and 1 hour prior to
the experiment, participants ingested 150 mg ranitidine orally (GlaxoSmithKline, Zeist, the
Netherlands) to suppress gastric acid production, which interferes with carbon dioxide, thereby
affecting tonometry results (16). A nasogastric Tonometrics catheter (8 French, Datex Ohmeda,
Finland) was introduced and fixed to both nasal flares. Gastric pCO2 was measured at 10-minute
intervals using an automated capnograph (Tonocap TC-200, Datex Ohmeda, Finland). To avoid
the use of an arterial catheter, an intravenous catheter (22 Gauge, BD) was placed in a dorsal
hand vein and the hand was placed in a hot box heated to 60°C, to arterialize the blood for
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measuring arterial pCO2 (22), using a Radiometer ABL 510 (Copenhagen, Denmark). Blood
samples were collected simultaneously with the tonometry measurements and gastric-arterialized
pCO2 (gapg-a pCO2) was calculated. 
Assessment of intestinal damage
Intestinal fatty acid binding protein (I-FABP), a sensitive marker of intestinal cell damage, was
used to determine small intestinal damage (9). Plasma I-FABP was determined using an enzyme
linked-immunosorbent assay (ELISA) (Hycult Biotechnology, Uden, the Netherlands; detection
window 20-5,000 pg/ml) according to the manufacturer’s instructions in samples taken before
(t=0), during (t=10-50 minutes) and after (t=60-120 minutes) cycling. Plasma ileal bile acid
binding protein (I-BABP), a sensitive damage marker of ileal epithelium, was measured before
(t=0) and after (t=60 minutes) cycling, using an in-house developed ELISA as previously
described (detection window 0.32-5.0 ng/ml) (5). 
   All plasma parameters were measured in pre-exercise and post exercise plasma of all partici-
pants, resulting in a total number of 20 paired samples (without overlap due to subjects partic-
ipating in more than 1 study), unless stated otherwise.
Assessment of liver damage
Liver injury was assessed by liver fatty acid binding protein (L-FABP), alanine transaminase
(ALT), and aspartate transaminase (AST). Plasma L-FABP is a sensitive indicator of hepato-
cellular injury (45). However, as expression of L-FABP has been described in renal and intestinal
epithelium (31), this marker was combined with the classically used parameters ALT and AST.
In addition, we determined plasma levels of a-glutathione S-transferase (a-GST), which is advo-
cated to be an early and more specific marker of liver injury and unaffected by muscle injury or
haemolysis (36, 47). All liver markers were determined before, immediately after, and 1 hour
after cessation of cycling. Plasma L-FABP was measured using a commercial ELISA according
to the manufacturer’s instructions (Hycult, detection window 0.20-25 ng/ml). Plasma ALT and
AST were determined by routine enzymatic assays at the Clinical Chemistry Laboratory (CCL).
Plasma a-glutathione S-transferase (a-GST) levels were assessed using a sandwich ELISA, as
described previously (24).
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Assessment of kidney damage
Urinary N-acetyl-beta-(D)-glucosaminidase (NAG) was determined using an enzyme colori-
metric assay according to the manufacturer’s instructions (HaemoScan, Groningen, the Nether-
lands). Concentrations were normalized to urinary creatinine values, measured by routine assays
at the CCL and expressed as Units/mmol creatinine.
Assessment of GI permeability 
Gastrointestinal permeability was determined using a mix of 1 g lactulose (Centrafarm, Etten-
Leur, the Netherlands), 1 g sucralose (Brenntag, Sittard, the Netherlands), 1 g erythritol (Danisco,
Copenhagen, Denmark), 1 g sucrose (Van Gilse, Dinteloord, the Netherlands), and 0.5 g L-rham-
nose (Danisco) dissolved in 150 ml tap water, in a subset of 6 participants.
   The study design, depicted in the Supplementary data, consisted of 2 test days, one to test
basal permeability and one for exercise-induced permeability. Participants fasted overnight. The
sugar bolus was ingested after 30 minutes of rest in supine position, or after 30 minutes of
cycling. Blood was sampled every 20 minutes and urine every hour, up to 5 hours post ingestion.
All subjects urinated in plastic cups within 10 minutes of the instructed time point. In addition,
subjects collected their 5-24 hour urine at home and returned the provided bottles the next
morning, when urine was immediately processed.
   Combined HPLC (Model PU-1980 pump, Jasco Benelux, Maarsen, the Netherlands) and
mass spectrometry (Model LTQ-XL, Thermo Electron, Breda, the Netherlands) were used to
determine urinary and plasma sugar concentrations. Lactulose and rhamnose, and the lactu-
lose/L-rhamnose (L/R) ratio were determined in urinary samples to assess small intestinal 
permeability. Since physiological, transient permeability changes were expected, and our novel
permeability assay allowed the detection of sugar probes in plasma, we also determined lactulose
and rhamnose concentrations, and L/R ratios in plasma. Both lactulose and rhamnose are
degraded in the colon. Therefore, the ratio between two other, inert sugar probes, i.e. the
sucralose/erythritol (S/E) ratio, was determined in the 5-24h urine to assess large intestinal per-
meability. Since we did not draw blood in this time period, we did not perform large intestinal
permeability analysis in plasma.
Assessment of inflammatory activation products and bacterial translocation
Circulating myeloperoxidase (MPO) and calprotectin, antimicrobial proteins that are excreted
from neutrophils upon activation, are considered early parameters of systemic inflammatory
activation (26, 42). Active MPO is known to elicit secretion of other cytokines including tumor
necrosis factor-a (TNF-a) and interleukins (19), which were therefore less useful. MPO was
measured in plasma before and after cycling using a commercial ELISA (Hycult; detection win-
dow 0.40-100 ng/ml). Since evidence is accumulating that inflammatory products are produced
in contracting and skeletal muscle (23, 30), we determined both circulating and faecal calpro-
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tectin. The latter is considered a strong indicator of intestinal inflammation in specific, and has
been found to correlate to other parameters of intestinal inflammation in inflammatory bowel
disease (43) and enteropathy induced by non-steroidal anti-inflammatory drugs (NSAID) (44).
Calprotectin was measured before and after cycling, using a commercial calprotectin ELISA
(standard 1.6-100 ng/ml). Faeces were collected by the participants in provided faecal sampling
cups. Time of collection was reported by the participants. All faecal samples were collected within
7 hours after cycling. For faecal analysis, faeces were thawed, and 100 mg was added to 4.9 ml
of extraction buffer (0.1 M Tris, 0.15 M NaCl, 1.0 M urea, 10 mM CaCl2 2H2O, 0.1 M citric
acid, 0.5% BSA, pH 8.0) was added (46). After 30 minutes shaking, 1 ml of suspension was
centrifuged at 10,000 rpm for 20 minutes at 4°C. Faecal calprotectin concentrations were meas-
ured in supernatant using the calprotectin ELISA.
   Endotoxin core antibodies in plasma were determined using EndoCab ELISA (Hycult Biotech-
nology, Uden, the Netherlands; detection window 0.13-8.0 IgG median units (GMU)/mL) accord-
ing to the manufacturer’s instructions in samples taken before and after cycling.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (Version 5.00, GraphPad Software for
Windows, San Diego California, USA). Normality of all data was verified by the Kolmogorov-
Smirnov test. All normally distributed data are presented as mean ± standard error of the mean
(SEM), not normally distributed data as median and range. Outliers identified using Grubbs
analysis were excluded from statistical analysis. Continuous data were analyzed using repeated
measures analysis of variance with Tukey’s or Dunnett’s post-hoc test for multiple comparisons.
Basal and post exercise values were compared using the non-parametric Wilcoxon signed rank
test, considering the small number of study participants. Within-person correlations between
gapg-apCO2 and plasma I-FABP, and plasma I-FABP and plasma L/R ratio were computed by
normalizing both data sets, which enables the assessment of the pure association of both variables
by calculating the Spearman correlation coefficient (rS). Linear regression was used to visualize
the correlation. A p<0.05 was considered statistically significant.
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RESULTS
Exercise-induced GI hypoperfusion 
Tonometry revealed a significant increase of gapg-apCO2 during exercise, from -0.85±0.15 kPa
to 0.85±0.42 kPa (p<0.001) after exercise, indicating functional splanchnic hypoperfusion 
(Figure 1A). The steepness of the gapg-apCO2 slope was most pronounced during the first 10
minutes of exercise, suggesting that functional splanchnic adaptations occur rapidly after altered
perfusion demands in other parts of the body during physical activity. The gapg-apCO2 approx-
imated baseline within 1 hour after exercise, reflecting fast recovery of splanchnic perfusion fol-
lowing a state of functional GI hypoperfusion. Interestingly, the recovery of GI perfusion was
most prominent during the first 10 minutes post exercise, which is in line with the rapid adap-
tation of abdominal perfusion during the first 10 minutes of cycling.
Exercise-induced small intestinal damage
To assess hypoperfusion-induced effects on the small intestinal epithelium, plasma I-FABP levels
were determined, which increased rapidly, from 309±46 pg/ml at baseline to 615±118 pg/ml
(p<0.001) after cycling (Figure 1B). Similar to the decreased gapg-apCO2 levels (Figure 1A), cir-
culating I-FABP levels declined substantially in the first 10 minutes post exercise, and gradually
decreased further until baseline I-FABP level was reached approximately 50 minutes after cycling
(Figure 1B). Interestingly, we did not observe a new peak in plasma I-FABP levels in the 60 min-
utes after cycling, suggesting that reperfusion injury did not occur in this time period.
   The short half-life of I-FABP in plasma (approximately 11 minutes) allows to analyze the
correlation of enterocyte damage with splanchnic hypoperfusion (45), calculating the within-
person correlation between gapg-apCO2 and the change in circulating I-FABP. Because this cor-
relation has not yet been described in healthy individuals, we determined the correlation between
gapg-apCO2 and I-FABP 3 times, i.e. with a delay of 10, 20, and 30 minutes. Interestingly,  
I-FABP levels significantly correlated with gapg-apCO2 assessed at all measured time points 
(rS: 0.579 (p<0.001); 0.592 (p<0.001) and 0.528 (p<0.001), respectively). The correlation
between gapg-apCO2 and I-FABP determined in samples taken 20 minutes later, is depicted in
Figure 1C.
   Similar to I-FABP, cycling increased I-BABP levels (5.06±1.27 to 14.3±2.20 ng/ml (p<0.001;
Figure 3A)), reflecting enterocyte damage in the ileum specifically.
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Exercise-induced gastrointestinal complaints
Two individuals reported nausea during the GI perfusion measurements with the nasogastric
tube in situ, which resolved after the nasogastric tube was removed upon completion of the exper-
iment. Three additional participants mentioned minor abdominal complaints during the test,
including pain in epigastrio, flatulence and belching. The individuals reporting abdominal com-
plaints did not show higher I-FABP levels during and post exercise than the individuals without
abdominal complaints.
Exercise-induced changes in liver parameters
To obtain information on liver injury during exercise, we analyzed a set of four parameters: 
L-FABP, ALT, AST, and a-GST. Plasma L-FABP levels significantly increased in all individuals
upon exercise (4.75±0.30 to 14.2±1.38 ng/ml (p<0.001; Figure 2A)). Plasma ALT and AST 
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Figure 1: Physical exercise results in splanchnic hypoperfusion and intestinal cell damage. 
A) Gastric tonometry shows decreased splanchnic perfusion during cycling and post cycling (n = 9). B) Plasma 
I-FABP levels reflect the development of intestinal epithelial cell damage during cycling and post cycling in healthy
volunteers (n=20). C)Normalized plasma I-FABP levels measured during exercise tonometry correlate significantly
with the normalized values of splanchnic hypoperfusion (gapg-a pCO2 t-20 min) in healthy men (samples from 9
men). Data are mean ± SEM. Different from baseline (t = 0) (*p<0.01, **p<0.001, ***p<0.0001).
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Figure 2: Physical exercise is associated with liver damage. 
Plasma L-FABP (A), ALT (B), AST (C), and a-GST (D) suggest liver injury after cycling. Data are mean 
± SEM (n = 20) of samples collected before, immediately after and 1 hour post cycling (*p<0.05, **p<0.01, 
***p<0.001).
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levels increased from baseline 16.5±1.40 to 20.0±1.60 U/l (p<0.01; Figure 2B) and 18.5±0.93
to 23.8±0.98 U/l (p<0.001; Figure 2C), respectively. a-GST levels also increased during and
after exercise (0.42±0.07 to 0.64±0.10 ng/ml (p=0.12)), reaching statistical significance at 
1 hour post exercise (0.85±0.16 ng/ml (p<0.01 vs. baseline, p<0.05 vs. post exercise; Figure 2D).
Prolonged release of L-FABP and a-GST was observed at least for 1 hour post exercise, whereas
plasma ALT and AST levels decreased 1 hour post exercise (Figure 2). 
Exercise-induced changes in renal parameters
While we assumed that exercise caused renal damage, no significant changes in urinary NAG
levels were observed (p>0.05; Figure 3B). NAG, expressed in tubular epithelial cells (18), which
are vulnerable to ischemic injury, is a sensitive marker of renal damage. Our data indicate that
exercise, accompanied by enterocyte and hepatocellular injury, does not cause renal damage.
Exercise-induced GI permeability changes 
To analyze whether the exercise-induced GI hypoperfusion and consequent enterocyte damage
resulted in GI permeability changes, we analyzed small intestinal permeability, which was assessed
as L/R ratio in urine and plasma. All subjects were able to urinate within 10 minutes of the
instructed time point, without using Foley catheters. Overall, a trend towards higher small intestinal
permeability after exercise was observed in urine, which was especially pronounced in the first two
hours of urinary collection (Figure 4A). However, no statistically significant changes were observed
in the urinary L/R ratio or the individual sugars after exercise. Since modest, transient changes in
intestinal permeability only increase sugar probe excretion transiently, we considered that this
increased probe excretion might be overshadowed by normal probe excretion, because all excreted
probes accumulate in the bladder before leaving the body. Using our novel approach for sugar
probe detection, we could assess the sugar probes in detail by analysis of plasma samples.
    Plasma analysis revealed an overall increase in small intestinal permeability after exercise com-
pared to rest (p<0.001; Figure 4B). This increased plasma L/R ratio was the result of significantly
elevated lactulose concentrations after exercise (p<0.05; data not shown), while plasma rhamnose
levels remained unchanged. Interestingly, the plasma L/R ratios correlated significantly with
plasma I-FABP levels measured in the same samples during exercise (rS: 0.50, p<0.001; data
not shown).
   Next, correlations between the 0-1h urinary L/R ratio and the AUC of the plasma L/R ratios
determined in the 0-1h time period were evaluated for similarity, resulting in a RS of 0.42
(p<0.05; data not shown). Finally, the S/E ratio was determined in the 5-24h urinary collections
to study large intestinal permeability changes. No changes in large intestinal permeability were
observed (Figure 4C). 
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Figure 3: Physical exercise results in ileal epithelial damage and activates the acute phase response, without leading to
renal injury. 
A) Increased plasma IBABP levels point toward the development of exercise-induced ileal epithelial cell damage.
B) Urinary NAG levels indicate absence of renal damage after cycling. B) Increased plasma MPO levels reveal an
exercise-induced acute phase response in healthy volunteers. C) Increased plasma calprotectin levels indicate an
exercise-induced acute phase response in healthy volunteers. Data are mean ± SEM (n = 20). Different from base-
line (t = 0) (NS, not significant; **p<0.001, ***p<0.0001).
Proefschrift laatste versie_Opmaak 1  6/10/13  10:10 AM  Pagina 129
Exercise-induced inflammatory response without bacterial translocation
Myeloperoxidase and calprotectin were analyzed as parameters of innate inflammation. Plasma
MPO levels increased significantly in all individuals upon exercise, from baseline 4.4±0.8 to
33±4.7 ng/ml after cycling (p<0.001; Figure 3C). In line with these results, a significant raise in
circulating calprotectin levels was observed (p<0.0001; Figure 3D). Moreover, faecal calprotectin
levels increased significantly upon exercise from baseline median 1.07 mg/g (range 0.49-2.20
mg/g) to 1.48 mg/g (range 0.59-40.82 mg/g, p<0.05; data not shown). 
PART III - CHAPTER 7                                                                                                                     
130
S/
E 
ra
ti
o
n
 in
 u
ri
n
e 
(x
10
–3
)
80
60
40
20
0
20
15
10
5
0
8
6
4
2
0
0 1 2 3 4 5 0–5
Time (hours)
0 1 2 3 4 5
Time (hours)
NS
Basal Exercise
L/
R
 r
at
io
n
 in
 u
ri
n
e 
 (
x1
0–
3 )
L/
R
 r
at
io
n
 in
 p
la
sm
a 
(x
10
–3
)
A
B
C
Figure 4: Physical exercise induces a mild increase in small intestinal permeability. 
A) Urinary L/R ratios over time are elevated from baseline, especially in the first 2 hours after cycling, but not to a
significant level. B) Plasma permeability analysis revealed an overall increase in small intestinal permeability after
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rest
excercise
Proefschrift laatste versie_Opmaak 1  6/10/13  10:10 AM  Pagina 130
   To assess the translocation of bacterial endotoxin in the circulation, EndoCab analysis was
performed. The data did not reveal significant changes in endotoxin core antibody levels before
and after cycling in the subgroup of participants that underwent permeability analysis (Supple-
mentary figure 2A) or in the total group of participants (Supplementary figure 2B). 
DISCUSSION 
The redistribution of blood away from the splanchnic area is an adaptation of the body enabling
perfusion of critical tissues in both physiological and pathophysiological situations. During phys-
ical exercise, reduction of the splanchnic circulation occurs to meet the increased demand for
oxygen and substrates in the active muscle, thereby inducing a physiological state of hypoperfusion
in the GI system (35). This study provides for the first time a comprehensive overview of the
processes occurring in response to splanchnic hypoperfusion. 
   In this study, we demonstrate that in healthy individuals, one hour of physical exercise results
in splanchnic hypoperfusion and small intestinal damage, reflected by an increase in plasma 
I-FABP. Interestingly, the extent of intestinal damage significantly correlated with the exercise-
induced hypoperfusion and with mild permeability changes in the small intestine. The most pro-
nounced change in splanchnic perfusion, i.e. the most obvious increase in gapg-apCO2, occurred
within the first 10 minutes of cycling, which implies that splanchnic perfusion rapidly decreases
following the onset of exercise. The speed of adaptation of the splanchnic blood flow is further
demonstrated by its fast recovery after cycling, which was also most prominent during the first
10 minutes following cessation of exercise. The rapid decline in splanchnic perfusion during
cycling was followed by the development of significant intestinal damage with a time lag of 20
minutes. The data show a correlation between the exercise-induced splanchnic hypoperfusion
and enterocyte damage (measured 20 minutes later), which is in line with animal studies and
studies performed in critically ill patients demonstrating that intestinal hypoperfusion and
ischemia result in intestinal cell damage (7). 
   The exercise-induced damage to the small intestine was measured using plasma I-FABP and
I-BABP, both sensitive plasma parameters of enterocyte damage that are predominantly
expressed in the upper half of the villi, where the mature enterocytes reside (5, 6, 9). The sus-
ceptibility of the mature enterocyte population to low-flow states and ischemic events has been
explained by the counter current exchange mechanism in the villus (1, 2), creating a constant
low oxygen environment at the villus tip. Intestinal hypoperfusion deteriorates the oxygen-
deprived status of the villus tip even more, resulting in rapid loss of epithelial cell membrane
integrity and concomitant I-FABP and I-BABP release. The increase in both I-FABP and I-
BABP indicates that exercise results in small intestinal damage in general, including the ileum.
Interestingly, plasma I-FABP levels gradually decreased in the 60-minute ‘reperfusion’ period.
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The absence of a second peak in plasma I-FABP levels in this 60-minute period after splanchnic
hypoperfusion indicates that detectable reperfusion injury did not occur in our healthy individ-
uals. Our observations are in line with recent work on human intestinal ischemia/reperfusion
(I/R) studies from our group showing that after 30 minutes of full intestinal ischemia in an iso-
lated part of the jejunum during a Whipple procedure, plasma I-FABP levels rapidly increase,
whereas during reperfusion, a gradual decrease in I-FABP levels was observed (8). During reper-
fusion, shedding of the damaged enterocytes prevented the jejunum from a massive I/R-induced
inflammatory response (21). Taken together, these results reflect the ability of the gut to with-
stand episodes of partial or total deprivation of blood flow, with relatively little damage to the
intestinal mucosa.
   Having obtained strong indications for reduced splanchnic blood flow, we hypothesized that
splanchnic outflow may be reduced during strenuous physical exercise, resulting in hepatocyte
damage. Plasma levels of all assessed liver parameters (i.e. L-FABP, ALT, AST, and a-GST)
elevated significantly after exercise. However, two other factors could be responsible for the phe-
nomenon. First, the increase in these plasma parameters could theoretically be partly attributed
to an exercise-induced reduction in plasma volume. The increases, however, largely exceeded
the 10% decrease in plasma volume that has been described in athletes in more extreme settings
than ours (15). Alternatively, muscle transaminase release is expected in response to (exercise-
induced) muscle injury (27, 34), while L-FABP release could be due to intestinal damage. There-
fore, we additionally analyzed plasma a-GST, an early marker of hepatocyte injury unaffected
by muscle injury, haemolysis, or intestinal injury (36, 47). In short, the significant rise in the
assessed liver parameters after exercise strongly suggests the development of mild hepatocyte
damage, which is in line with García-Pagàn et al. who reported a decrease in hepatic blood flow
in patients with liver cirrhosis and portal hypertension after only 10 minutes of cycling at sub-
maximal workload (10).
   In contrast to the intestinal and liver data, we did not observe indications for renal damage
during exercise. At this stage, it is unclear whether there was no hypoperfusion in the kidneys
during cycling, or whether the kidney is more resistant to physiological hypoperfusion. Previous
studies support the former, showing relatively unchanged renal flow after short-term splanchnic
blood redistribution (3, 32). 
   In addition to the observed epithelial cell integrity loss, activation of the inflammatory
response was observed. Inflammation is characterized by neutrophil influx and activation, result-
ing in the release of MPO and calprotectin, as seen in the present study. MPO plays a role in
oxidative processes, while calprotectin and one of its constituents, myeloid-related protein-8
(Mrp8, S100A8), are identified as strong activators of the innate Toll-like receptor 4 signaling
pathway, resulting in the expression of pro-inflammatory cytokines (48). In addition to a rise in
plasma calprotectin levels, increased faecal calprotectin concentrations were found after cycling
in our healthy individuals, reflecting sequestration and activation of neutrophils in the intestinal
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mucosa, suggesting the gut to be an additional source of inflammatory products after physical
exercise. Inflammation and neutrophil influx have been described previously in the human intes-
tine, as part of ischemia/reperfusion injury (12), while a study by Mortensen et al., assessing
femoral arterial-venous differences during knee extensor exercise, pointed towards release of
calprotectin from muscle tissue during exercise (23).  We consider the release of both calprotectin
and MPO to be enhanced in sites of tissue injury and inflammation, including muscle tissue
(during exercise), but also the gut mucosa. Loss of gut barrier function, due to cellular injury
and inflammation, could result in bacterial translocation. Indeed, Jeukendrup et al. found mild
endotoxaemia (5-15 pg/ml) and increased levels of C-reactive protein in the majority of partic-
ipants after finishing an approximately 12h long-distance triathlon (14). While our data did not
point towards bacterial translocation, the existence of mucosal damage and inflammation in the
GI tract did suggest loss of epithelial barrier function in our healthy volunteers. In line, analysis
of the sugar probes in plasma using our novel HPLC/MS approach revealed increased small
intestinal permeability, while these permeability changes correlated with the observed intestinal
injury. Interestingly, the classical analysis of sugar probes in urine did not reveal significant
changes in permeability, which might be explained by the mild and temporary nature of the
increase in small intestinal permeability. In short, the absence of endotoxaemia and the mild
changes in small intestinal permeability found in the current study underline the physiological
basis of the exercise-induced changes in GI homeostasis. 
   In the current study, exercise did not significantly increase large intestinal permeability. It
could be argued that the large intestine is better protected against episodes of hypoperfusion, or
that blood flow in the large intestine is better maintained to prevent the translocation of bacteria
and their products from the lumen to the circulation. The latter is suggested by a study of Murray
et al. that found a decrease in rectal mucosal blood flow of almost 30% after acute physical stress
(25), while decreases ranging from 43 to approximately 80% have been reported for splanchnic
blood flow during physical exercise (35, 37).
   In this study, we show the development of intestinal damage due to physiological hypoper-
fusion. Our data imply that the healthy human small intestine can withstand transient hypoper-
fusion, since the observed enterocyte injury did not produce gastrointestinal symptoms in our
healthy individuals. However, prolonged episodes of hypoperfusion may cause more severe
epithelial injury that may give rise to abdominal symptoms, as observed in endurance trained
athletes (41). Furthermore, it is tempting to speculate that in individuals with hampered vascular
function or decreased cardiac output, physiological conditions such as ‘regular’ physical exercise
and other daily activities, will rapidly result in splanchnic hypoperfusion, ultimately leading to
enterocyte damage and increased gut permeability. In patients with compromised vascular func-
tion, hypoperfusion-induced epithelial dysfunction may give rise to endotoxaemia, thereby
enhancing their state of chronic inflammation, as suggested by the group of Anker for patients
with chronic heart failure (17, 38). 
EXERCISE-INDUCED SPLANCHNIC HYPOPERFUSION RESULTS IN GUT DYSFUNCTION IN HEALTHY MEN
133
Proefschrift laatste versie_Opmaak 1  6/10/13  10:10 AM  Pagina 133
   We assume that in addition to such patients, also relatively healthy elderly experience episodes
of splanchnic hypoperfusion during daily activities due to the ageing of the splanchnic vascular
system. 
   In conclusion, our study demonstrates that a single, 60-minute bout of moderate-to-high
intensity exercise is accompanied by splanchnic hypoperfusion and transient epithelial integrity
loss in healthy young males, reflecting the ability of the gut to withstand to episodes of physio-
logical stress with minor consequences. 
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CHAPTER 8
Dietary protein digestion and absorption are impaired 
during acute post-exercise recovery in healthy young men
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ABSTRACT
Previously, we demonstrated that exercise can cause small intestinal injury, leading to loss of gut
barrier function. The functional consequences of such exercise-induced intestinal injury on sub-
sequent food digestion and absorption are unclear. The present study determined the impact of
resistance-type exercise on small intestinal integrity and in vivo dietary protein digestion and
absorption kinetics.
   Twenty four young males ingested 20 g specifically produced intrinsically L-[1-13C]pheny-
lalanine-labeled protein at rest or after performing a single bout of resistance-type exercise. Con-
tinuous intravenous infusions with L-[ring-2H5]phenylalanine were employed, and blood samples
were collected regularly to assess in vivo protein digestion and absorption kinetics and to quantify
plasma levels of intestinal fatty-acid binding protein (I-FABP) as a measure of small intestinal
injury. 
   Plasma I-FABP levels were increased after exercise by 35%, reaching peak values of 344±53
pg/mL compared to baseline 254±31 pg/mL (P<0.05). In resting conditions, I-FABP levels
remained unchanged. Dietary protein digestion and absorption rates were reduced during post-
exercise recovery when compared with resting conditions (P<0.001), with average peak exoge-
nous phenylalanine appearance rates of 0.18±0.04 vs. 0.23±0.03 mmol phenylalanine.kg lean
body mass-1.min-1, respectively. Plasma I-FABP levels correlated with in vivo rates of dietary
protein digestion and absorption (RS= -0.57, P<0.01). 
   In conclusion, resistance-type exercise induces small intestinal injury in healthy, young men,
causing impairments in dietary protein digestion and absorption kinetics during the acute post-
exercise recovery phase. To the best of our knowledge, this is first evidence that shows that exercise
attenuates dietary protein digestion and absorption kinetics during acute post-exercise recovery.
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INTRODUCTION
The gut is challenged with two major functions, digestion and absorption of nutrients and the
maintenance of an intact barrier against potentially harmful luminal compounds. Exercise is
known to cause gastrointestinal (GI) injury and gut barrier dysfunction, reflected by increased
small intestinal permeability (20, 23, 24), bacterial translocation and inflammation after exercise
(6, 15). We demonstrated that one hour of exercise induced small intestinal injury, leading to
gut barrier dysfunction in healthy young athletes (30). These data gave rise to the intriguing
question whether exercise-induced intestinal injury compromises the digestive and absorptive
capacities of the GI tract.
   Dietary protein ingestion following exercise has been reported to increase post-exercise muscle
protein synthesis rates, thereby promoting early recovery after strenuous exercise (1). Impair-
ments in dietary protein digestion and absorption may reduce the appearance rate of dietary
protein-derived amino acids in the circulation (12), thereby lowering the postprandial availability
of these amino acids for muscle damage repair and reconditioning. As muscle protein synthesis
is maximally stimulated during acute post-exercise recovery, a rapid supply of exogenous protein
is required to allow muscle protein synthesis rates to increase (1, 16, 18, 19). The latter is impor-
tant to athletes as well as patients with chronic diseases to allow proper adaptation to each suc-
cessive exercise bout within exercise intervention programs designed to improve performance
and health. Impairments in food digestion and nutrient absorption during and immediately after
exercise may jeopardize the adaptive response to the combined effect of exercise and proper
nutrition (1, 14, 16).
    We hypothesized that exercise-induced intestinal injury impairs dietary protein digestion and
absorption kinetics during acute post-exercise recovery. The present study was designed to deter-
mine the impact of a single bout of resistance type exercise on intestinal damage and on the sub-
sequent digestive and absorptive function of the GI tract. Small intestinal injury and dietary pro-
tein digestion and absorption kinetics were assessed following ingestion of a single meal-like bolus
of dairy protein at rest and after a single bout of resistance-type exercise in 24 healthy young
males. By combining the use of specifically produced intrinsically L-[1-13C]phenylalanine labeled
dairy protein with continuous intravenous L-[ring-2H5]phenylalanine infusion we assessed in vivo
dietary protein digestion and absorption kinetics (26, 29). This study shows novel evidence that
resistance-type exercise induces small intestinal damage and impairs in vivo dietary protein diges-
tion and absorption during acute post-exercise recovery in young, healthy men.
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METHODS AND MATERIALS
Ethical approval
The current study was approved by the medical ethical committee of Maastricht University
Medical Centre+, and conducted in accordance with the Declaration of Helsinki (revised ver-
sion, October 2008, Seoul). The study is part of a trial registered at clinicaltrials.gov as
NCT00557388.
Participant characteristics
Twenty-four young, healthy male volunteers (21±1 years of age) were included in the current
study. The volunteers had no abdominal complaints during daily activities, had not taken any
medication for at least one month prior to participation, had no history of GI disease, and had
had no abdominal surgery. All participants of the current study were recreationally active people,
reporting to spend 5-10 hours a week on physical exercise. Participants were randomly assigned
to the rest or exercise experiment. Participant characteristics, presented in Table 1, did not differ
between groups. All participants were informed about the nature and risks of the experiments
before written consent was obtained.
Pre-test arrangements 
Prior to the experiments, body composition analysis was performed using a dual energy X-ray
absorptiometry scan (DXA™, Hologic Inc., Bedford, MA), and leg volume was determined as
described previously (31). Electrocardiography was performed at rest and during exercise to
exclude any heart failure in the selected volunteers. In addition, the subject’s maximal strength
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Table 1: Baseline characteristics of the healthy male participants.
Rest Exercise p value
Group size (no. of participants) 12 12
Age (years) 21 ± 1 21 ± 1 0.86
Weight (kg) 76.2 ± 3.6 77.0 ± 2.1 0.85
Body Mass Index (kg/m²) 23.4 ± 1.0 22.8 ± 0.5 0.61
Body fat percentage (%) 15.2 ± 0.9 15.9 ± 0.9 0.56
Fat free mass (kg) 64.5 ± 2.8 64.7 ± 1.6 0.95
Leg volume (L) 8.7 ± 0.5 9.1 ± 0.3 0.55
Plasma glucose (mmol/L) 5.1 ± 0.1 5.2 ± 0.1 0.71
Plasma insulin (mU/L) 10.4 ± 0.7 9.7 ± 1.0 0.60
Blood HbA1C (%) 5.4 ± 0.1 5.3 ± 0.1 0.21
HOMA-IR 2.4 ± 0.2 2.2 ± 0.2 0.58
1 RM leg press (kg) 254 ± 17 243 ± 8 0.56
1 RM leg extension (kg) 122 ± 6 121 ± 5 0.96
Data are presented as mean ± SEM. HbA1C, glycated hemoglobin; HOMA-IR, homeostasis model of insulin
resistance; 1 RM, one-repitition maximum leg strength. 
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(one repetition maximum, 1RM) was estimated after a session of multiple repetitions of leg press
and leg extension exercises (21). Subsequently, during a second session, the subject’s true 1RM
was determined by setting the load to 90-95% of the estimated 1RM, and increased after each
successful lift. An interval of 7 days or more was scheduled between the screening sessions and
the experimental day. 
   Participants maintained normal activities of daily living, but refrained from strenuous physical
activity for 3 days prior to the experiments. The evening before the experimental day, participants
received a standardized meal (33±2 kJ/kg body weight, providing 55% of energy as carbohydrate,
15% as protein and 30% as fat) at ~8:00 P.M. after which they remained fasted.
Study design and sampling 
In the morning, a catheter was placed in the participant’s forearm vein for stable-isotope infusion.
A second catheter was inserted in a heated dorsal hand vein of the contralateral arm and placed
in hot box heated to 60˚C for arterialized blood sampling. Blood was collected before (-30 min),
immediately post-exercise/rest (0 min), and 15, 30, 45, 60, 75, 90, 105 and 120 minutes post-
exercise/rest to enable thorough analysis of enterocyte integrity and protein digestion and absorp-
tion especially in the immediate post-exercise period. Blood was sampled in EDTA tubes, 
centrifuged at 1000g for 5 min at 4˚C, and stored until analysis at -80˚C. After baseline sampling
(t = -120 min), a single intravenous (IV) dose of the tracer, L-[ring-2H5]phenylalanine 
(2 mmol/kg) was infused to prime the plasma phenylalanine pool. Subsequently, the continuous
tracer infusion was started at a rate of 0.044±0.001 mmol·kg-1·min-1, after which the participants
rested in upright position for 90 minutes. Subjects then either performed a 30-minute standard-
ized exercise protocol or remained seated for another 30 minutes of rest according to random
assignment. The exercise protocol comprised a 5-minute self-paced cycling bout at 1.4±0.1 W/kg
body weight at a pace of 70-90 rotations per minute, combined with 6 sets of 10 repetitions on
a horizontal leg press machine (Technogym BV, Rotterdam, the Netherlands) and 6 sets of 10
repetitions on a leg extension machine (Technogym BV). Each first two sets were performed at
40% of the subject’s 1 RM. Sets 3-4 and 5-6 were performed at 55% and 75% of 1 RM, respec-
tively, with a 2-minute rest interval between sets. 
   After baseline sampling (t = 0 min), subjects received a single 250-mL bolus flavored drink
containing 20 g intrinsically L-[1-13C]phenylalanine-labeled casein protein. The latter was
obtained by infusing a Holstein cow with large amounts of L-[1-13C]phenylalanine and collecting
the milk produced by this cow (29). The L-[1-13C]phenylalanine enrichment in the purified
casein fraction of the cow milk averaged 29.2 moles percent excess. The drink met all specifica-
tions for safe human consumption. 
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Assessment of small intestinal injury
To determine whether resistance-type exercise leads to small intestinal injury, concentrations of
human Intestinal Fatty Acid Binding Protein (I-FABP) were analyzed by an enzyme linked-
immunosorbent assay (ELISA) in plasma samples collected before and after exercise. No samples
were obtained during the short exercise bout. In short, 96-well plates (Greiner Microlon F, Greiner
Bio-One GmbH, Frickenhausen, Germany) were coated overnight with anti-I-FABP immunoglob-
ulin G (IgG) in a 2.5 mg/ml concentration in phosphate-buffered saline (PBS) at 4ºC.
   Free sites were blocked with 1% bovine serum albumin (BSA) in PBS for one hour at room
temperature. Subsequently, plasma samples and human recombinant I-FABP, used to produce
standard calibration curves, were allowed to incubate for 1 hour at room temperature, after which
0.5 mg/ml of biotinylated anti-I-FABP IgG in 0.1% BSA-0.05% Tween 20-PBS was added to
the plates and left to incubate for 1 hour at room temperature. Horseradish peroxidase-strepta-
vidin conjugate (Zymed Laboraties Inc., San Francisco, CA) in 0.1% BSA-PBS and 3,3,5,5-
tetramethylbenzidine (Kirkegaard & Perry Laboratories, Gaithersburg, MD) in substrate buffer
were used to induce a color reaction, which was stopped after approximately 35 minutes by
adding H2SO4. Color intensity was measured using an ELISA reader set at 450 nm. The detec-
tion window was 12.5 to 800 pg/mL. 
Assessment of dietary protein-derived phenylalanine uptake
Plasma amino acid concentrations were determined by HPLC after deproteinization. The latter
was done on ice with 10 mg of dry 5-sulfosalicylic acid, which was mixed with 100 mL of plasma
and centrifuged, after which clear supernatant was collected. HPLC was used to determine
plasma amino acid concentrations after precolumn derivatization with o-phtaldialdehyde (28).
Plasma phenylalanine enrichment was measured using its t-butyldimethylsilyl derivative, and its
13C and 2H enrichments were determined by electron ionization gas chromatography in combi-
nation with mass spectrometry (GC-MS; 6890 GC/5973N MSD; Agilent, Little Falls, DE).
Molecular masses 336, 337 and 341 were assessed for unlabeled phenylalanine, 1-13C pheny-
lalanine, and ring-2H5 phenylalanine, respectively (32). Standard regression curves were used in
all isotopic enrichment analyses. Enrichments were calculated according to Biolo et al (2) to
correct for the presence of the 13C and 2H5 isotopes.
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Calculations
The total and exogenous (exo) rate of phenylalanine appearance (Ra) and plasma availability of
phenylalanine (Pheplasma) were determined by modified Steele equations (5, 8). These parameters
were calculated as:
Total Ra = 
F – pV · C (t) · dEiv/dt
Eiv (t)
Exo Ra = 
Total Ra · Epo (t) + pV · dEiv/dt
Eprot
Pheplasma = 
AUCExo Ra · 100
Pheprot
Where F is the intravenous (iv) tracer infusion rate, pV is the distribution volume for phenylala-
nine (pV=0.125), C (t) is the mean plasma phenylalanine concentration between two consecutive
time points, dEiv /dt is the time-dependent variation of plasma phenylalanine enrichment derived
from the iv tracer, and Eiv (t) is the mean plasma phenylalanine enrichment from the iv tracer
between two consecutive time points. Epo is the mean plasma phenylalanine enrichment form
the oral tracer, dEpo/dt represents the time-dependent variations in plasma enrichment from the
oral tracer, Eprot is the L-[1-
13C]phenylalanine enrichment in the dietary protein, Pheprot is the
amount of dietary phenylalanine ingested. AUCExo Ra represents the area under the curve (AUC)
of Exo Ra, corresponding to the amount of dietary phenylalanine appearing in the circulation
over the 6h period after intake of the drink. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism (Version 5.00, GraphPad Software for
Windows, San Diego California, USA). All data are presented as mean ± standard error of the
mean (±SEM). Normal distribution was tested using the D’Agostino and Pearson omnibus test.
Paired data were analyzed by Friedman test/Wilcoxon signed rank test or repeated-measures
analysis of variance/Student's paired t-test. Unpaired variables were assessed by Mann-Whitney
U test or Student's unpaired t-test. Correlation analysis was performed and expressed using
Spearman correlation coefficient (RS). Linear regression was used to visualize the correlation.
Correlations between plasma I-FABP levels and protein digestion and absorption rates were
determined in samples collected immediately after rest/exercise and 45 minutes after rest/exer-
cise, respectively, since we expected this to be the time interval in which the largest differences
could be observed. A P-value<0.05 was considered statistically significant.
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RESULTS
Small intestinal injury following resistance-type exercise 
The 12 participants assigned to the exercise experiment all completed the 30-min standardized
exercise protocol, consisting of 5-min cycling and resistance-type leg exercises. Intensity of
cycling and leg exercises were based on the individual’s body weight and maximal strength,
respectively. Plasma levels of I-FABP increased from 254±31 pg/ml at baseline to 344±53 pg/ml
measured directly after the last leg exercise, i.e. an increase of 35.4% from baseline (P<0.05),
while I-FABP levels did not change in resting conditions (Figure 1). Plasma I-FABP levels after
exercise, depicted as a percentage from baseline,  were increased compared to levels observed in
the resting control treatment (P<0.05; Figure 1). 
Uptake of amino acids from ingested dietary protein 
Digestion and absorption of dietary L-[1-13C]phenylalanine-labeled protein was studied in 12
athletes after 30 minutes at rest and in 12 athletes after a single bout of exercise. Both in resting
and in post-exercise conditions, a trend towards increased plasma I-FABP levels was associated
with protein intake (total increase of ca. 17% compared with pre-intake levels; n=24, P=0.06;
Figure 1). Oral intake of the labeled dietary protein increased plasma phenylalanine levels both
in both the resting and post-exercise condition, reaching peak levels 30 min after protein intake
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Figure 1: Resistance-type exercise increases plasma I-FABP levels
Thirty minutes of resistance-type exercise increased plasma I-FABP levels when compared with rest (P<0.01).
Solid squares represent post-exercise data and open squares represent data obtained from athletes at rest. Squares
represent mean data, with the SEM as black lines.
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(Figure 2A). Plasma phenylalanine concentrations were higher in resting compared with post-
exercise conditions (P<0.0001; Figure 2A).
   Ingestion of the labeled dietary protein did not only elevate the circulating levels of pheny-
lalanine, but also increased plasma concentrations of other essential amino acids both in resting
and post-exercise conditions (Figure 2B). In line with the phenylalanine data, the postprandial
rise in plasma essential amino acid levels was attenuated in the post-exercise situation when
compared to the resting condition (P<0.0001; Figure 2B). Post-prandial plasma non-essential
amino acid concentrations were not significantly different between resting and post-exercise 
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Figure 2: Plasma phenylalanine (A) and total essential amino acid (B) concentrations 
A) Postprandial increases in plasma phenylalanine levels were more pronounced at rest when compared with post-
exercise conditions (P<0.0001). B) Plasma essential amino acid concentrations increased after protein ingestion at
rest and after exercise, but post-exercise concentrations were lower when compared with values observed during
resting conditions (P<0.0001). Solid squares represent post-exercise data and open squares represent data obtained
from athletes at rest. Data represent mean ± SEM. 
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conditions (data not shown). In the post-exercise situation, plasma L-[1-13C]phenylalanine
enrichments were lower when  compared to resting conditions (P<0.05; Figure 3A). In line, a
trend towards a lower AUC0-120min of Exo Ra was observed after exercise when compared with
resting conditions (16±2.0 vs 20±1.5 mmol phenylalanine.kg body mass-1·min-1, respectively;
P=0.09).
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Figure 3: Plasma L-[1-13C]phenylalanine enrichment (A) and exogenous phenylalanine rate of appearance (B)
A) Plasma L-[1-13C]phenylalanine enrichments were more pronounced in resting conditions compared to post-
exercise (P<0.05) B) The dietary phenylalanine appearance rate was decreased in the 0-120 min post-exercise
recovery period when compared with resting conditions (P<0.001). Solid squares represent post-exercise data and
open squares represent data obtained from athletes at rest. Data represent mean ± SEM. MPE, moles percent
excess.
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   Following protein consumption, plasma exogenous phenylalanine appearance rates increased
both in resting and post-exercise conditions, reaching peak levels 30-45 minutes after protein
ingestion (Figure 3B). Interestingly, plasma phenylalanine appearance rates derived from the
ingested dietary protein were lower during post-exercise recovery when compared with resting
conditions. Exogenous phenylalanine plasma appearance rates peaked at 0.18±0.04 mmol
phenylalanine.kg lean body mass-1·min-1 after exercise compared with 0.23±0.03 mmol pheny-
lalanine·kg lean body mass-1·min-1 at rest (Figure 3B). 
Exercise-induced intestinal injury attenuates post-exercise dietary protein digestion and
absorption kinetics 
Changes in plasma I-FABP levels at rest or immediately after exercise correlated with in vivo
dietary protein digestion and absorption rates (RS=–0.57, n=24, p<0.01 at 45 minutes). 
   Specific analysis of the subset of exercising participants revealed a correlation between changes
in plasma I-FABP levels with in vivo dietary protein digestion and absorption rates (RS=–0.62,
n=12, p<0.05 at 45 minutes; Figure 4). A correlation was observed between the total peak area
of plasma I-FABP levels and total exogenous phenylalanine uptake (RS = –0.41, n=24, P<0.05).
The latter correlation was also found if only the subset of exercising participants was analyzed
(RS=-0.62, n=12, p<0.05 at 45 minutes).
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Figure 4:  Correlation of plasma I-FABP levels with exogenous Phe rates of appearance 
Exercise-induced small intestinal injury, reflected by plasma I-FABP levels, correlated negatively with in vivo dietary
protein digestion and absorption rates (RS=–0.62, n=12, p<0.05 at 45 minutes).
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DISCUSSION
The current study shows that resistance-type exercise increases plasma I-FABP levels, reflecting
small intestinal cellular injury. In line, postprandial dietary protein digestion and absorption
kinetics are shown to be attenuated during acute post-exercise recovery. Plasma levels of I-FABP
correlated with the appearance of the dietary protein-derived amino acids in the circulation,
indicating that exercise-induced small intestinal injury impairs dietary protein digestion and
absorption kinetics during acute post-exercise recovery.
   Previously, we demonstrated that exercise-induced small intestinal injury is caused by splanch-
nic hypoperfusion (30). Splanchnic hypoperfusion during exercise is a result of rapid redistrib-
ution of blood from the abdominal region towards the active muscle groups (7), and is known
to predominantly affect the mature enterocytes at the upper half of the intestinal villi. The reason
for the susceptibility of these cells to hypoperfusion is the countercurrent exchange mechanism
in the villi resulting in a low-flow and low-oxygen environment at the top of the villi (3, 4). The
reduction of the splanchnic blood flow during exercise contributes to the physiological low-flow
state of these enterocytes, further depriving the cells from nutrients and oxygen. I-FABP is a
small protein present in the susceptible mature enterocytes, and is rapidly released upon cellular
injury due to hypoperfusion and ischemia (10, 13). The noted rise in I-FABP during exercise
found in this study suggests the occurrence of ischemia-induced injury. These observations are
in line with previous data showing a twofold increase in baseline I-FABP levels after a single 60-
minute session of endurance-type exercise (30). Similar plasma I-FABP levels have been reported
in patients with splanchnic hypoperfusion during non-abdominal surgery (increase of ~60%
from pre-surgical levels) (11) and in trauma patients brought into the emergency room (9).
These data imply that the observations in the present study are not only relevant for athletes but
may also be of important clinical relevance for more compromised patient groups.   
   Interestingly, a trend towards increasing plasma I-FABP levels was observed during the first
15 minutes after consuming a single 20-g bolus of dietary protein, both in rest and after exercise,
suggesting that protein intake slightly disturbs enterocyte integrity. This observation might be
explained by the fact that the presence of food in the GI tract rapidly increases the need for
splanchnic blood flow (27). We speculate that in the short time period directly after food intake,
splanchnic blood flow may not be adequate, leading to minor GI compromise. Nonetheless, this
rapid post-prandial increase in plasma I-FABP levels is relatively small when compared with the
substantial 40-100% increase in I-FABP levels observed after resistance-type or endurance-type
exercise.
   The production and use of intrinsically L-[1-13C]phenylalanine labeled dairy protein in com-
bination with continuous intravenous infusion of the tracer L-[ring-2H5]phenylalanine  in this
study provides a unique opportunity to assess dietary protein digestion and absorption in an in
vivo human model (26, 29). Immediately after protein ingestion, protein-derived phenylalanine
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appeared rapidly in the circulation both at rest and after exercise. The post-prandial rise in plasma
1-13C Phenylalanine appearance rate was attenuated in the acute post-exercise recovery period
when compared with resting conditions. Uptake rates were lower after exercise than at rest, lead-
ing to reduced protein uptake during acute post-exercise recovery. In line, lower postprandial
increases in plasma essential amino acid concentrations were observed after resistance-type exer-
cise when compared with resting conditions. Altogether, these data show that dietary protein
digestion and absorption are compromised during acute post-exercise recovery. The latter is of
considerable interest as dietary protein digestion and absorption kinetics are at least partly
responsible for the post-prandial muscle protein synthetic response to food intake (17, 25). How-
ever, despite diminished dietary protein digestion and absorption, postprandial muscle protein
fractional synthesis rates were found to increase after exercise compared to rest in this population
(25). In addition, studies showed that especially in the immediate postexercise period, protein
intake stimulates muscle protein synthesis compared with late protein intake (19). Hence, we
do not believe that protein intake should be delayed based on the current findings; but, since
even small changes can make the difference between winning and losing in athletic competition,
it may be useful to determine whether such a difference in absorption found in this study has a
meaningful effect on postexercise net muscle protein balance. Because a more rapid supply of
amino acids following exercise has previously been shown to maximize postexercise muscle pro-
tein synthesis rates and improve the skeletal muscle adaptive response to more prolonged exercise
training, new insights on gastrointestinal functioning may be used for fine-tuning the nutritional
strategies to meet both gastrointestinal and muscle capacity. Our present findings indicate that
dietary protein digestion and absorption are compromised in the post-exercise recovery phase.
In agreement, we previously demonstrated that exercise especially affects the proximal part of
the GI tract (30), which is the primary location of dietary protein digestion and absorption (22).
To further clarify the effects of exercise on post-exercise dietary protein uptake, the relation
between exercise-induced intestinal injury and plasma appearance of the protein-derived amino
acids was studied. Data revealed a strong, negative relation between plasma I-FABP levels and
plasma appearance rates of exogenous phenylalanine. The presence of such a significant corre-
lation between plasma I-FABP levels and in vivo dietary protein digestion and absorption kinetics
implies that the extent of small intestinal injury measured by I-FABP is a good reflection of the
impact of exercise on intestinal function with respect to dietary protein digestion and absorption.
Determination of plasma I-FABP levels may be used to obtain valuable information on gut
integrity and gut function of athletes and patients during training sessions and during exercise
intervention programs, respectively. This may be of particular interest in more compromised
patient populations that are subjected to a lifestyle intervention or rehabilitation program. As
gut function is generally compromised in the elderly population it may be of considerable interest
to also assess the impact of exercise on gut function and the subsequent delivery of exogenous
amino acids to allow post-exercise muscle protein synthesis in an elderly population.
DIETARY PROTEIN DIGESTION AND ABSORPTION ARE IMPAIRED DURING ACUTE POST-EXERCISE
153
Proefschrift laatste versie_Opmaak 1  6/10/13  10:11 AM  Pagina 153
   From this study we conclude that exercise-induced loss of enterocyte integrity attenuates
dietary protein digestion and absorption, impairing dietary protein derived amino acid uptake
during acute post-exercise recovery in healthy, young recreationally active individuals. These
data implicate that work is needed to address the impact of exercise on GI integrity and GI func-
tion. Dietary strategies need to consider compromised gut function and food intake regimens
should be modulated to allow proper nutrient delivery during exercise and subsequent acute
post-exercise recovery. The latter could be of considerable interest to optimize post-exercise mus-
cle reconditioning in both health and disease. 
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ABSTRACT 
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used by athletes to prevent
anticipated exercise-induced pain, thereby putatively improving physical performance. However,
these drugs may have potentially hazardous effects on the gastrointestinal (GI) mucosa during
strenuous physical exercise. The aim of the current study was to determine the effect of oral
ibuprofen administration prior to exercise on GI integrity and barrier function in healthy indi-
viduals. 
   Nine healthy, trained men were studied on four different occasions: 1) 400 mg ibuprofen twice
prior to cycling, 2) cycling without ibuprofen, 3) 400 mg ibuprofen twice at rest, and 4) rest
without ibuprofen intake. To assess small intestinal injury, plasma intestinal fatty acid binding
protein (I-FABP) levels were determined, whereas urinary excretion of orally ingested multi-
sugar test probes was measured using liquid chromatography and mass spectrometry to assess
GI permeability. 
   Both ibuprofen consumption and cycling resulted in increased I-FABP levels, reflecting small
intestinal injury. Levels were higher after cycling with ibuprofen than after cycling without
ibuprofen, rest with ibuprofen, or rest without ibuprofen (peak I-FABP 875±137, 474±74,
507±103, and 352±44 pg/mL, respectively, P<0.002). In line, small intestinal permeability
increased, especially after cycling with ibuprofen (0-2h urinary lactulose/rhamnose (L/R) ratio
0.08(0.04-0.56) compared to 0.04(0.00-0.20), 0.05(0.01-0.07), and 0.01(0.01-0.03), respec-
tively), reflecting loss of gut barrier integrity. Interestingly, the extent of intestinal injury and
barrier dysfunction correlated significantly (RS=0.56, P<0.001).
   In conclusion, this is the first study to reveal that ibuprofen aggravates exercise-induced small
intestinal injury and induces gut barrier dysfunction in healthy individuals. We conclude that
NSAID consumption by athletes is not harmless and should be discouraged.
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INTRODUCTION 
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used by athletes to reduce
existing or prevent anticipated musculoskeletal pain related to physical exercise, especially in the
competitive season (1,15). Athletes have reported the use of NSAIDs both during training and
competition (16). It is generally assumed that NSAIDs improve athletic performance by enabling
more frequent and more intensive training sessions, but no clear evidence exists. The reported
prevalence of NSAID use among athletes differs widely between various sport types and ranges
from 12% in cyclists to over 90% in professional soccer players (16,29,32). 
   A major adverse effect of NSAIDs is their known tendency to cause gastrointestinal (GI) com-
plications such as mucosal ulceration, bleeding, perforation, and the formation of diaphragm-
like strictures (2,35). Several mechanisms of action have been suggested to play a role in the
development of these NSAID-induced complications: inhibition of cyclo-oxygenase (COX)-1
and reduction of local nitric oxide (NO) production via regulation of the NF-κ-B pathway may
impair perfusion of the upper GI tract (20), whereas COX-2 inhibition compromises
immunomodulation, potentially resulting in the onset of an inflammatory response (4). 
   We previously demonstrated that one hour of exhaustive physical activity leads to small intes-
tinal injury and short-term loss of gut barrier function in otherwise healthy individuals (33). In
the light of such exercise-induced GI compromise, it seems that the hazardous effects of NSAIDs
on the GI mucosa may put athletes at risk for more severe abdominal distress. We hypothesize
that the combination of short-term NSAID consumption with the physiological exercise-induced
splanchnic hypoperfusion may lead to aggravated intestinal injury in athletes. The current study
shows that the use of NSAIDs intensifies exercise-induced small intestinal injury and loss of
intestinal barrier integrity in healthy athletes. 
METHODS AND MATERIALS
Subjects’ characteristics
Power calculation performed prior to the start of the study revealed that a sample size of 9 subjects
was required to achieve 80% statistical power and detect statistically significant differences in the
current experimental setting. Therefore, nine healthy male cyclists or triathletes (age: 27±0.9 years,
body mass index: 20.6±0.6 kg/m²) were selected to participate in the present study. Maximal work-
load capacity (Wmax) was 5.5±0.2 W/kg, with maximum heart rate at 192±2 bpm. All volunteers
spent 3 to 10 hours per week performing endurance sports as part of their normal life style. The
volunteers had no abdominal complaints during daily activities, had not taken any medication for
at least one month prior to participation, had no history of GI disease, and had no history of
abdominal surgery. Volunteers were informed about the nature and risks of the experiments. 
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   Written consent was obtained at least 5 days prior to the experiments. This study was approved
by the medical ethics committee of Maastricht University Medical Centre+, and conducted in
accordance with the Declaration of Helsinki (revised version, October 2008, Seoul).
   
Pre-exercise arrangements 
Wmax was assessed prior to the experiments on a stationary cycle ergometer (Lode Excalibur,
Groningen, The Netherlands) (18). Electrocardiographic monitoring (MAC 5500, GE Medical
Systems, Freiburg, Germany) was performed to exclude cardiologic abnormalities such as exer-
cise-induced cardiac ischemia or arrhythmia. An experienced cardiological resident interpreted
the results and found no abnormalities. Participants maintained normal activities of daily living,
but refrained from strenuous physical activity for the 2 days prior to the test days, and were not
allowed to consume alcohol and artificial sweeteners the day prior to the experiments. Ibuprofen
(400 mg, iso-butyl-propanoic-phenolic acid, GlaxoSmithKline, Brentford, Middlesex, United
Kingdom) was ingested by the participants on the evening prior to the ibuprofen test days. An
additional 400 mg of ibuprofen was consumed on the morning of these test days, at 7:00 a.m.,
being 60 minutes before start of the experiments to mimic the normal use of ibuprofen by athletes. 
Study design and sampling 
All 9 subjects were tested consecutively in random order in 4 different situations: (1) during and
after cycling after intake of ibuprofen, (2) during and after cycling without ibuprofen, (3) rest
with prior intake of ibuprofen, (4) rest without prior ibuprofen intake. Time between test days
was at least 7 days. All experiments were performed after an overnight fast. Upon arrival to the
sports laboratory at 08:00 a.m., a catheter (20 Gauge, Braun, Melsungen, Germany) was placed
in the participant’s forearm vein to obtain blood samples, which were put into pre-chilled EDTA
tubes (Vacucontainer, Becton Dickinson (BD), Helsingborg, Sweden) and kept on ice. 
   On test days that participants were assigned to cycling, participants started cycling at a work-
load of 150 W after collection of baseline plasma and urine samples. After 3 minutes, workload
was increased to 70% of the individual’s pre-assessed Wmax (70% of Wmax was 268±9 W, depicted
as mean±SEM of the 9 participants). Subjects maintained pedal rates of at least 60 rpm, and
workload was decreased by 25 W if participants were unable to maintain 60 rpm. Participants
consumed tap water ad libitum, with a minimum of 50 mL and a maximum of 150 mL every
10 minutes. After 30 minutes of cycling, the test subjects ingested a 150-mL multi-sugar drink
to enable whole gut permeability analysis. A second urine sample was collected by the partici-
pants at 90 minutes after exercise. Resting test days were similar in setup, with the exception
that the participants were tested during and after 1 hour of rest in supine position instead of
during and after cycling. On all test days, blood and urine samples were centrifuged within 
1 hour of collection at 4°C at 2300 x g for 15 minutes, and stored at -80°C until analysis. Analy-
ses were performed when sample collection was complete for all participants, in order to perform
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analyses in consecutive runs. Any GI complains of the subjects during the test days were regis-
tered by the researcher, and subjects were contacted 2 days after the test day to assess the occur-
rence of GI complaints on the day following each test day. 
Assessment of small intestinal injury
To evaluate the presence and the extent of small intestinal injury in the above-described situa-
tions, plasma concentrations of human Intestinal Fatty Acid Binding Protein (I-FABP) were
determined by an analyst who was blinded for the specific test conditions. I-FABP is a 15-kD
cytosolic protein present especially in the mature enterocytes of the small intestine that rapidly
diffuses through the interstitial space into the circulation upon enterocyte injury, making it an
early and sensitive marker of small intestinal injury (19,25). I-FABP was measured by an in-
house developed enzyme linked-immunosorbent assay (ELISA). In short, ELISA plates were
coated with anti-I-FABP immunoglobulin G (IgG) overnight at 4ºC, free sites were blocked
with 1% bovine serum albumin (BSA) in PBS. Plasma samples and human recombinant I-FABP
for standard calibration curves were incubated at room temperature, after which biotinylated
anti-I-FABP IgG was added. After washing, horseradish peroxidase-streptavidin conjugate
(Zymed Laboraties Inc., San Francisco, CA) in 0.1% BSA-PBS and 3,3,5,5-tetramethylbenzi-
dine (Kirkegaard & Perry Laboratories, Gaithersburg, MD) were added. The reaction was
stopped and color intensity was measured with an ELISA reader at 450 nm. The detection win-
dow of the I-FABP assay was 12.5 to 800 pg/mL. 
Assessment of GI permeability 
GI permeability was determined as a measure of GI barrier integrity, using a multi-sugar test
drink as described previously (34). The food grade sugar probes included in the test drink were
1 g lactulose (Centrafarm, Etten-Leur, The Netherlands), 1 g sucralose (Brenntag, Sittard, The
Netherlands), 1 g erythritol (Danisco, Copenhagen, Denmark), 1 g sucrose (Van Gilse, Dintelo-
ord, The Netherlands), and 0.5 g L-rhamnose (Danisco) dissolved in 150 mL tap water. GI per-
meability was assessed by determination of the 0-2h urinary excretion of these orally ingested
sugar probes using a combined high performance liquid chromatography (HPLC, Model PU-
1980 pump, Jasco Benelux, Maarsen, The Netherlands) and mass spectrometry (Model LTQ-
XL, Thermo Electron, Breda, The Netherlands) approach (34). Gastroduodenal permeability
was assessed by calculation of the 0-2h urinary ratio of sucrose (342 D) and L-rhamnose (164
D), whereas the urinary 0-2h ratio of lactulose (342 D) and L-rhamnose, the L/R ratio, was
computed to assess small intestinal permeability. 
Statistical analysis
Statistical analysis was performed using GraphPad Prism (Version 5.00, GraphPad Software for
Windows, San Diego, CA). Normality of all data was verified by the Kolmogorov-Smirnov test.
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All normally distributed data are presented as mean±standard error of the mean (SEM), not
normally distributed data as median and range. Continuous data were analyzed using two-way
analysis of variance with Bonferroni post-hoc test for multiple comparisons. Correlations were
determined by calculating the Spearman correlation coefficient (RS). Linear regression was used
to visualize the correlation. Correlations between small intestinal injury and small intestinal per-
meability were computed using indvidually normalized I-FABP levels and P<0.05 was deemed
statistically significant.
RESULTS
Ibuprofen aggravates exercise-induced intestinal injury 
Plasma I-FABP levels were determined to assess loss of cellular integrity within the small intes-
tine. In line with our previous study (33), plasma I-FABP levels gradually increased during
cycling at 70% of Wmax from baseline 295±46 pg/mL to mean peak levels of 474±74 pg/mL
immediately post-exercise (P<0.05; Figure 1A). Interestingly, cycling with ibuprofen resulted in
even higher levels of circulating I-FABP (P<0.0001; Figure 1A). In the latter situation, peak I-
FABP levels of 875±137 pg/mL were observed immediately post-exercise, being a significant
increase from baseline (328±32 pg/mL; P<0.05; Figure 1A). These peak I-FABP levels were sig-
nificantly higher than I-FABP levels after cycling without ibuprofen (875±137 vs 474±74 pg/mL,
P<0.05; Figure 1A,C). 
   Ibuprofen consumption also increased levels of small intestinal injury at rest (P<0.05; Figure
1B,C). Two out of nine participants reported minor abdominal complaints during the study,
including epigastric pain, flatulence and belching after ibuprofen administration. One individual
(individual A) reported these symptoms only after ibuprofen administration at rest, and his symp-
toms were not accompanied by high plasma I-FABP levels (259 vs 273 pg/mL with and without
ibuprofen at rest, respectively). The other, individual B, reported symptoms on both test days
after ibuprofen administration and had elevated plasma I-FABP levels (579 vs 495 pg/mL with
and without ibuprofen at rest, and post-exercise levels of 1493 vs 865 pg/mL for cycling with
and without ibuprofen, respectively). Additionally, the I-FABP levels of participant B were con-
siderably higher than the mean I-FABP levels of the total group depicted in Figure 1A,C.
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Figure 1: Ibuprofen significantly increases plasma I-FABP levels in rest and during cycling
A) Plasma I-FABP levels in athletes during and after cycling with prior intake of ibuprofen compared to cycling
without ibuprofen (P<0.0001). Squares represent mean data, with the SEM as black lines. B) Plasma I-FABP levels
after intake of ibuprofen compared to control (i.e. no ibuprofen) in athletes at rest (P=0.0003). Squares represent
mean data, with the SEM as black lines. C) Peak plasma I-FABP levels in healthy athletes during rest and cycling
conditions with or without ibuprofen. Squares represent individual data, with the mean±SEM depicted as black
lines (*P<0.05, **P≤0.001).
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Figure  2:  Ibuprofen increased 0-2h urinary sucrose/rhamnose (S/R) and lactulose/rhamnose (L/R) ratios 
A) 0-2h urinary S/R ratios in athletes after cycling with ibuprofen compared to rest without ibuprofen (P=0.06).
Squares represent individual data, with the median depicted as horizontal line. B) 0-2h urinary L/R ratios in athletes
after cycling with ibuprofen compared to cycling and rest without ibuprofen. Squares represent individual data,
with the median depicted as horizontal line (*P<0.05). C) Correlation of 0-2h urinary L/R ratios with normalized
plasma I-FABP levels. Squares represent individual data. 
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Ibuprofen prior to exercise increases gastroduodenal and small intestinal permeability 
Upper GI permeability increases after cycling with ibuprofen (0-2h S/R ratio 0.041(0.000-1.000)
vs 0.000(0.000-0.020) compared with rest; P=0.06; Figure 2A).Urinary S/R ratios showed a weak
but statistically significant correlation with peak plasma I-FABP levels (RS=0.49, P<0.005). 
    Consistent with gastroduodenal permeability, small intestinal permeability increased after
cycling with ibuprofen in 0-2h urinary L/R ratio to 0.08(0.04-0.56) compared with 0.03(0.00-
0.20) for cycling without ibuprofen. In addition, the 0-2h urinary L/R ration increased at rest with
ibuprofen use to 0.05(0.01-0.07) compared with 0.01(0.01-0.04) without ibuprofen (P<0.05; Fig-
ure 2B). Interestingly, levels of intestinal injury correlated significantly with small intestinal per-
meability.
   Peak plasma I-FABP levels of each test day correlated with 0-2h urinary L/R ratios (RS =
0.56, P<0.001; Figure 2C). In line, total shedding of I-FABP from injured enterocytes, reflected
by the Area Under the Curve (AUC) of plasma I-FABP levels, correlated with the 0-2h urinary
L/R ratios (RS = 0.48, P<0.05; data not shown). Gastroduodenal and small intestinal permeability
outcomes were not significantly different between symptomatic and asymptomatic participants,
but individual A did show relatively high permeability ratios after ibuprofen consumption. In
rest, the 0-2h S/R ratio of individual A was 0.475, and 0.398 after cycling. The 0-2h L/R ratio
of this individual was 0.058 in rest and 0.564 after cycling. 
   In summary, both gastroduodenal and small intestinal permeability increased after cycling
following ibuprofen intake. Additionally, a clear relation was found between exercise-induced
intestinal injury and small intestinal permeability after exercise.
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DISCUSSION 
NSAID consumption is common among athletes. Alarmingly, its prevalence among athletes has
been reported to reach 90% in specific sports (16,29,32). Especially endurance athletes are well
acquainted with the occurrence of GI problems during or after exercise (26,31). However, these
athletes have limited awareness of the potentially hazardous effects of NSAIDs on the GI tract
and their potential to induce GI discomfort (16). This study demonstrates that the use of ibupro-
fen prior to exhaustive exercise exacerbates exercise-induced small intestinal injury resulting in
the loss of gut barrier function in healthy men.
   Small intestinal injury as assessed by plasma I-FABP levels developed within one hour of
cycling at 70% of Wmax and gradually returned to baseline levels during 60 minutes of subsequent
post-exercise recovery. These data corroborated the findings of our previous study, in which we
demonstrated that the exercise-induced intestinal compromise is at least partly caused by the
rapid onset of splanchnic hypoperfusion (33). The latter is a result of the redistribution of
splanchnic blood flow that occurs to secure adequate perfusion of muscles, skin, heart and lungs
(24,27). Hypoperfusion decreases the supply of oxygen and nutrients to the gut, leading to injury
of the enterocytes lining the small intestinal villi (5,6), as reflected by leakage of I-FABP from
the affected enterocytes into the circulation (10). In line, injury of the GI tract after exercise has
also been established using endoscopy, showing mucosal inflammation and erosive mucosal
lesions in athletes after endurance running (8,23). 
    The exact mechanisms by which NSAID consumption leads to GI damage and increased risk
of upper GI complications such as mucosal lesions and perforation (11,12,14) have not yet been
fully elucidated. One of the major pathways considered to be involved is the inhibition of COX
isotypes 1 and 2, resulting in local inflammation and vascular dysregulation, ultimately reducing
perfusion and promoting mucosal integrity loss within the splanchnic area (9,12,30). In addition,
interference of NSAIDs with the production of NO due to prostaglandin-mediated microvascular
dysfunction may further reduce mucosal blood flow (20). This NSAID-induced reduction of the
splanchnic blood flow may deteriorate the exercise-induced state of splanchnic hypoperfusion,
putting athletes at risk for serious GI compromise. Endurance athletes have been observed to have
significant GI injury after endurance running without using NSAIDs (8,23), and the combination
of exercise and NSAIDs may aggravate this intestinal injury. Moreover, the negative effects of
NSAIDs may not be restricted to the GI tract. Recent studies have demonstrated an increased risk
of cardiovascular adverse events associated with the use of NSAIDs (7,13,17,22). 
    In the present study, high levels of plasma I-FABP were observed in athletes after cycling, strongly
suggesting intestinal injury. This intestinal damage was significantly more pronounced after admin-
istration of two (400 mg) oral doses of the over-the-counter drug ibuprofen than after cycling with-
out ibuprofen. Furthermore, ibuprofen intake induced abdominal discomfort in 2 out of the 9 ath-
letes. The recommended maximum daily dose for oral ibuprofen intake varies from 1.2 g for
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non-prescription use to 2.4 g for prescribed oral administration (28). Our results clearly demonstrate
that a considerably lower dose of ibuprofen prior to strenuous exercise aggravates exercise-induced
small intestinal injury, leading to intestinal compromise. Since endurance athletes often use higher
doses of NSAIDs and exercise for more than 1 hour, it may be expected that the intestinal compro-
mise is more pronounced in daily practice. Although in the current study, the NSAID-induced small
intestinal injury is reversible within 2 hours, long-term use of NSAIDs may prolong GI compromise,
increasing the risk of GI complications, and potentially affecting performance and recovery.
   Another key issue in the pathophysiology of NSAID-induced intestinal compromise is the
development of barrier integrity loss and subsequent translocation of bacteria and permeation
of harmful digestive enzymes (4,21). These processes contribute to the local inflammatory
response via activation of Toll-like receptor 4 and MyD88 (36). In the current study, loss of gut
barrier function was demonstrated by an increase in urinary sugar permeability ratios. The com-
pounding effect of NSAID consumption and heavy physical exercise led to increased gastroduo-
denal and small intestinal permeability, reflected by elevated urinary S/R and L/R ratios. The
strong correlation that was found between cellular injury and the loss of barrier function in the
small intestine emphasizes the extent of the intestinal compromise in the current study. Addi-
tionally, these data lead to the question whether the exercise-induced intestinal injury may also
negatively affect the digestive and absorptive function of the GI system, thereby impeding post-
exercise recovery. In case of extensive intestinal damage, both the intestinal barrier function and
the absorptive capacity of the GI tract may be compromised, yet future studies are warranted. 
   A limitation of the current study may be that we did not perform measurements to assess
hydration status or renal function that may potentially affect plasma and urinary markers of
intestinal compromise. GI permeability analysis in the current study was based on the urinary
excretion of large and small sugar permeability probes, but because these probes are equally
affected by factors as intestinal transit and renal function (3), alterations in renal function could
not have influenced permeability analysis. Furthermore, all 15 athletes participating in our pre-
vious study had normal hydration status and no detectable kidney damage after completion of
the same exercise protocol as applied in the current study (33). These data strongly suggest nor-
mal renal function in healthy athletes after 1 hour of cycling in our experimental setting.
Endurance athletes exercising in a hot environment are more prone to become dehydrated,
thereby potentially compromising renal function and clearance of NSAIDs. 
   In conclusion, the current study shows that in healthy endurance athletes, NSAID consump-
tion can aggravate exercise-induced small intestinal injury and induces loss of gut barrier func-
tion. Although the ergogenic properties of NSAIDs remain questionable, evidence is provided
to show that NSAIDs consumption is not harmless and may give rise to abdominal distress
(11,12,14). We consider it of utmost importance to increase the awareness of athletes and trainers
toward the potential negative effects of NSAIDs, and recommend that the use of NSAIDs in
the absence of a clear medical indication should be discouraged. 
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ABSTRACT
Splanchnic hypoperfusion is a physiological phenomenon during strenuous exercise. It has been
associated with gastrointestinal symptoms, intestinal injury, and increased intestinal permeability
in healthy athletes. We hypothesize that L-citrulline is able to improve splanchnic perfusion and
decrease intestinal injury by enhancing the availability of arginine, the direct precursor of
vasodilator nitric oxide. The aim of this study was to determine the effect of oral L-citrulline
supplementation on splanchnic perfusion, intestinal injury and GI barrier function during and
after exercise.
   In this randomized, double-blinded crossover study, ten men cycled for 60 minutes at 70%
of maximum workload after pre-exercise oral supplementation with L-citrulline (10 gram) or
placebo (L-alanine) 30 minutes prior to exercise. Splanchnic hypoperfusion was assessed using
gastric air tonometry. Sublingual microcirculation was evaluated by sidestream dark-field imag-
ing. Blood, sampled every 10 minutes, was analyzed for amino acid levels and the enterocyte
damage parameter intestinal fatty-acid binding protein (I-FABP). Changes in intestinal perme-
ability were assessed using sugar probes.
   Oral L-citrulline supplementation enhanced plasma citrulline (1840.3±142.3 mM) and plasma
arginine levels (238.5±9.1 mM) during exercise compared to placebo (45.7±4.8 mM and
101.5±6.1 mM, respectively), resulting in increased arginine availability following L-citrulline.
L-citrulline supplementation preserved splanchnic circulation, reflected by stable gapg-apCO2
levels (-1.70±0.19 to -1.45±0.63 kPa), and an increased number of perfused small sublingual
vessels (7.8±6.0 vs. -2.0±2.4 following placebo), while exercise-induced hypoperfusion was
observed with placebo. Plasma I-FABP levels were attenuated during exercise following L-cit-
rulline supplementation compared to placebo (AUC0-60min -185±506 vs. 1318±553; P<0.01).
No significant differences were observed for intestinal permeability.
   In conclusion, pre-exercise oral L-citrulline supplementation preserves splanchnic perfusion
during exercise compared to placebo in athletes, probably via enhanced arginine availability.
Interestingly, oral L-citrulline also attenuated hypoperfusion-induced intestinal injury during
exercise. These results suggest that oral L-citrulline supplementation is a promising therapy to
combat splanchnic hypoperfusion-induced intestinal integrity loss. 
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INTRODUCTION 
Gastrointestinal (GI) symptoms are common during strenuous physical exercise, and range from
mild nausea to ‘angine abdominale’ and hemorrhagic stool (40, 49). Incidence rates of gastroin-
testinal symptoms during strenuous exercise vary from 25 to 70%, depending on exercise inten-
sity and duration (40, 49). While the etiology of GI symptoms during exercise is thought to be
multifactorial, decreased splanchnic perfusion has been postulated as a key mechanism (15, 36,
48, 49). During strenuous physical exercise, blood is redistributed away from the splanchnic
area towards active muscles, the cardiopulmonary system and skin (7, 44), thereby strongly
reducing splanchnic blood flow (38, 54). We have recently demonstrated that splanchnic hypop-
erfusion is associated with small intestinal cellular injury and loss of gut barrier function in
healthy individuals (54). Intestinal cellular and barrier integrity loss are undesirable phenomena
especially for athletes, since they may lead to abdominal distress, compromised food uptake and
may interfere with early recovery (53). Disruption of the intestinal barrier may lead to more GI
injury, since it exposes the submucosal tissue to bacteria, potentially harmful pancreatic juices
and digestive products (4). The splanchnic microcirculatory blood flow is a potential target to
prevent exercise-induced splanchnic compromise (26). One way to enhance the intestinal micro-
circulation is to increase the local availability of nitric oxide (NO), an important endogenous
regulator of the microcirculation (32). NO is produced in the intestine via oxidation of L-arginine
upon activation of endothelial nitric oxide synthetase (eNOS) in endothelial cells and inducible
NOS (iNOS) during ischemia-induced intestinal damage (33). NO inhalation has been applied
as therapeutic agent in experimental settings in patients with pulmonary arterial hypertension
to induce local vasodilatation (21) and was found to attenuate lung ischemia-reperfusion injury
in animal studies (20). However, since NO is a gas, it cannot easily be applied locally to other
organs than the lungs. Therefore, many NO-donors have been studied to increase local NO levels
to improve mucosal oxygenation. L-arginine was one of the first agents studied in this respect,
and while its administration did increase plasma arginine levels and NO availability to some
extent, the results were not unequivocally positive (5, 8, 41, 43). Oral supplementation of cit-
rulline, a non-protein amino acid and an important precursor of arginine (50, 60), has been
shown to increase L-arginine availability for NO production to a greater extent than L-arginine
supplementation itself (11, 45, 46). The latter is explained by a combination of factors: (a) L-
citrulline is transported more efficiently from the lumen into the circulation than L-arginine;
(b) a balanced, probably near null flux across the liver exists for L-citrulline, which means that
L-citrulline hepatic uptake is counterbalanced by L-citrulline release (11, 50, 51) and citrulline
released from the gut enters the systemic circulation ‘untouched’; and (c) L-citrulline is actively
converted to L-arginine within endothelial cells so that L-arginine can be used for NO-produc-
tion rather than to induce ureagenesis (61). Metabolisation of L-citrulline occurs in the kidneys,
where it is converted via argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL)
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into L-arginine (1, 11). Ten gram of oral L-citrulline supplementation in healthy subjects has
been shown to increase plasma citrulline and arginine levels and to improve muscle protein syn-
thesis (22), without causing negative side effects such as diarrhea, GI discomfort and nausea, as
seen after L-arginine supplementation (24). Therefore, L-citrulline seems to be a promising sub-
strate to enhance the intestinal L-arginine availability (34, 59), thereby restoring the intestinal
NO production in endothelial cells and increasing the intestinal microcirculatory perfusion (59).
Based on these findings, we hypothesized that oral supplementation of 10 gram L-citrulline prior
to strenuous exercise increases the arginine availability in healthy athletes; thereby improving
splanchnic perfusion and reducing exercise-induced GI injury, and GI barrier loss. This was
tested in a randomized, double-blinded, placebo-controlled crossover study.
METHODS AND MATERIALS
Subjects’ characteristics
Ten healthy recreationally active men (age: 24.9±1.0 years, body mass index: 21.1±0.4 kg/m²)
were selected to participate in the present study. Maximal workload capacity (Wmax), assessed
prior to the experiments on a stationary cycle ergometer (Lode Excalibur, Groningen, the
Netherlands) (29) was 5.0±0.1 W/kg, with maximum heart rate of 194±2 bpm. The selected
volunteers all spent 3 to 15 h per wk performing endurance sports as part of their normal life
style. The volunteers had no abdominal complaints during daily activities, had not taken any
medication for at least one month prior to participation, had no history of GI disease, and had
no history of abdominal surgery. Selected volunteers were informed about the nature and risks
of the experiments, after which written consent was obtained at least 5 d prior to the experiments.
This study was approved by the medical ethics committee of Maastricht University Medical
Centre+ (MEC 10-3-064), and conducted in accordance with the Declaration of Helsinki
(revised version, October 2008, Seoul).
   Participants maintained normal activities of daily living, but refrained from strenuous physical
activity for 2 d prior to each test day. Participants were not allowed to consume alcohol and arti-
ficial sweeteners the day prior to the experiments. Ranitidine (150 mg, GlaxoSmithKline, Zeist,
the Netherlands) was ingested by the participants on the evening prior to each test day to inhibit
gastric acid production and secretion. The latter is necessary to enable gastric tonometry meas-
urements, since the presence of acid in the stomach during tonometry can buffer carbon dioxide
molecules, thereby interfering with the outcome of the tonometry measurements (28). An addi-
tional 150 mg of ranitidine was consumed on the morning of the test days, at 07:00, being 60
min before start of the experiments. 
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Study design and nutritional intervention 
In this double-blind randomized controlled crossover study, the participants were randomized
for two different interventions, i.e. oral L-citrulline supplementation and placebo supplementa-
tion. All subjects performed the two test days in random order: (1) after oral intake of a 10 g
bolus of L-citrulline dissolved in 125 mL tap water and (2) after intake of the 125 mL placebo
drink, containing 20 g of L-alanine in tap water. Both L-citrulline and the placebo were tested
safe for human oral consumption by Basic Pharma Group (Geleen, the Netherlands), and sup-
plied as powders to be dissolved 30 minutes prior to intake by the participants. The test drinks
were isonitrogenous and had no specific taste. No additives or sweeteners were used. Time
between test days was at least 7 d. 
Experiments and sampling
All experiments were performed after an overnight fast. Upon arrival to the sports laboratory at
08:00 A.M., participants were instructed to collect a urinary sample. To enable collection of arte-
rialized blood for analysis of arterial pCO2 levels, a catheter (22 Gauge, Braun, Melsungen, Ger-
many) was inserted in a dorsal hand vein of the participant, and the hand was placed in a hot box
set at 60ºC (27). To measure gastric pCO2, an 8 French tonometrics catheter (Datex Ohmeda,
Finland) was introduced via the nose into the stomach of the participant, and fixed to the nasal
flares. Gastric pCO2 was measured at 10-minute intervals before, during, and after cycling using
an automated capnograph (Tonocap TC-200, Datex Ohmeda, Finland). Arterialized blood samples
were collected simultaneously with the tonometry measurements in heparin tubes and gastric-
arterialized pCO2 (pg-a pCO2 gap) was calculated. At each time point, a second blood sample was
collected into pre-chilled ethylenediaminetetraacetic acid (EDTA) tubes (Vacucontainer, Becton
Dickinson (BD), Helsingborg, Sweden) for analysis of plasma parameters. After calibration of the
tonometry device, side-stream dark field (SDF) sublingual imaging was performed for baseline
assessment of the microcirculation as described below. After baseline measurements, participants
ingested the test drink they were assigned to for that day. 30 minutes after intake of the test drink,
participants started cycling at a workload of 150 W. After 3 min, workload was increased to 70%
of the individual’s pre-assessed Wmax (70% of Wmax was 248.2±7.6 W). Subjects maintained pedal
rates of at least 60 rpm, and workload was decreased by 25 W if participants were unable to main-
tain the 60 rpm. Participants consumed tap water ad libitum, with a minimum of 50 mL and a
maximum of 150 mL every 10 min. After 30 minutes of cycling, the test subjects ingested a 150-
mL multi-sugar drink to enable whole gut permeability analysis, while cycling to complete the 60-
minute exercise bout. Immediately post-exercise, SDF imaging was performed to measure sublin-
gual microcirculation. Additional SDF imaging was performed at 30 minutes and 1 hour after
cycling, while a second urinary sample was collected 90 minutes after cycling. All collected blood
and urine samples were centrifuged as soon as possible after collection at 4°C at 2300 x g for 15
min, and stored at -80°C until analysis. Any GI complaints of the subjects during the test days
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were registered by the researchers, and subjects were contacted 2 d after the test day to assess
the occurrence of GI complaints on the day following each test day. 
Assessment of circulating amino acids 
To evaluate whether the L-citrulline supplementation resulted in an enhanced arginine avail-
ability index, plasma amino acids concentrations were measured and the arginine availability
index (AAI) was calculated as (9, 35) [arginine]
   [ornithine] + [lysine]
and is an index based on the cellular uptake of arginine, ornithine, and lysine by the same trans-
port system, the y+ transporter. Plasma amino acid analysis was performed after blood collection
and centrifugation. A 100 mL plasma aliquot was pipetted into a 1.5 mL Eppendorf tube that
already contained 5.5 mg solid sulfosalicylic acid (SSA), vortex-mixed immediately to depro-
teinize the plasma samples, snap frozen in liquid nitrogen and stored at -80°C until analysis. 
   Before analysis, deproteinized plasma samples were thawed, vortex-mixed and centrifuged for
10 min at 50,000 x g at 4°C in a Biofuge Stratos centrifuge (Heraeus, Haarlem, the Netherlands).
Next, 5 mL of the clear supernatant was diluted 100-fold in ice-cold water into a 1 mL WISP-
style vial (Waters, Etten-Leur, the Netherlands).  Amino acid analysis was performed by HPLC
after automated pre-column derivatization using ophthaldialdehyde (OPA) as described before
(52). Briefly, at the start of each cycle, 5 mL of the diluted sample, stored in the pre-chilled sample
compartment of a WISP autosampler, was automatically mixed with 5 mL of OPA reagent. The
resulting OPA-amino acid derivatives were separated on a 150x4.6 mm (inner diameter) Allsphere
ODS 2 3 mM High-Performance Liquid Chromatography (HPLC) column (Grace, Breda, the
Netherlands), using an acetonitrile gradient against an aqueous citric acid buffer (25 mmol/L,
pH=6.8) and detected by fluorescence (330 nm excitation, 440 nm emission). 
Assessment of microcirculation
To evaluate the intestinal microcirculation during exercise, the sublingual microcirculation was
measured to reflect with an SDF imager (25, 47). SDF imaging was used to discriminate
between vessels of different diameter and to assess the proportion of perfused sublingual vessels.
The SDF imager uses 530nm light absorbed by the hemoglobin in red blood cells which allows
observation of these cells in the microcirculation (6). All imaging measurements were done 
by an experienced investigator. Using a camera magnification of 5x, sharp real-time images of
the sublingual microcirculation were obtained in a field of 1000x750 m. In total 20-sec contin-
uous image sequences per time-point, each consisting of 200 images, were recorded at five 
sublingual sites according to the consensus of a round table conference (6, 14, 57). Videos were
analyzed by 2 independent researchers according to De Backer et al. using the Automated 
Vascular Analysis (AVA) software 3.0 (Microscan, Amsterdam, The Netherlands) (14). The total
number of perfused small vessels and the total number of perfused vessels were measured. 
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Assessment of small intestinal injury
To evaluate the extent of small intestinal injury during and after cycling in both situations, plasma
concentrations of human Intestinal Fatty Acid Binding Protein (I-FABP) were determined by a
researcher blinded for the specific test conditions. I-FABP is a small, 15-kD cytosolic protein
that is present especially in mature enterocytes of the small intestine. Upon enterocyte injury,
the protein rapidly diffuses through the interstitial space into the circulation, enabling its detec-
tion in plasma samples (31, 39). Plasma I-FABP levels were measured by an in-house developed
enzyme-linked immunosorbent assay (ELISA): ELISA plates were coated with anti-I-FABP
immunoglobulin G (IgG) overnight at 4ºC; free sites were blocked with 1% bovine serum albu-
min (BSA) in PBS. The samples and human recombinant I-FABP for standard calibration curves
were incubated at room temperature and biotinylated anti-I-FABP IgG was added. After wash-
ing, horseradish peroxidase-streptavidin conjugate (Zymed Laboraties Inc., San Francisco, CA)
in 0.1% BSA-PBS and 3,3,5,5-tetramethylbenzidine (Kirkegaard & Perry Laboratories,
Gaithersburg, MD) were added. The reaction was stopped and color intensity was measured
with an ELISA reader at 450 nm. The detection window of the I-FABP assay was 12.5 to 800
pg/mL. 
Assessment of GI permeability 
Permeability analysis was performed as a measure of GI barrier integrity, using a multi-sugar
test drink as described previously (55, 56). The food grade sugar probes included in the test
drink were 1 g lactulose (Centrafarm, Etten-Leur, the Netherlands), 1 g sucralose (Brenntag,
Sittard, the Netherlands), 1 g erythritol (Danisco, Copenhagen, Denmark), 1 g sucrose (Van
Gilse, Dinteloord, the Netherlands), and 0.5 g L-rhamnose (Danisco) dissolved in 150 mL tap
water. GI permeability was assessed by determination of urinary concentrations of these orally
ingested sugar probes using a combined HPLC (Model PU-1980 pump, Jasco Benelux,
Maarsen, the Netherlands) and mass spectrometry (Model LTQ-XL, Thermo Electron, Breda,
the Netherlands) approach (55). Small intestinal permeability was reflected by the 0-2h urinary
excretion ratio lactulose (342 D) and L-rhamnose (164 D), the L/R ratio. 
Statistical analysis
Statistical analysis was performed using GraphPad Prism (Version 5.00, GraphPad Software for
Windows, San Diego, CA). Normality of all data was verified by the Kolmogorov-Smirnov test.
Data are presented as mean±standard error of the mean (SEM). Continuous data were analyzed
using two-way analysis of variance with Bonferroni post-hoc test for multiple comparisons. For
within group comparisons, either one-way analysis of variance with Bonferroni post-hoc test or
Friedman with Dunn’s post-hoc test were used depending on data normality. A P<0.05 was
considered statistically significant.
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RESULTS
Oral L-citrulline supplementation prior to exercise enhances the arginine availability
index during exercise compared with placebo
As expected, oral L-citrulline supplementation led to increased plasma citrulline concentrations
(peak 1840.3±142.3 mM) compared to baseline (33.6±2.9 mM) and compared to placebo 
L-alanine (peak 45.7±4.8 mM; Figure 1A). Plasma citrulline concentrations remained low
throughout the studied period after placebo supplementation (Figure 1A), while L-alanine levels
increased profoundly following placebo administration (peak 1639.1±112.0 mM versus peak
434.8±25.5 mM after L-citrulline; Figure 1B). 
   The increased citrulline concentrations after L-citrulline supplementation were accompanied
by a significant increase in plasma arginine concentrations during exercise (238.5±9.1 mM
directly after exercise compared to 81.8±3.4 mM at baseline; Figure 1C), while supplementation
with placebo only slightly increased plasma arginine concentrations (101.5±6.1 mM vs. 78.4±3.4
mM; Figure 1C). The increase in arginine concentrations following oral L-citrulline supplemen-
tation significantly enhanced the AAI (0.76±0.02 vs. baseline 0.38±0.02; Figure 1D), while
placebo supplementation did not influence AAI (0.38±0.02 to 0.42±0.03; Figure 1D). Interest-
ingly, both the plasma L-arginine levels and AAI remained elevated after oral L-citrulline sup-
plementation during 1h of exercise and at least until the end of our experiments, 1h post-exercise
(Figure 1C and D). These observations indicate a prolonged effect of a single 10g bolus of L-cit-
rulline prior to exercise. No arginine deficiency was observed during exercise after either of the
supplementation strategies.
Oral citrulline supplementation prior to exercise maintains adequate splanchnic
perfusion during exercise
Pg-apCO2 gap levels, measured by gastric tonometry, reflect splanchnic perfusion. Tonometry
data were obtained from 9 participants, due to inability to introduce the nasogastric catheter
into the stomach of one of the participants. Strenuous exercise quickly resulted in a significant
change in pg-apCO2 gap levels during exercise after pre-exercise placebo supplementation 
(-1.67±0.32 to a peak of -0.55±0.46 kPa at 30 minutes of exercise), while no significant change
from baseline was observed during exercise after oral L-citrulline supplementation (-1.70±0.19
to -1.45±0.63 kPa; Figure 2A), pointing to preserved perfusion if L-citrulline was applied prior
to exercise. The inter-individual differences in pg-apCO2 gap levels were relatively high during
exercise, reflected by relatively large SEMs. 
   Nonetheless, area under the curve (AUC) calculations of pg-apCO2 gap during exercise revealed
a trend (P=0.10) towards a difference between L-citrulline and L-alanine supplementation (-3.3±
20.1 vs. 40.1±20.6, respectively; Figure 2B). After exercise, a trend towards an increase in pg-apCO2
gap levels was seen after both supplementation strategies, but no statistical significance was reached. 
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Citrulline maintains sublingual vessel perfusion after exercise
In line with the tonometry data, analysis of the sublingual microcirculation revealed that citrulline
preserves the perfusion of the microvessels. After L-citrulline supplementation, the number of
perfused small vessels under the tongue was (P=0.06) higher immediately post-exercise and 30
minutes post-exercise than after L-alanine supplementation (Figure 3A), indicating a trend
towards a positive change in perfusion of the small sublingual vessels in favor of L-citrulline
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Figure 1: Mean (±SEM) plasma concentrations of L-citrulline (A), L-alanine (B), L-arginine (C) and L-arginine avail-
ability (D) after oral bolus of placebo or L-citrulline in men (n=10) during and after exercise. 
The data were analyzed with two-way repeated measures ANOVA. Citrulline: time effect, P<0.0001; treatment
effect, P<0.0001; alanine: time effect, P<0.0001; treatment effect, P<0.0001; arginine: time effect, P<0.0001; treat-
ment effect, P<0.0001, and arginine availability: time effect, P<0.0001; treatment effect, P<0.0001.
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(7.8±6.0 for L-citrulline vs. -2.0±2.4 following placebo; Figure 3B). Additionally, the total num-
ber of perfused vessels significantly improved post-exercise in case of L-citrulline supplementa-
tion prior to exercise, compared to a decrease in sublingual perfusion in case of placebo admin-
istration (50.7±2.9 and 38.0±1.7, respectively; Figure 3C). In line, the AUC calculations revealed
a significant increase in total sublingual perfusion of vessels post-exercise in case of L-citrulline
supplementation, compared to a decrease in perfusion if placebo was supplemented before exer-
cise (12.0±6.1 vs. -7.4±1.7; Figure 3D).
Citrulline reduces exercise-induced small intestinal injury during exercise
To assess the effect of oral L-citrulline supplementation on small intestinal epithelium, plasma
I-FABP levels were determined every ten minutes before, during and after exercise. The increase
in plasma I-FABP levels, depicted as percentage from baseline, indicating small intestinal ente-
rocyte damage, reached significance after 1 hour of strenuous exercise in case of oral placebo
supplementation prior to exercise, while the increase in plasma I-FABP levels was less pro-
nounced after L-citrulline administration prior to exercise (Figure 4A). Post-exercise levels of 
I-FABP increased by approximately 72% above baseline after both citrulline and alanine, and
gradually declined towards baseline levels in the post-exercise recovery period (Figure 4A). A
marked difference of the effect of citrulline- and alanine-supplementation was observed especially
during exercise. AUC calculations of the IFABP levels (as percentage from baseline) during 
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Figure 2: Mean and SEM of gapg-a pCO2 levels during and after exercise (A) and area under the curve (AUC) of 
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Figure 3: Total number of sublingual perfused microcirculatory vessels (mean ±SEM) (A), change in microcirculatory
vessel number (B), total number of perfused sublingual vessels (C), change in total vessel number (D) during and after
exercise in men (n=10) after consumption of placebo or L-citrulline. 
The data over time were analyzed with two-way repeated measures ANOVA. Microcirculatory vessel number until
30 min post-exercise: time effect, P= 0.37; treatment effect, P=0.09. Total vessels number until 30 min post-exercise:
time effect, P<0.05; treatment effect, P<0.001; asterisks indicate different from baseline (t = 0 min) ***P<0.001.
Changes in microcirculatory and total vessel number until 30 min post-exercise were analyzed with paired t-test.
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exercise revealed a significant difference (P<0.01) between L-citrulline and L-alanine supple-
mentation (-185±506 vs. 1318±553, respectively; Figure 4B). Hence, oral L-citrulline supple-
mentation was able to prevent a net increase in plasma I-FABP levels during exercise, compatible
with diminished exercise-induced intestinal injury.
PART III - CHAPTER 10                                                                                                                   
182
1500
500
–500
Exercise
       Placebo            Citrulline
A
U
C
 p
la
sm
a 
IF
A
B
P
A
B P=0.01
0.03
0.02
0.01
0.00
       Placebo            Citrulline
0–
2h
 u
ri
n
ar
y 
L/
R
 r
at
io
C
Placebo      Citrulline
Pl
as
m
a 
IF
B
A
B
P 
(%
 f
ro
m
 n
as
el
in
e) 200
150
100
50 Exercise Post-exercise
0 20 40 60 80 100 120
Time (min)
Figure 4: Mean (±SEM) percentage changes in plasma IFABP during and after exercise (A), area under the curve (AUC)
of percentage IFABP change during exercise (B), and L/R urinary excretion over 2-hour period (C) in men (n=10) after
consumption of placebo or L-citrulline. 
The data over time were analyzed with two-way repeated measures ANOVA. Time effect, P<0.0001; treatment
effect, P=0.07; asterisks indicate different from baseline (0 min) *P<0.05, **P<0.01. AUC data over the first 60
minutes and urinary sugar excretion were analyzed with paired t-test.
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Exercise-induced GI permeability changes
To analyze whether oral L-citrulline supplementation prior to exercise would maintain GI barrier
function during exercise, permeability L/R ratios were determined in urine collected in the 0-2h
post-exercise recovery period. Urinary L/R ratio was 0.027±0.003 after oral administration of
L-alanine prior to exercise, compared to 0.024±0.002 after administration of L-citrulline (Figure
4C). These data indicate that no significant difference was observed between the two nutritional
interventions with respect to small intestinal permeability or small intestinal barrier function.
Gastrointestinal complaints and exercise performance
No gastrointestinal complaints were reported by the individuals when specifically asked for any
GI disturbances experienced on the test days or the day following each test day. No differences
in exercise performance, exhaustion or heart rate were observed between the two supplementa-
tion strategies (data not shown).
DISCUSSION 
In the present randomized controlled study, the effect of oral citrulline supplementation prior
to strenuous exercise on the development of splanchnic (micro)circulation, small intestinal injury
and gut barrier function was studied. Oral L-citrulline supplementation prior to exercise was
demonstrated to significantly increase plasma levels of citrulline and arginine in healthy athletes
compared to placebo. As a result, elevated plasma arginine levels following oral L-citrulline sup-
plementation increased the AAI, reflecting an increased availability of the NO-donor L-arginine,
which persisted at least until one hour post-exercise. The increased arginine availability after
oral L-citrulline supplementation was associated with preserved splanchnic perfusion during
exercise compared to placebo, and reduced enterocyte damage. The presumed mechanism by
which oral L-citrulline supplementation results in improved integrity in the splanchnic area is
via increased intracellular availability of the NO-donor arginine. Intracellular arginine regener-
ation from citrulline via the conversion of citrulline by the ASS and ASL enzyme was previously
found to be essential for eNOS-mediated NO production in endothelial cells (22), which may
result in enhanced local blood flow through NO-mediated local vasodilatation (11).
   Previously, we demonstrated that one hour of cycling at 70% Wmax rapidly increased pg-apCO2
gap levels by more than 1kPa, reflecting the development of splanchnic hypoperfusion during
exercise in the fasted state (54). Although the increase in pg-apCO2 gap was smaller in the present
study than previously reported (54), it was comparable to other studies showing exercise-induced
increases in pg-apCO2 gap in healthy volunteers (38). Importantly, the present study reveals that
a single pre-exercise dose of L-citrulline is able to avert the distinct increase in pg-apCO2 gap
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level during exercise, which is observed after placebo supplementation. Although we could not
measure local arginine availability in the healthy participants of the current study, experimental
data indicated that intravenous L-citrulline supplementation is able to increase both plasma and
intestinal arginine availability and increase the intracellular NO production in the intestine (59).
In line with these studies, clinical studies indicated that oral supplementation of L-citrulline was
able to increase plasma arginine concentrations and tissue NO-production without causing side
effects (17, 18). Previously, we demonstrated that the small intestinal microcirculation was main-
tained during endotoxin-induced inflammation in mice if L-citrulline was applied intravenously
(59). In line with these previous findings, the current study revealed that oral supplementation of
L-citrulline prior to a trigger for splanchnic hypoperfusion, such as strenuous exercise, improves
sublingual microcirculation, strongly suggesting improved intestinal microcirculation (42, 58).
   Splanchnic hypoperfusion during strenuous cycling was reported to correlate with small intes-
tinal injury in healthy athletes (54). Hypoperfusion-induced intestinal compromise occurring
during strenuous exercise may hamper the athlete (48, 49) and can jeopardize early post-exercise
recovery (53). We hypothesized that oral supplementation of L-citrulline improved splanchnic
circulation during exercise, thereby reducing exercise-induced enterocyte injury. The present
study revealed significantly lower plasma I-FABP levels during exercise in case of pre-exercise
supplementation of L-citrulline compared to placebo, indicating that L-citrulline helps to reduce
small intestinal cellular injury. In line with these data, L-citrulline was recently shown to reduce
intestinal injury after experimentally induced small bowel obstruction, as reflected by reduced
immunoglobulin concentrations in intestinal fluids of mice (2). High plasma I-FABP levels were
found in patients surviving cardiac arrest, indicating the presence of profound small intestinal
injury, most likely due to a period of little or no splanchnic perfusion (23). Interestingly, these
high plasma I-FABP levels were associated with low circulating citrulline concentrations (23)
which are considered a parameter of functional enterocyte mass (10), but which may also jeop-
ardize arginine availability in this condition. These observations give emphasis to the promising
results of oral L-citrulline supplementation to improve splanchnic perfusion and to diminish
intestinal injury in situations of splanchnic hypoperfusion. Additionally, it insinuates that it might
be useful to study the applicability of oral L-citrulline supplementation in other situations of
splanchnic hypoperfusion, such as systemic hypotension, sepsis and maybe even high-risk sur-
gery, which is associated with a high rate of complications (3, 16). 
   In contrast to the promising effects of oral L-citrulline supplementation on intestinal injury,
no statistically significant effect could be found in the current study between L-citrulline and
placebo supplementation with respect to GI permeability, reflecting intestinal barrier function.
In our previous study, we found a small increase in small intestinal permeability after exercise
(54). We consider that the small intestinal injury observed in the current study was not to such
an extent that it led to loss of GI barrier function. Prolonged or more extensive reductions in
splanchnic perfusion may lead to more profound GI compromise with loss of barrier integrity. 
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   The results of this study may be useful for athletes suffering from abdominal angina during
strenuous exercise. It would be very interesting to test the effects of oral L-citrulline supplemen-
tation in symptomatic athletes. If L-citrulline supplementation is found to be beneficial in these
athletes, it may also be interesting to extrapolate the results to asymptomatic athletes, and to
find out whether oral L-citrulline supplementation also has advantages such as improved nutrient
uptake and stimulation of early recovery. It was previously reported that oral L-citrulline sup-
plementation improves muscle protein synthesis, comparable to the stimulating effect of leucine
(13, 37). Both amino acids seem to exert this effect via the mTOR signaling pathway (19, 30).
Interestingly, orally administered L-citrulline in combination with a low-protein diet in healthy
volunteers was found to increase muscle protein synthesis compared to an isonitrogenous diet
(13). Oral supplementation of L-citrulline may be used to improve nitrogen availability for via
L-arginine resynthesis from L-citrulline in the kidney (13). A high-protein intake is not likely to
cause the same effect, because (a) citrulline is not present in a normal protein-rich diet, and (b)
blood with a relatively high concentration of L-arginine floats from the intestines through the
portal vein, the highly concentrated L-arginine leads to ureagenesis in the liver, which decreases
the systemic L-arginine available for NO production (13). The results of oral L-citrulline sup-
plementation during a high-protein diet may be more promising compared to L-arginine, as 
circulating L-arginine is scavenged by the liver-derived enzymes, whereas the liver is unable to
scavenge citrulline, resulting in more arginine availability for NO-production (12).
   In conclusion, the current study demonstrates that oral administration of L-citrulline prior
to exercise preserves splanchnic perfusion and reduces intestinal injury during exercise. The
mechanism probably entails increased arginine availability for NO-mediated vasodilatation.
These data suggest oral L-citrulline supplementation to be a promising strategy to improve
splanchnic perfusion and prevent intestinal injury in athletes.
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CHAPTER 11
General discussion
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The integrity of the gastrointestinal (GI) tract is tightly controlled by its complex and highly
dynamic architecture (22, 33), resulting in a remarkable flexibility and regenerative capacity to
adapt to for example an increased metabolic demand (8) and to recuperate if damage has
occurred (12). An important factor that can compromise GI integrity is splanchnic hypoperfu-
sion (46). The experimental in vivo studies described in this thesis focused on splanchnic hypop-
erfusion and GI integrity loss in man. In the current chapter, I will elaborate on the physiological
and pathophysiological aspects of splanchnic hypoperfusion and ischemia, and discuss GI
integrity in this context.
Splanchnic hypoperfusion and ischemia
Splanchnic hypoperfusion is a state in which blood flow in the splanchnic area is reduced to a
suboptimal level. Hypoperfusion is inextricably linked to ischemia, a state in which the splanchnic
circulation is restricted to such an extent that mucosal hypoxia and depletion of adenosine triphos-
phate (ATP) occur, leading to local acidosis and tissue injury (12). Both entities are the result of
a mismatch of blood supply and demand in the splanchnic area, which may be induced by either
a critically reduced blood supply, an increased metabolic demand, or both. Many conditions exist
in which the amount of blood flowing through the splanchnic area does not meet the requirements
for nutrients and oxygen, ranging from mild to severe hypoperfusion. Included in the current the-
sis are physiological and pathophysiological conditions of critically reduced splanchnic perfusion,
i.e. during exercise-induced redistribution of blood flow at the expense of the splanchnic area in
athletes (chapter 7), during exercise with prior intake of non-steroidal anti-inflammatory drugs
(NSAIDs; chapter 9) and during acute obstruction of splanchnic vessel(s) in patients with intes-
tinal ischemia (chapter 3). I will discuss the interplay between these physiological and pathophys-
iological manifestations of splanchnic hypoperfusion and GI integrity loss. 
Exercise-induced splanchnic hypoperfusion and GI integrity: physiology or
pathophysiology?
The splanchnic vascular system has a remarkable capacity to adapt to physiological stressors via
regulation of the mesenteric vascular resistance by neuroendocrine, humoral, and paracrine
mechanisms (34). During strenuous exercise, splanchnic vasoconstriction occurs as a result of
a norepinephrine-induced increase in splanchnic vascular resistance (17, 35, 64), thereby rapidly
redistributing blood from the splanchnic area towards heart, lungs, active muscle and skin (5,
43) to enable athletic performance and evaporate excessive heat via the skin. Doppler ultrasound
and contrast extraction studies revealed a critical reduction in hepatosplanchnic blood flow dur-
ing exercise by as much as 80% during heavy physical exercise (5). Animal studies have demon-
strated that ischemia occurs when splanchnic blood flow decreases to less than 40-50% of normal
flow (25, 29). In line, it was reported that heavy physical exercise resulted in splanchnic hypop-
erfusion and ischemia in healthy (39, 43). 
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   These data give rise an intriguing question: Is exercise-induced splanchnic hypoperfusion a
physiological or pathophysiological phenomenon?
   In the study described in chapter 7, the pattern of the exercise-induced hypoperfusion during
prolonged exercise was studied. Hypoperfusion occurred within the first ten minutes of strenuous
exercise, was maintained during the full duration of the 60-minute exercise bout, and was rapidly
reversed in the first ten minutes post-exercise (chapter 7), emphasizing the highly responsive
adaptive capacity of the splanchnic vascular bed. Alternatively, previous studies reported
increased postprandial mesenteric blood flow by as much as 60-250% to meet the increased cir-
culatory demand associated with digestion and absorption (35), lasting for approximately 2-3h
before returning to baseline levels (34). The gut is built to adapt to such changes in splanchnic
perfusion, and the quick restoration of blood flow to baseline levels, after fluctuations due to
food intake or exercise, strongly suggests that we should consider exercise-induced splanchnic
hypoperfusion to be a physiological phenomenon.
   Exercise-induced splanchnic hypoperfusion is closely related to loss of enterocyte integrity in
the small intestine in our human exercise study (chapter 7), indicating that the physiologically
induced hypoperfusion led to GI integrity loss. Critical reductions of the splanchnic blood flow
have been demonstrated to enhance the physiological low-flow state in the upper half of the
small intestinal villi, resulting in disruption of mucosal integrity (3, 4). The mature enterocytes
located at the upper half of the intestinal villi are the first cells to be affected, while the undiffer-
entiated intestinal epithelial cells are relatively safe in the crypt and lower part of the villus. In
the human exercise studies described in this thesis, we observed significant increases in circulat-
ing intestinal fatty acid binding protein (I-FABP) levels (chapter 7-10), reflecting loss of cellular
integrity of the especially the mature enterocytes. These differentiated, mature enterocytes are
cells that have gained pro-apoptic properties during their journey along the crypt-villus axis (16),
making them prone to undergo apoptosis as part of the physiological process of constant epithe-
lial renewal and anoiksis. Deprivation of oxygen in the villus tip as a result of hypoperfusion is
one of the triggers to initiate this physiological process (3), suggesting that hypoperfusion-
induced loss of cellular integrity, triggered by exercise, may be a physiological phenomenon. Of
the athletes participating in our exercise studies, 87% (26/30) had small intestinal cellular injury
after exercise, reflected by a considerable increase in plasma (I-FABP), defined as a rise of at
least 35% above pre-exercise levels.
   Compromised intestinal integrity caused by significant reductions in splanchnic flow may
comprise more than cell damage. Previous studies in animals reported that energy depletion fol-
lowing ischemia/reperfusion injury led to relocalization of the apical cell membrane and disrup-
tion of the apical actin cytoskeleton (1, 51), leading to loss of intestinal integrity with paracellular
leakage of microbial products and other potentially harmful luminal components (15). More
recently, intestinal cytoskeleton disruption and tight junction integrity loss were reported in rats
following intestinal hypoperfusion (54). Furthermore, gut barrier dysfunction with compromised
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enterocyte integrity and tight junction protein loss was observed following intestinal mucosal
hypoperfusion in patients undergoing major non-abdominal surgery (13). Based on these studies,
it was hypothesized that exercise-induced intestinal hypoperfusion and the subsequent small
intestinal injury compromise gut barrier function. Urinary tight junction protein levels remained
undetectable in the majority of athletes after 1h of cycling at 70% of maximum capacity (unpub-
lished data), and no significant changes in plasma endotoxin antibodies were observed (supple-
mental data chapter 7), suggesting that the extent of injury was not enough to induce profound
tight junction integrity loss with bacterial translocation. These findings corroborate outcomes
of permeability assessment using our sensitive multi-sugar assay in the same healthy athletes,
showing that plasma appearance of sugar probes and plasma permeability ratios increased, while
urinary ratios of these probes were marginally elevated compared to rest (chapter 7). The small
changes in GI permeability after exercise in healthy athletes can partly explain why data on this
subject are controversial (27, 28, 32, 59, 60). Only the use of a sensitive permeability test may
detect the small changes that occur during strenuous exercise. The variety in exercise-related
permeability data may therefore also partly be explained by the variety of tests and experimental
study designs used to assess alterations in intestinal permeability after exercise, including the
moment of sugar probe intake. The modest permeability changes observed after one hour of
cycling (chapter 7) are apparently part of the physiological fluctuations in GI permeability. More
profound increases in GI permeability were observed if cycling was combined with prior intake
of NSAIDs (chapter 9), indicating aggravated loss of gut barrier function in healthy athletes.
Does the combination of exercise and NSAIDs raise the exercise-induced GI compromise to a
pathophysiological level? The fact that I-FABP levels approximate baseline levels one hour post-
exercise points in the opposite direction. Our exercise studies emphasize the capacity of the
human gut to withstand short periods of splanchnic hypoperfusion and other potentially harmful
influences such as NSAID consumption without major GI compromise. Nonetheless, it is impor-
tant to point athletes and trainers to the potentially harmful NSAIDs, and to discourage the use
of these drugs as ergogenic aids, especially in the absence of a clear medical indication. 
   Recurrent episodes of intestinal injury and barrier integrity loss (caused by exercise or a com-
bination of exercise and NSAIDs) require a remarkable regenerative capacity of the gut. While
exercise itself increases the need for adequate energy supply and nutrient uptake in the intestine,
such renewal of the epithelium also increases the metabolic demand of the GI system. Data of
the study described in chapter 7 gave rise to the intriguing question whether  the exercise-
induced intestinal injury also compromises the digestive and absorptive capacities of the GI
tract. In the study described in chapter 8, we used specifically produced intrinsically labeled
dairy protein in combination with continuous intravenous tracer infusion to confirm that the
exercise-induced intestinal injury impairs in vivo dietary protein digestion and absorption in the
acute post-exercise recovery phase. Especially in professional athletes and in patients, such
impaired uptake of energy and nutrients caused by hypoperfusion-induced small intestinal injury
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in combination with an increased metabolic demand may delay early and complete recovery. In
line with the extent of intestinal injury and gut barrier integrity loss, the observed changes in
the absorptive function of the gut are considered to be within the physiological range. 
   Naturally, there are cases in which strenuous exercise led to extensive mucosal injury, includ-
ing mucosal erosions (7, 42), (bloody) diarrhea and haemorrhagic colitis (36-38). Additionally,
healthy individuals with exercise-induced pain that is explained by the celiac artery compression
syndrome (CACS), in which flow through the celiac artery is significantly reduced due to exter-
nal compression most often by a crus of the diaphragm, are considered to suffer from a patho-
physiological condition that is relatively easily resolved (14). In these cases, the physiological
exercise-induced in vivo changes have evolved to pathophysiological phenomena.  
Splanchnic hypoperfusion and GI integrity in other conditions
Splanchnic hypoperfusion induced by exercise in healthy individuals leads to small intestinal injury
and loss of GI integrity within the physiological range (chapter 7 and 9). Other examples in which
splanchnic hypoperfusion occurs are trauma patients especially when in shock (10), burn victims
(30), and patients undergoing cardiopulmonary bypass (40, 41, 47). Additionally, patients under-
going major non-abdominal surgery were described to develop gut barrier dysfunction associated
with systemic hypotension and splanchnic hypoperfusion if no specific attention was paid to main-
tain the mean arterial pressure during surgery above 60 mm Hg (13). The hypoperfusion-associated
small intestinal injury during surgery in these patients was of similar extent as the exercise-induced
intestinal damage that was observed in healthy athletes of our exercise studies (chapter 7 and 10).
It seems logical that patients with cardiopulmonary dysfunction have an increased risk to develop
splanchnic hypoperfusion for example during surgery, even when they are relatively fit and found
to be eligible for surgery according to the classifications of the American Society of Anesthesiolo-
gists (9). In case of chronic underlying disease such as chronic heart failure (CHF) or obstructive
pulmonary disease, hypoperfusion likely results in more profound or prolonged intestinal com-
promise, due to a more delicate balance in splanchnic perfusion and GI integrity, and a reduced
capacity to recover following recurrent episodes of hypoperfusion-induced intestinal injury (48,
49). CHF leads to increased sympathetic activity, which decreases splanchnic blood flow (49). In
line with these results, intestinal ischemia has been observed in patients with CHF during low-
intensity exercise (26), emphasizing the susceptibility of this population to GI compromise due to
decreased splanchnic circulation.
   Severely impaired splanchnic perfusion in critically ill patients in the intensive care unit is
associated with poor outcome (23, 58). Specific routine nursing procedures such as airway suc-
tioning, determining the patient’s level of sedation, and changing the patient’s position were
associated with decreases in hepatosplanchnic oxygen saturation, suggesting impaired perfusion
in this area (23). Other therapeutic interventions that may critically reduce splanchnic circulation
are the administration of vasoactive drugs such as vasopressine (57) and hemodialysis (24). 
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   Patients with acute intestinal ischemia probably form the archetypical population at the end
of the splanchnic hypoperfusion scale, i.e. severe splanchnic hypoperfusion. In the study
described in chapter 3, we have demonstrated that these patients have very high levels of circu-
lating gut-derived FABPs, indicating profound intestinal damage, which may be located in a
specific part of the intestine or may affect the whole intestinal area. From the patients with intes-
tinal ischemia in this study, 7 patients died due to too profound damage or too late intervention,
indicating a serious life-threatening condition. Studies aiming at improving the diagnostic work-
up for splanchnic hypoperfusion and its sequelae in athletes during and after exercise may help
to develop strategies to enable early diagnosis of the problem, to improve splanchnic blood flow,
and reduce or prevent hypoperfusion-induced small intestinal injury and loss of barrier integrity
in patients.
Improving the diagnostic work-up of splanchnic hypoperfusion and its sequelae
The anatomy of the splanchnic circulation, including any vascular abnormalities may be visual-
ized using computed tomography angiography, classic or magnetic resonance angiography, or
transcutaneous abdominal duplex ultrasound (35). Alternative emerging techniques to assess
GI ischemia, analyze the mucosal oxygen saturation of hemoglobin in red blood cells of the
intestinal microcirculation by emission and detection of backscattered light during endoscopy
(chapter 2). The only functional test currently available to determine the presence of splanchnic
hypoperfusion is gastric air tonometry (35). The latter is considered most useful in combination
with assessment of the sequelae of splanchnic hypoperfusion through determination of GI
integrity and functionality.
   GI barrier integrity assessment was briefly discussed in the light of exercise-induced intestinal
compromise. Barrier integrity can be assessed by of (a) urinary or plasma levels of components
of the GI barrier, by (b) plasma concentrations or urinary excretion of permeability probes after
oral ingestion, and (c) bacterial products in the systemic circulation (21). In chapter 3, the loss
of intestinal cellular integrity in patients with intestinal ischemia was determined using intestinal
fatty acid binding proteins, which are small, 15-kD cytosolic proteins present in the intact ente-
rocytes of the intestine. These proteins, especially I-FABP, have been found to be reliable param-
eters of small intestinal cellular injury in many different situations, including in patients with
intestinal ischemia (chapter 3), celiac disease (63), intestinal necrosis after aortic surgery (61)
and during exercise in healthy individuals (chapter 7-10). However, the GI barrier consists of
many more components than the intestinal epithelial cells (IECs), one example being the highly
dynamic tight junctional complexes that seal the paracellular space between the epithelial cells.
   Intestinal ischemia and reperfusion have been found to change myosin light-chain kinase lev-
els, suggesting contraction of the actomyosin skeleton in the IECs and tight junction opening at
sites where IECs have lost contact with the basal membrane (20). In case of prolonged ischemia,
epithelial barrier loss was observed, with loss of tight junction proteins and significant translo-
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cation of bacterial endotoxin (19). Accordingly, both determination of tight junction proteins
such as claudin-3 in urine or plasma and determination of circulating endotoxin levels can be
used to assess GI barrier function (55), but only in case of profound barrier integrity loss, i.e. in
mainly in pathophysiological conditions. In addition, results should be interpreted with caution,
as these components are not specific for the intestine. 
   Novel GI permeability tests were developed in an attempt to improve the available diagnostics
for site-specific GI barrier integrity assessment both in physiological and pathophysiological
conditions. Three tests for GI permeability assessment were described in this thesis, all building
on the same principle: urinary or plasma permeability probe levels are determined following oral
intake of these probes by the test subject (2). The application of differently sized probes allows
assessment of the severity of the GI barrier dysfunction, while the use of degradable and non-
degradable probes enables analysis of specific parts of the GI system (2). The three tests
described in this thesis are a permeability test based on polyethylene glycols (PEG), a novel
multi-sugar (MS) assay, and the classical dual sugar (DS) lactulose-rhamnose test. Since we
optimized the method of detection and changed the composition of the PEG test and MS test,
the first question to be answered was whether these novel tests could detect experimentally
increased GI permeability in healthy individuals. Test outcomes and accuracy were evaluated
and compared with the most commonly used DS test. The study results reported in chapter 4
demonstrated that the PEG test and DS test had similar accuracy rates when used for perme-
ability analysis in healthy individuals after NSAID intake. Since we sought to improve the tech-
niques available for permeability testing, we were not satisfied with these results. In chapter 5,
our novel analytical approach towards a multi-sugar permeability assay is described, which is
validated in chapter 6. With a reduced lactulose load, additional sugars for site-specific GI per-
meability analysis, and the possibility to determine sugar probe levels in plasma samples to allow
detection of smaller, transient permeability changes, this test has clear advantages over the other
two permeability tests (chapter 5 and 6). The accuracy of this test in healthy individuals with
experimentally increased GI permeability was slightly higher than the classical DS test. This, in
combination with the previously mentioned advantages, led us to conclude that the MS test is
a promising tool for accurate, site-specific GI permeability analysis. The MS test gave reliable
results in healthy individuals under different circumstances, such as during strenuous exercise
and after intake of NSAIDs. Future research is needed to prove whether the MS test provides
advantages for permeability assessment in pathophysiological conditions as well. 
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Strategies to treat or prevent hypoperfusion-induced GI integrity loss
Preventive and therapeutic strategies for splanchnic hypoperfusion-induced GI integrity loss are
important in case of pathophysiological hypoperfusion. Additionally, such strategies may be ben-
eficial in specific physiological conditions such as professional athletes and symptomatic recre-
ationally active individuals. Up to 70% of athletes have exercise-associated GI symptoms (44),
and studies so far have mainly focused on the prevention of these symptoms. To my knowledge,
no studies have demonstrated a direct relationship between exercise-induced GI integrity loss
and abdominal symptoms. However, most strategies to resolve the exercise-induced problems
are likely to reduce intestinal injury as well, potentially due to their beneficial effect on splanchnic
blood flow during exercise and directly post-exercise. Recurrent episodes of intestinal injury and
barrier integrity loss require a remarkable regenerative capacity of the gut. While exercise itself
increases the need for adequate energy supply and nutrient uptake in the intestine, such renewal
of the epithelium also increases the metabolic demand of the GI system. In chapter 8, we have
demonstrated that exercise and the associated small intestinal injury may impair the digestion
and absorption of proteins consumed immediately post-exercise in healthy young athletes com-
pared to resting conditions. Especially in professional athletes and in patients, such impaired
uptake of nutrients caused by hypoperfusion-induced small intestinal injury in combination with
an increased metabolic demand may delay early and complete recovery. Training the gut for the
intake of small amounts of food during exercise-induced splanchnic hypoperfusion is thought
to maintain blood flow at a higher level than in fasted state (53) due to the food-induced phys-
iological rise in GI blood flow (65). Additionally, specific nutritional strategies may be initiated
to improve splanchnic perfusion, reduce small intestinal integrity loss, and maintain adequate
energy intake in athletes and patients. An overview of such strategies is included in chapter 2 of
this thesis. As stated, most of the supplementation strategies are still being developed and should
be tested in larger groups of athletes and patients before clear recommendations for individual
use can be done. 
   Oral supplementation of L-citrulline 30 minutes prior to cycling was observed to maintain
adequate splanchnic perfusion during cycling, while oral supplementation of L-alanine prior to
exercise did not prevent from exercise-induced splanchnic hypoperfusion (chapter 10). Preserved
splanchnic blood flow after L-citrulline supplementation reduced the extent of exercise-induced
loss of enterocyte integrity. Interestingly, five individuals of the citrulline supplementation study
also participated in the study in which no supplementation was given prior to exercise (chapter
7), allowing a comparison of data with and without nutrient supplementation. It was clear that
the increase in gapg-apCO2 levels, reflecting splanchnic hypoperfusion, was more obvious during
exercise if no supplementation was given prior to exercise compared to data after L-alanine or
L-citrulline supplementation, respectively (Figure 1A). In line with these data, plasma I-FABP
levels during exercise were higher in case of cycling without supplementation, while cycling with
prior intake of either L-alanine of L-citrulline resulted in lower plasma I-FABP levels during
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Figuur 1: Oral intake of amino acids, especially citrulline, improves splanchnic perfusion and preserves intestinal integrity
during exercise
A) Pre-exercise oral intake of amino acids, especially citrulline, preserves gapg-apCO2 levels at pre-exercise levels
compared to gapg-apCO2 levels measured in the same individuals during exercise without prior oral supplementation.
B) Plasma I-FABP levels are maintained at pre-exercise levels if prior to exercise, oral supplementation of L-alanine
of L-citrulline is administered, while cycling without supplementation raised plasma I-FABP levels. Circles represent
mean data of five participants, with the SEM as black lines.
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exercise, suggesting better preserved small intestinal integrity (Figure 1B). These data suggest
that oral intake of amino acids, and possibly other nutrients, prior to exercise improves splanchnic
perfusion and GI integrity during exercise compared to the situation in which no supplementa-
tion is used. Maintenance of splanchnic blood flow may also stimulate nutrient uptake during
exercise and in the acute post-exercise recovery phase, but specific future studies are warranted
to prove such an effect after pre-exercise oral citrulline supplementation. Additionally, while we
observed a 100% tolerance for the oral intake of citrulline and the placebo alanine prior to exer-
cise, future studies should take into account the additional burden that a pre-exercise oral cit-
rulline upload may put on the gastrointestinal tract.  
   An additional potentially useful nutritional supplementation strategy is lipid-rich enteral nutri-
tion, which has been shown to prevent GI integrity loss and subsequent intestinal inflammation
during an episode of splanchnic hypoperfusion in rats (11). Recently, these data have been con-
firmed in a highly interesting study using lipid-rich enteral nutrition in experimentally-induced
endotoxemia in otherwise healthy individuals (31). These effects have yet to be confirmed in
athletes. Studies on lipid-rich nutrition in athletes have mainly focused on the utilization of lipids
for enhancement of fat oxidation during exercise in order to improve endurance capacity (6,
18), but an additional beneficial effect on endurance capacity via stimulation of splanchnic blood
flow, maintained GI integrity and preserved digestive and absorptive GI functioning is well pos-
sible. It would be interesting to apply the recent experiences on lipid-rich enteral nutrition to
other situations with splanchnic hypoperfusion, more specifically in case of exercise-induced
splanchnic hypoperfusion. 
   In addition to food intervention strategies, both in athletes and in (surgical) patients, adequate
hydration helps to maintain circulating blood volume (45, 50, 52, 62), thereby contributing to
the prevention of GI compromise. Avoiding the use of NSAIDs also helps to avoid profound
intestinal damage in case of splanchnic hypoperfusion in athletes (chapter 9) and may do so in
patients with hypoperfusion. An effective measure to improve splanchnic perfusion in surgical
patients was demonstrated by Thuijls et al (56). Maintenance of the mean arterial pressure above
the critical value of 60 mm Hg was reported to secure splanchnic perfusion throughout the sur-
gical procedure, thereby preserving mucosal integrity of the small intestine (56). This strategy
may also be used in critically ill patients and in trauma patients on the intensive care unit or
during resuscitation. 
   In conclusion, at this stage various promising strategies are available that may reduce or even
prevent GI compromise associated with splanchnic hypoperfusion. Future studies are warranted
to determine the specific usefulness of these strategies for application in athletes and patients. 
PART IV - CHAPTER 11                                                                                                                   
198
Proefschrift laatste versie_Opmaak 1  6/10/13  10:12 AM  Pagina 198
REFERENCES
1. Ashworth SL, Sandoval RM, Hosford M, Bamburg JR, and Molitoris BA. Ischemic injury induces ADF relocal-
ization to the apical domain of rat proximal tubule cells. American journal of physiology Renal physiology 280:
F886-894, 2001.
2. Bjarnason I, MacPherson A, and Hollander D. Intestinal permeability: an overview. Gastroenterology 108: 1566-
1581, 1995.
3. Blikslager AT. Life in the gut without oxygen: adaptive mechanisms and inflammatory bowel disease. Gastroen-
terology 134: 346-348, 2008.
4. Blikslager AT, Moeser AJ, Gookin JL, Jones SL, and Odle J. Restoration of barrier function in injured intestinal
mucosa. Physiological reviews 87: 545-564, 2007.
5. Bradley SE, Childs AW, Combes B, Cournand A, Wade OL, and Wheeler HO. The effect of exercise on the splanch-
nic blood flow and splanchnic blood volume in normal man. Clin Sci (Lond) 15: 457-463, 1956.
6. Brouns F, and van der Vusse GJ. Utilization of lipids during exercise in human subjects: metabolic and dietary
constraints. The British journal of nutrition 79: 117-128, 1998.
7. Choi SC, Choi SJ, Kim JA, Kim TH, Nah YH, Yazaki E, and Evans DF. The role of gastrointestinal endoscopy in
long-distance runners with gastrointestinal symptoms. European journal of gastroenterology & hepatology 13: 1089-
1094, 2001.
8. Cox GR, Clark SA, Cox AJ, Halson SL, Hargreaves M, Hawley JA, Jeacocke N, Snow RJ, Yeo WK, and Burke
LM. Daily training with high carbohydrate availability increases exogenous carbohydrate oxidation during
endurance cycling. Journal of applied physiology 109: 126-134, 2010.
9. Davenport DL, Bowe EA, Henderson WG, Khuri SF, and Mentzer RM, Jr. National Surgical Quality Improvement
Program (NSQIP) risk factors can be used to validate American Society of Anesthesiologists Physical Status Clas-
sification (ASA PS) levels. Annals of surgery 243: 636-641; discussion 641-634, 2006.
10.de Haan JJ, Lubbers T, Derikx JP, Relja B, Henrich D, Greve JW, Marzi I, and Buurman WA. Rapid development
of intestinal cell damage following severe trauma: a prospective observational cohort study. Critical care 13: R86,
2009.
11.de Haan JJ, Thuijls G, Lubbers T, Hadfoune M, Reisinger K, Heineman E, Greve JW, and Buurman WA. Protection
against early intestinal compromise by lipid-rich enteral nutrition through cholecystokinin receptors. Critical care
medicine 38: 1592-1597, 2010.
12.Derikx JP, Matthijsen RA, de Bruine AP, van Bijnen AA, Heineman E, van Dam RM, Dejong CH, and Buurman
WA. Rapid reversal of human intestinal ischemia-reperfusion induced damage by shedding of injured enterocytes
and reepithelialisation. PloS ONE 3: e3428, 2008.
13.Derikx JP, van Waardenburg DA, Thuijls G, Willigers HM, Koenraads M, van Bijnen AA, Heineman E, Poeze M,
Ambergen T, van Ooij A, van Rhijn LW, and Buurman WA. New Insight in Loss of Gut Barrier during Major
Non-Abdominal Surgery. PloS ONE 3: e3954, 2008.
14.Duffy AJ, Panait L, Eisenberg D, Bell RL, Roberts KE, and Sumpio B. Management of median arcuate ligament
syndrome: a new paradigm. Annals of vascular surgery 23: 778-784, 2009.
15.Fink MP DR. Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dys-
function at the cellular level. Critical Care Clinic 21: 177-196, 2005.
16.Gassler N, Roth W, Funke B, Schneider A, Herzog F, Tischendorf JJ, Grund K, Penzel R, Bravo IG, Mariadason
J, Ehemann V, Sykora J, Haas TL, Walczak H, Ganten T, Zentgraf H, Erb P, Alonso A, Autschbach F, Schirmacher
P, Knuchel R, and Kopitz J. Regulation of enterocyte apoptosis by acyl-CoA synthetase 5 splicing. Gastroenterology
133: 587-598, 2007.
17.Gil SM, Yazaki E, and Evans DF. Aetiology of running-related gastrointestinal dysfunction. How far is the finishing
line? Sports medicine (Auckland, NZ) 26: 365-378, 1998.
18.Gonzalez JT, and Stevenson EJ. New perspectives on nutritional interventions to augment lipid utilisation during
exercise. The British journal of nutrition 107: 339-349, 2012.
19.Grootjans J, Lenaerts K, Derikx JP, Matthijsen RA, de Bruine AP, van Bijnen AA, van Dam RM, Dejong CH, and
Buurman WA. Human intestinal ischemia-reperfusion-induced inflammation characterized: experiences from a
new translational model. The American journal of pathology 176: 2283-2291, 2010.
20.Grootjans J, Thuijls G, Derikx JP, van Dam RM, Dejong CH, and Buurman WA. Rapid lamina propria retraction
and zipper-like constriction of the epithelium preserves the epithelial lining in human small intestine exposed to
ischaemia-reperfusion. The Journal of pathology 224: 411-419, 2011.
21.Grootjans J, Thuijls G, Verdam F, Derikx JP, Lenaerts K, and Buurman WA. Non-invasive assessment of barrier
integrity and function of the human gut. World J Gastrointest Surg 2: 61-69, 2010.
22.Guan Y, Watson AJ, Marchiando AM, Bradford E, Shen L, Turner JR, and Montrose MH. Redistribution of the
tight junction protein ZO-1 during physiological shedding of mouse intestinal epithelial cells. American journal of
physiology Cell physiology 300: C1404-1414, 2011.
GENERAL DISCUSSION
199
Proefschrift laatste versie_Opmaak 1  6/10/13  10:12 AM  Pagina 199
23.Jakob SM, Parviainen I, Ruokonen E, Hinder R, Uusaro A, and Takala J. Increased splanchnic oxygen extraction
because of routine nursing procedures. Critical care medicine 37: 483-489, 2009.
24. Jakob SM, Ruokonen E, Vuolteenaho O, Lampainen E, and Takala J. Splanchnic perfusion during hemodialysis:
evidence for marginal tissue perfusion. Critical care medicine 29: 1393-1398, 2001.
25.Knichwitz G, Rotker J, Mollhoff T, Richter KD, and Brussel T. Continuous intramucosal PCO2 measurement
allows the early detection of intestinal malperfusion. Critical care medicine 26: 1550-1557, 1998.
26.Krack A, Richartz BM, Gastmann A, Greim K, Lotze U, Anker SD, and Figulla HR. Studies on intragastric PCO2
at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure. European
journal of heart failure 6: 403-407, 2004.
27.Lambert GP. Intestinal barrier dysfunction, endotoxemia, and gastrointestinal symptoms: the 'canary in the coal
mine' during exercise-heat stress? Med Sport Sci 53: 61-73, 2008.
28.Lambert GP, Lang J, Bull A, Pfeifer PC, Eckerson J, Moore G, Lanspa S, and O'Brien J. Fluid restriction during
running increases GI permeability. International journal of sports medicine 29: 194-198, 2008.
29.Larson MV, Ahlquist DA, Karlstrom L, and Sarr MG. Intraluminal measurement of enteric mucosal perfusion:
relationship to superior mesenteric artery flow during basal and postprandial states in the dog. Surgery 115: 118-
126, 1994.
30.Lorente JA, Ezpeleta A, Esteban A, Gordo F, de la Cal MA, Diaz C, Arevalo JM, Tejedor C, and Pascual T. Systemic
hemodynamics, gastric intramucosal PCO2 changes, and outcome in critically ill burn patients. Critical care medicine
28: 1728-1735, 2000.
31.Lubbers T, Kox M, de Haan JJ, Greve JW, Pompe JC, Ramakers BP, Pickkers P, and Buurman WA. Continuous
Administration of Enteral Lipid- and Protein-Rich Nutrition Limits Inflammation in a Human Endotoxemia
Model. Critical care medicine 2013.
32.Marchbank T, Davison G, Oakes JR, Ghatei MA, Patterson M, Moyer MP, and Playford RJ. The nutriceutical
bovine colostrum truncates the increase in gut permeability caused by heavy exercise in athletes. Am J Physiol Gas-
trointest Liver Physiol 300: G477-484, 2011.
33.Marchiando AM, Shen L, Graham WV, Edelblum KL, Duckworth CA, Guan Y, Montrose MH, Turner JR, and
Watson AJ. The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal
epithelial shedding. Gastroenterology 140: 1208-1218 e1201-1202, 2011.
34.Matheson PJ, Wilson MA, and Garrison RN. Regulation of intestinal blood flow. J Surg Res 93: 182-196, 2000.
35.Mensink PB, Moons LM, and Kuipers EJ. Chronic gastrointestinal ischaemia: shifting paradigms. Gut 60: 722-
737, 2011.
36.Moses FM. The effect of exercise on the gastrointestinal tract. Sports medicine (Auckland, NZ) 9: 159-172, 1990.
37.Moses FM. Exercise-associated intestinal ischemia. Current sports medicine reports 4: 91-95, 2005.
38.Moses FM. Gastrointestinal bleeding and the athlete. The American journal of gastroenterology 88: 1157-1159, 1993.
39.Nielsen HB, Svendsen LB, Jensen TH, and Secher NH. Exercise-induced gastric mucosal acidosis. Medicine and
science in sports and exercise 27: 1003-1006, 1995.
40.Ohri SK, Becket J, Brannan J, Keogh BE, and Taylor KM. Effects of cardiopulmonary bypass on gut blood flow,
oxygen utilization, and intramucosal pH. The Annals of thoracic surgery 57: 1193-1199, 1994.
41.Ohri SK, Somasundaram S, Koak Y, Macpherson A, Keogh BE, Taylor KM, Menzies IS, and Bjarnason I. The
effect of intestinal hypoperfusion on intestinal absorption and permeability during cardiopulmonary bypass. Gas-
troenterology 106: 318-323, 1994.
42.Oktedalen O, Lunde OC, Opstad PK, Aabakken L, and Kvernebo K. Changes in the gastrointestinal mucosa after
long-distance running. Scand J Gastroenterol 27: 270-274, 1992.
43.Otte JA, Oostveen E, Geelkerken RH, Groeneveld AB, and Kolkman JJ. Exercise induces gastric ischemia in healthy
volunteers: a tonometry study. J Appl Physiol 91: 866-871, 2001.
44.Peters HP, Bos M, Seebregts L, Akkermans LM, van Berge Henegouwen GP, Bol E, Mosterd WL, and de Vries
WR. Gastrointestinal symptoms in long-distance runners, cyclists, and triathletes: prevalence, medication, and eti-
ology.The American journal of gastroenterology 94: 1570-1581, 1999.
45.Poeze M, Greve JW, and Ramsay G. Meta-analysis of hemodynamic optimization: relationship to methodological
quality. Critical care 9: R771-779, 2005.
46.Rahman SH, Ammori BJ, Holmfield J, Larvin M, and McMahon MJ. Intestinal hypoperfusion contributes to gut
barrier failure in severe acute pancreatitis. J Gastrointest Surg 7: 26-35; discussion 35-26, 2003.
47.Rapp-Kesek D, Joachimsson PO, and Karlsson T. Splanchnic blood flow and oxygen consumption: effects of
enteral nutrition and dopexamine in the elderly cardiac surgery patient. Acta anaesthesiologica Scandinavica 51:
570-576, 2007.
48.Sandek A, Anker SD, and von Haehling S. The gut and intestinal bacteria in chronic heart failure. Curr Drug
Metab 10: 22-28, 2009.
49.Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, Schroedl W, Karhausen T, Doehner
W, Rauchhaus M, Poole-Wilson P, Volk HD, Lochs H, and Anker SD. Altered intestinal function in patients
with chronic heart failure. J Am Coll Cardiol 50: 1561-1569, 2007.
PART IV - CHAPTER 11                                                                                                                   
200
Proefschrift laatste versie_Opmaak 1  6/10/13  10:12 AM  Pagina 200
50.Sawka MN, Young AJ, Francesconi RP, Muza SR, and Pandolf KB. Thermoregulatory and blood responses dur-
ing exercise at graded hypohydration levels. Journal of applied physiology 59: 1394-1401, 1985.
51.Schwartz N, Hosford M, Sandoval RM, Wagner MC, Atkinson SJ, Bamburg J, and Molitoris BA. Ischemia acti-
vates actin depolymerizing factor: role in proximal tubule microvillar actin alterations. The American journal of
physiology 276: F544-551, 1999.
52.Shoemaker WC, Appel PL, Kram HB, Waxman K, and Lee TS. Prospective trial of supranormal values of sur-
vivors as therapeutic goals in high-risk surgical patients. Chest 94: 1176-1186, 1988.
53.Ter Steege RW, Geelkerken RH, Huisman AB, and Kolkman JJ. Abdominal symptoms during physical exercise
and the role of gastrointestinal ischaemia: a study in 12 symptomatic athletes. Br J Sports Med 2011.
54.Thuijls G, de Haan JJ, Derikx JP, Daissormont I, Hadfoune M, Heineman E, and Buurman WA. Intestinal
cytoskeleton degradation precedes tight junction loss following hemorrhagic shock. Shock 31: 164-169, 2009.
55.Thuijls G, Derikx JP, de Haan JJ, Grootjans J, de Bruine A, Masclee AA, Heineman E, and Buurman WA. Urine-
based detection of intestinal tight junction loss. Journal of clinical gastroenterology 44: e14-19, 2010.
56.Thuijls G, Derikx JP, de Kruijf M, van Waardenburg DA, van Bijnen AA, Ambergen T, van Rhijn LW, Willigers
HM, and Buurman WA. Preventing enterocyte damage by maintenance of mean arterial pressure during major
nonabdominal surgery in children. Shock 37: 22-27, 2012.
57.van Haren FM, Rozendaal FW, and van der Hoeven JG. The effect of vasopressin on gastric perfusion in cate-
cholamine-dependent patients in septic shock. Chest 124: 2256-2260, 2003.
58.van Haren FM, Sleigh JW, Pickkers P, and Van der Hoeven JG. Gastrointestinal perfusion in septic shock. Anaesth
Intensive Care 35: 679-694, 2007.
59.van Nieuwenhoven MA, Brouns F, and Brummer RJ. The effect of physical exercise on parameters of gastroin-
testinal function. Neurogastroenterol Motil 11: 431-439, 1999.
60.van Nieuwenhoven MA, Brouns F, and Brummer RJ. Gastrointestinal profile of symptomatic athletes at rest
and during physical exercise. European journal of applied physiology 91: 429-434, 2004.
61.Vermeulen Windsant IC, Hellenthal FA, Derikx JP, Prins MH, Buurman WA, Jacobs MJ, and Schurink GW.
Circulating intestinal fatty acid-binding protein as an early marker of intestinal necrosis after aortic surgery: a
prospective observational cohort study. Annals of surgery 255: 796-803, 2012.
62.von Duvillard SP, Arciero PJ, Tietjen-Smith T, and Alford K. Sports drinks, exercise training, and competition.
Current sports medicine reports 7: 202-208, 2008.
63.Vreugdenhil AC, Wolters VM, Adriaanse MP, Van den Neucker AM, van Bijnen AA, Houwen R, and Buurman
WA. Additional value of serum I-FABP levels for evaluating celiac disease activity in children. Scandinavian
journal of gastroenterology 46: 1435-1441, 2011.
64.Wright H, Collins M, Villiers RD, and Schwellnus MP. Are splanchnic hemodynamics related to the development
of gastrointestinal symptoms in ironman triathletes? A prospective cohort study. Clin J Sport Med 21: 337-343,
2011.
65.Zacho HD, Kristensen NB, Henriksen JH, and Abrahamsen J. Validation of (9)(9)mTechnetium-labeled mebro-
fenin hepatic extraction method to quantify meal-induced splanchnic blood flow responses using a porcine
model. Journal of applied physiology 112: 877-882, 2012.
GENERAL DISCUSSION
201
Proefschrift laatste versie_Opmaak 1  6/10/13  10:12 AM  Pagina 201
202
Proefschrift laatste versie_Opmaak 1  6/10/13  10:12 AM  Pagina 202
CHAPTER 12
Summary
Proefschrift laatste versie_Opmaak 1  6/10/13  10:12 AM  Pagina 203
Gastrointestinal (GI) integrity is essential to preserve the two key functions of the gut, i.e. the
absorption of dietary nutrients and water and the maintenance of an effective barrier against
harmful luminal compounds. Chapter 1 outlines the anatomy and regulation of the GI epithelial
barrier, including a brief overview of situations associated with GI barrier dysfunction. The
anatomical architecture of the epithelial barrier mainly builds on small intestinal epithelial cells
and junctional complexes between these cells. Rapid renewal of the epithelium along the small
intestinal crypt-villus axis contributes to the remarkable ability of the intestinal epithelium to
adapt to physiological and pathophysiological stimuli such as non-steroid anti-inflammatory
drug (NSAID) consumption and strenuous physical exercise (chapter 2). 
   Intestinal epithelial integrity loss can be established by detection of components of the epithe-
lial barrier in blood or urine, detection of circulating (anti)bacterial products or by permeability
analysis. Part II of this thesis focused on markers for enterocyte injury and permeability analysis.
Enterocyte injury was measured by detection of fatty acid binding proteins (FABP). Data of
previous human studies revealed that intestinal (I)-FABP and liver (L)-FABP are expressed in
the mucosa of the small intestine, especially the jejunum, while ileal-bile acid binding protein
(I-BABP) is specifically expressed in the ileum. Additionally, it was shown that especially the
mature enterocytes at the top of the intestinal villi contain I-FABP. Since these proteins are rap-
idly released upon cellular injury, they are established as useful, early markers of intestinal
integrity loss. The use of I-FABP, L-FABP and I-BABP for diagnosis of intestinal ischemia with
ischemia-induced intestinal injury was studied in chapter 3 of this thesis. All three markers were
found to be increased in urine of patients with intestinal ischemia compared to patients with
other final diagnoses, and plasma I-FABP and L-FABP levels were also higher in case of intes-
tinal ischemia. Detection of these proteins above their cut-off point increased post-test proba-
bility for intestinal ischemia, strongly suggesting that detection of I-FABP, L-FABP and I-BABP
can improve early diagnosis of intestinal ischemia. 
   Permeability analysis is an additional, more functional measure of GI epithelial barrier
integrity. Detection of orally ingested permeability probes with different molecular weights in
urine or plasma reflects the permeability of the GI mucosa. Many permeability tests are available,
but currently no consensus exists. An important aim of this thesis was to compare probe excre-
tion and accuracy of different permeability tests and to determine whether one of the tested
assays could be recommended above the others. Chapter 4 describes the comparison of two
permeability tests in a randomized controlled trial: The first is based on the urinary excretion of
three differently sized polyethylene glycol (PEG) probes, while the dual sugar test uses 5 g of
lactulose and 0.5 g of rhamnose to evaluate small intestinal permeability. Healthy individuals
received two oral doses of NSAID indomethacin, a drug known to increase GI permeability.
Loss of barrier integrity was confirmed by significantly increased plasma I-FABP levels in the
indomethacin-challenged state compared to placebo. Urinary excretion of PEG and sugars
increased after indomethacin. Urinary excretion data and diagnostic accuracy of the tests showed
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high similarity for detection of indomethacin-induced increases in gastrointestinal permeability.
These tests do not allow site-specific GI permeability analysis and require the oral intake of rel-
atively large probe doses, thereby possibly affecting epithelial homeostasis. A novel multi-sugar
test was developed to allow site-specific assessment in a more physiological setting, i.e. with a
reduced oral probe load. In chapter 5 and 6, the improved analytical work-up and validation of
this multi-sugar test are reported. The multi-sugar assay contains sucrose for gastroduodenal
permeability, lactulose and rhamnose to reflect small intestinal permeability, and sucralose and
erythritol for large intestinal permeability. Probes were first separated using liquid chromatog-
raphy (LC), after which mass spectrometry (MS) was used for final detection. This LC-MS
approach resulted in a considerably decreased limit of detection, allowing a 5-fold reduction of
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Figure 1: Schematic overview of the processes proposed to play a role in the development of exercise-induced gastrointesti-
nal injury
Strenuous physical exercise leads to redistribution of blood, shunting blood away from the splanchnic area, thereby
significantly reducing splanchnic blood flow. The ensuing ischemia leads to tissue hypoxia, local depletion of
adenosinetriphosphate (ATP), and acidosis. After exercise, when splanchnic circulation is restored, reperfusion
injury may develop, characterized by local inflammation and formation of reactive oxygen species (ROS). Both
ischemia and reperfusion sequelae lead to mucosal damage and gut wall integrity loss, which is accompanied by
increased permeability, bacterial translocation and intestinal inflammation. 
It remains to be clarified whether the exercise-induced mucosal injury impairs nutrient uptake, potentially
decreasing athletic performance and delaying post-exercise recovery.
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the oral lactulose dose. The novel multi-sugar test was tested against the classical dual sugar test
in a randomized crossover study in chapter 6. Urinary sucrose excretion and the sucrose/rham-
nose ratio increased after indomethacin intake compared to placebo, suggesting increased gas-
troduodenal permeability determined by the multi-sugar test. Increased small intestinal perme-
ability was detected by both tests after indomethacin intake, as reflected by elevated
lactulose/rhamnose (L/R) ratios compared to placebo. However, individual probe analysis sug-
gested that the high lactulose dose of the dual sugar test decreases monosaccharide permeability.
Large intestinal permeability was unchanged after indomethacin. Altogether, the multi-sugar
test was found to provide a physiological test condition for site-specific whole-gut permeability
analysis. While clinical validation studies are essential to determine the usefulness of the multi-
sugar test in different patient groups, the comparative studies described in this thesis improved
our knowledge of GI permeability analysis in man.
Part III of this thesis focused on exercise-induced splanchnic hypoperfusion and GI integrity
loss, and a comprehensive overview of these phenomena was given in chapter 2 of this thesis,
summarized in Figure 1.
   In short, heavy physical exercise leads to redistribution of the GI blood flow in favor of active
muscle, heart and skin, thereby significantly reducing perfusion in the splanchnic area. This phe-
nomenon was studied and described in chapter 7 using gastric air tonometry. During one hour
of intensive cycling, splanchnic hypoperfusion rapidly developed and continued to exist in the
post-exercise recovery period. Intestinal ischemia leads to cellular hypoxia, energy depletion and
tissue acidosis, ultimately leading to small intestinal injury, reflected by significantly elevated
plasma I-FABP levels. The latter significantly correlated with loss of GI barrier integrity, reflected
by increased plasma L/R ratios. Additionally, intestinal damage may impair nutrient uptake,
which may in turn affect physical performance and post-exercise recovery. In chapter 8, this
hypothesis was studied. In line with the results in chapter 7, exercise induced small intestinal
injury in healthy young men, and this intestinal injury correlated negatively with in vivo rates of
protein digestion and absorption, when proteins are consumed directly post-exercise. These data
imply that exercise attenuates protein digestion and absorption kinetics during acute post-exer-
cise recovery compared to resting conditions due to enterocyte damage. These findings suggest
an additional challenge for professional athletes and patients with chronic diseases, since espe-
cially these populations benefit from nutritional stimulation of early and complete recovery after
physical exertion. While from chapter 7 and 8 it is clear that exercise itself induces significant
small intestinal injury and compromises GI functioning, the intake of the NSAID ibuprofen
prior to exercise was found to significantly worsen exercise-induced intestinal injury and increase
GI permeability (chapter 9).These data are important, since many athletes use NSAIDs on a
regular basis to prevent anticipated pain without being aware of the adverse effects of these drugs.
Our findings in combination with the alarming indications that NSAIDs may induce cardiac
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events strongly discourage the use of NSAIDs, especially for non-existing pain. In chapter 10,
oral supplementation of L-citrulline prior to exercise was shown to improve splanchnic perfusion
during exercise in healthy athletes compared to placebo amino acid L-alanine. Consequently,
enterocyte damage was attenuated during exercise in case of pre-exercise L-citrulline supple-
mentation, while parameters of cardiac function and performance did not change. These results
suggest L-citrulline administration to be a promising therapy for improvement of splanchnic
blood flow in case of hypoperfusion.
SUMMARY
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Een intacte darmbarrière is van essentieel belang om de twee belangrijkste functies van de darm
te behouden. Deze functies zijn (1) opname van voedingsstoffen en water en (2) preventie van
het binnendringen van potentieel schadelijke stoffen die zich in het darmkanaal bevinden, zoals
bacteriële producten en verteringssappen. Hoofdstuk 1 schetst de anatomie en de regulatie van
de darmbarrière, inclusief een kort overzicht van enkele situaties waarin sprake is van darm-
barrièreverlies. Belangrijke onderdelen van de darmbarrière zijn de darmepitheelcellen en de
verbindende complexen tussen deze cellen. Het darmepitheel wordt volledig vernieuwt in 3-4
dagen. Deze snelle vernieuwing draagt bij aan het opmerkelijke vermogen van de darm om zich
aan te passen aan veranderende omstandigheden, zoals het gebruik van ‘non-steroid anti-
inlammatory drugs’ (NSAIDs) en zware fysieke inspanning (hoofdstuk 2).
   Darmbarrièreverlies kan worden vastgesteld door het detecteren van componenten van deze
barrière in bloed of urine, door detectie van (anti)bacteriële producten in de bloedbaan, of door
analyse van de doorlaatbaarheid van de darmwand, ook wel darmpermeabiliteit genoemd. 
    Deel II van dit proefschrift richt zich op markers voor darmcelschade en op het testen van de
darmpermeabiliteit. Darmcelschade werd gemeten middels ‘intestinal’ en ‘liver fatty acid binding
proteins’ (I-FABP en L-FABP, respectievelijk), en ‘ileal bile acid binding protein’ (I-BABP), kleine
eiwitten die zich bevinden in het epitheel van de dunne darm. Eerdere studies toonden aan dat
met name de volgroeide darmcellen op de toppen van de darmvilli deze eiwitten bevatten, en dat
deze snel worden afgegeven wanneer darmcelschade optreedt. Hierdoor zijn deze specifieke eiwit-
ten goed bruikbaar als vroege herkenners van darmcelschade. Het gebruik van I-FABP, L-FABP
en I-BABP voor de diagnose van darmischemie en door ischemie ontstane darmschade werd
bestudeerd in hoofdstuk 3 van dit proefschrift. Darmischemie is een aandoening waarbij er geen
of te weinig bloed naar de darm gaat, waardoor darmschade optreedt. Alle drie de markers bleken
verhoogd aanwezig te zijn in de urine van patiënten met darmischemie, vergeleken met patiënten
met andere diagnoses. Daarnaast waren de bloedwaarden voor I-FABP en L-FABP ook hoger in
geval van darmischemie. Wanneer de bloed- of urinewaarden van deze eiwitten boven hun drem-
pelwaarde uitstegen, bleek er sprake te zijn van een verhoogde kans op darmischemie bij deze
patiënten. Deze bevindingen suggereren dat de detectie van I-FABP, L-FABP en I-BABP kan 
bijdragen aan het vroeg vaststellen van darmischemie in patiënten. 
   Permeabiliteitstesten zijn een andere manier om informatie te krijgen over de darmbarrière.
De proefpersoon of patiënt drinkt een oplossing met teststoffen van verschillende grootte, waarna
de concentraties van deze stoffen in bloed of urine bepaald wordt als weerspiegeling van de door-
laatbaarheid van de darmwand. Er zijn veel verschillende tests beschikbaar, maar er is geen 
consensus over welke test gebruikt moet worden. Een belangrijk doel van dit proefschrift was
om de uitkomsten en de nauwkeurigheid van de verschillende permeabiliteitstesten te vergelijken
en om te bepalen of een van de onderzochte tests kon worden aanbevolen boven de anderen. 
   Hoofdstuk 4 beschrijft de vergelijking van twee permeabiliteittesten, elk bestaande uit ver-
schillende teststoffen: De eerste bestaat uit drie verschillende polyethyleenglycol-polymeren
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(PEG); de andere, klassieke test bestaat uit 5 g lactulose en 0,5 g rhamnose, allebei suikers. Voor
het onderzoek ontvingen de proefpersonen tweemaal indometacine, een NSAID waarvan bekend
is dat het de doorlaatbaarheid van de darmwand tijdelijk verhoogt. Dit laatste werd bevestigd
door een evidente stijging van I-FABP na inname van indomethacine in vergelijking met placebo.
PEG en suikerwaarden in urine namen beiden toe na inname van indomethacine. Beide testen
bleken veel gelijkenis te vertonen, zowel in de testuitkomsten als in de diagnostische nauw keurig -
heid van de testen voor de detectie van door indomethacine veroorzaakte toege nomen
darmpermea biliteit. Helaas kan de permeabiliteit van specifieke delen van de darm niet bepaald
worden met deze testen. Bovendien dient de proefpersoon relatief grote hoeveelheden van de
teststof in te nemen, waardoor mogelijk het natuurlijk evenwicht in de darm verstoord wordt.
Zodoende werd er een nieuwe multi-suikertest ontwikkeld om wel specifieke informatie te kun-
nen verkrijgen en waarbij kleinere hoeveelheden teststof ingenomen hoeft te worden. 
   In hoofdstuk 5 en 6 van dit proefschrift werden de verbeterde detectiemethode en de validatie
van deze multi-suikertest beschreven. De multi-suikertest bevat sucrose voor bepaling van de
permeabiliteit van de maag en twaalfvingerige darm, lactulose en rhamnose voor de dunne darm-
permeabiliteit, en sucralose en erytritol voor de dikke darmpermeabiliteit. Voor detectie van de
suikers wordt er eerst gebruik gemaakt van vloeistofchromatografie (LC), waarna middels massa -
spectrometrie (MS) de suikergehaltes in bloed en urine worden bepaald. Deze LC-MS aanpak
verlaagde de minimale detectiegrens aanzienlijk, waardoor het mogelijk werd om lagere suiker-
concentraties accuraat te meten en bovendien een 5-voudige reductie van de in te nemen dosis
lactulose mogelijk was. De nieuwe multi-suikertest werd getoetst aan de klassieke suikertest in
een gerandomiseerde cross-over studie beschreven in hoofdstuk 6. Zowel sucrose als de
sucrose/rhamnose ratio in urine steeg na inname van indomethacine in vergelijking met de
placebo, wat erop wijst dat er sprake was van een verhoogde gastroduodenale permeabiliteit na
indomethacine inname, gemeten middels de multi-suikertest. Verhoogde dunne darmper-
meabiliteit werd gevonden na indomethacine inname met beide tests, zoals weerspiegeld door
hogere lactulose/rhamnose (L/R) ratio's, vergeleken met placebo. Echter, de resultaten suggereer-
den ook dat de hoge dosis lactulose in de klassieke suikertest ervoor zorgt dat er minder 
rhamnose wordt uitgescheiden, wat betekent dat de testsubstanties zelf de resultaten kunnen
beïnvloeden. Concluderend gaven de studieresultaten aan dat de multi-suikertest een geschikte
en vooral betrouwbare test is om de permeabiliteit van het gehele maagdarmstelsel te beoordelen.
Hoewel klinische validatiestudies essentieel zijn om het nut van de multi-suikertest in verschil-
lende patiëntengroepen te bepalen, zijn de studies beschreven in dit proefschrift belangrijk omdat
zij onze kennis van de darmpermeabiliteitsanalyses in de mens vergroten.
   Deel III van dit proefschrift heeft betrekking op de verminderde doorbloeding van het maag-
darmstelsel en de daaropvolgende darmbarrièreverlies die optreden tijdens intensieve licha me -
lijke inspanning. Een uitgebreid overzicht van deze fenomenen werd gegeven in hoofdstuk 2
van dit proefschrift. Kort samengevat leidt zware lichamelijke inspanning tot een herverdeling
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van de bloedvoorziening. Het maagdarmstelsel wordt tijdelijk minder goed doorbloed, zodat de
actieve spieren, het hart en de huid meer bloed kunnen ontvangen. De kritieke vermindering
van de doorbloeding van het maagdarmstelsel wordt hypoperfusie genoemd, en is onderzocht
in de studie beschreven in hoofdstuk 7. Gedurende een uur intensief fietsen, ontwikkelde de
hypoperfusie in het maagdarmstelsel zich snel, en bleef bestaan in de herstelperiode na het
sporten. Hypoperfusie kan leiden tot een tekort aan zuurstof en energie in de darmcellen, waar-
door verzuring van het weefsel en uiteindelijk dunne darmschade ontstaan, weerspiegeld door
verhoogde I-FABP-waarden in het bloed. Deze darmschade gaf aanzet tot darmbarrièreverlies,
weerspiegeld door verhoogde L/R ratio’s ten opzichte van rust. Darmschade kan de opname van
voedingsstoffen bemoeilijken, waardoor mogelijk ook de fysieke prestaties en hersteltijd na het
sporten negatief beïnvloed worden. 
   In hoofdstuk 8 werd deze hypothese onderzocht. In lijn met hoofdstuk 7, leidde intensieve
inspanning tot darmschade bij gezonde jonge mannen, en deze darmschade had een negatief
effect op de vertering en absorptie van eiwitten die de atleten innamen direct na de fysieke inspan-
ning. Met andere woorden, inspanning vermindert de verterings- en absorptiecapaciteit voor eiwit
in de herstelperiode na inspanning vergeleken met rust. Deze bevindingen suggereren een extra
uitdaging voor professionele atleten en patiënten met chronische ziekten, omdat vooral bij deze
mensen voeding een belangrijk middel is om het herstel na de fysieke inspanning te bevorderen. 
   Uit hoofdstuk 7 en 8 is reeds gebleken dat inspanning dunne darmschade en verminderde
darmfunctie veroorzaakt. 
   De resultaten in hoofdstuk 9 lieten zien dat de inname van de NSAID ibuprofen vóór inspan-
ning deze darmschade en darmbarrièreverlies aanzienlijk verergert. Deze gegevens zijn van
belang, omdat veel atleten regelmatig NSAIDs gebruiken in de hoop geanticipeerde pijn te
voorkomen, zonder dat daar bewijs voor is en zonder zich bewust te zijn van de nadelige effecten
van deze geneesmiddelen. Onze bevindingen in combinatie met de alarmerende aanwijzingen
dat NSAID’s hartproblemen kunnen veroorzaken, ontraden het gebruik van NSAID’s sterk,
indien hier geen medisch aanwijzing voor is. 
   Ten slotte trachten we in de crossover studie beschreven in hoofdstuk 10middels een specifieke
voedingsinterventie voorafgaand aan de inspanning de doorbloeding van het maagdarm-stelsel 
tijdens en na inspanning te verbeteren en de inspannings-gerelateerde darmschade te reduceren of
zelfs te voorkomen. Inderdaad toonden de resultaten van deze studie aan dat hypoperfusie tijdens
inspanning kon worden voorkomen door voorafgaand aan de inspanning L-citrulline te consumeren,
terwijl inname van placebo aminozuur L-alanine dit effect niet had. Het behoud van de circulatie
in het maagdarmstelsel tijdens inspanning zorgde ervoor dat ook de integriteit van het darmepitheel
minder verstoord was, terwijl de parameters van de hartfunctie en de inspanningsprestatie niet ver-
slechterden. Deze studieresultaten suggereren dat L-citrulline inname een veelbelovend middel is
voor verbetering van de circulatie in geval van hypoperfusie van het maagdarmstelsel.
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Beste Kaatje! Dank voor de vele uurtjes overleggen, manuscripten doorlezen, en nóg eens kritisch
naar de stukken, de referenties en de figuren te kijken! Je hebt een engelengeduld! Ook heel veel
dank voor je hulp bij de perikelen onderweg. Het is klaar!
Prof. Stassen, beste Laurents, toen ik eerst als Kim Holland en later gewoon als Kim van Wijck
met je sprak over mijn voornemen om na mijn promotie-onderzoek het team van de heelkunde
aan te sterken, was jij meteen enthousiast. Ik wil je graag bedanken voor dat enthousiasme en
voor het vertrouwen dat ik kreeg om zo vlot aan de slag te mogen in de kliniek. Ik hoop nog veel
van je te mogen leren; binnenkort een eerste laparoscopische ingreep samen? 
Dr. Hoofwijk, beste Ton. Bedankt voor je steun en vertrouwen in de Blitzkrieg van onderzoeker
tot clinicus. Je wijze woorden over het vak en het leven daaromheen heb ik graag ter harte
genomen. Ik kom met plezier terug naar het Orbis na mijn eerste jaren in het Maastrichtse, en
dan gaan we er iets moois van maken! 
Prof. Van Loon, beste Luc. Onderzoeker en sportman in hart en spieren. Dank voor je zeer 
toegankelijke hulp bij onze projecten samen! De snelheid en secuurheid waarmee jij de manu-
scripten doornam, was elke keer weer verademend. Nu ik weer in het Maastrichtse verblijf, 
misschien binnenkort een keer samen zitten om te brainstormen over mooie vervolgplannen? 
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Prof. Soeters, beste Peter. Toen wij u benaderden en vroegen om op te treden als voorzitter van
de leescommissie zei u direct ja. Hartelijk dank voor uw bereidwilligheid om deze taak te
vervullen en voor het flitsend optreden om de antwoorden van alle commissieleden tijdelijk te
verkrijgen. Ik ben vereerd dat u aanwezig bent bij de oppositie. 
   Ook de overige leden van de corona en van de leescommissie wil ik graag hartelijk danken
voor de tijd en de interesse voor het lezen en beoordelen van dit proefschrift.
De studies beschreven in dit proefschrift zijn gedaan binnen het framework van Top Institute
Food and Nutrition (TIFN). Ik wil met name graag Jan Dekker en de leden van de Maastrichtse
TIFN (MDL) groep graag bedanken voor de mogelijkheden die mij geboden zijn en voor de
brainstormsessies op de woensdagochtenden.
Prof. Kolkman, beste Jeroen. Dank voor je inwijding in de wondere wereld van de tonometrie
zo’n 5 jaar geleden. Toen ik vroeg of ik de kunst eens af zou mogen komen kijken, nodigde je me
meteen uit in Twente waarbij je alle tijd nam om me de kunsten van de darmischemie diagnostiek
te laten zien. Dank voor je enthousiasme en voor je tijd bij het lezen en beoordelen van mijn
promotieboekje. Ik zie ernaar uit met je van gedachten te wisselen! 
Dr. Poeze, beste Martijn. Ook jou wil ik graag bedanken voor je introductie in de tonometrie en
voor de samenwerking over de jaren om toch samen een aantal mooie artikelen te publiceren.
Nu die ene laatste nog! 
   Beste Nina, partner in de citrulline crime, dank voor je hulp bij het review en voor al je werk
voor ons artikel. Ik hoop dat je snel ook op de promotie-sneltrein kan stappen, want dat heb je
na de doorgemaakte tegenspoed wel verdiend!
Naast bovenstaande personen zijn er natuurlijk nog veel meer mensen die bijgedragen hebben
aan dit promotiewerk. Graag wil ik al mijn collega’s in het onderzoek en in de kliniek, zowel in
Sittard als in Maastricht, hartelijk danken voor de gezelligheid en steun! En iets minder voor
het moment waarop ik weer eens in de papierbak belandde. 
Graag wil ik bij naam noemen Annemarie, de ELISA-koningin; Bas, dan minstens prins van de
ELISA en natuurlijk proefpersoon ten top; Babs, PEG-liefhebber, en Hans - dank voor alle
analyses die jullie met zoveel precisie hebben uitgevoerd! Ook dank aan alle student-onderzoekers
die hun bijdrage hebben geleverd aan de tot standkoming van dit proefschrift, met name Thomas,
Nele, Carola, Nadine, Ilja, Esther en Ben.
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Paula, hartelijk dank voor je enorme hulp bij de layout van boekje en website! Er gingen geen
drie dagen voorbij of ik had alweer een nieuwe mail terug, zodat ik in mijn nachtelijke uurtjes
altijd iets te doen had. Het ziet er super uit!
Proefpersonen! Veel dank ben ik jullie verschuldigd, want zonder proefpersonen die zich voor
mij in het zweet wilden werken, waren we mooi aan de kade blijven liggen. Gelukkig is een
kinderhand al snel gevuld, en waren we na wat dikbelegde boterhammen al snel weer on speaking
terms. Natuurlijk wilden jullie over een week wel weer die tonometriekatheter in de neus. Heren,
en dan vooral proefpersonen van het eerste uur, Bas en Kostan, heel veel dank voor al jullie inzet
en het doortrappen als ik jullie naar de denkbeeldige finish stond te schreeuwen. Wees gerust,
het MEC protocol van deze studie is afgesloten. 
Vrienden en familie, hopelijk ben ik er door de jaren heen in geslaagd om duidelijk te maken
hoeveel jullie voor mij betekenen. Met jullie om mij heen, life is good! 
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